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With the over prescription and use of antibiotic drugs the evolution of drug resistant 
bacteria strains has become a world wide health crisis.  In response to this crisis, the search for 
new drugs to kill bacteria via a novel mode of action has become of critical importance to 
modern medicine. Natural and synthetic antimicrobial peptides (AMPs) have exhibited a broad 
spectrum of activity against various infectious microorganisms while exhibiting little to no 
mammalian cell toxicity. It’s because of this selectivity that AMPs are considered as a potential 
new source of therapeutics for drug-resistant bacteria. It is believed that the selectivity for 
bacteria cell membranes over host cells and the potency between different bacteria strains is 
derived from the ability of the AMPs to exploit the differences in chemical composition of 
various organism’s membranes. The hypothesis guiding this research states: The 
physicochemical surface properties of the target cell’s membrane interact with the 3D 
physicochemical surface properties of the approaching AMP inducing a conformational change 
onto the AMP maximizing the interactions between the two to facilitate AMP-membrane binding 
and the formation of pores leading to intracellular leakage and cell death. There are two binding 
interactions that are of interest, the S-state and I-state. The S-state, or surface state, refers to the 
binding of the peptide to the surface of the membrane, while the I-state involves the insertion of 
  
the peptide into the bilayer. By understanding the interactions of various AMPs with different 
target cell membranes one can develop novel analogs with increased potency and selectivity for a 
particular strain of bacteria. This knowledge would eventually lead to the design of antimicrobial 
peptides used as pharmaceuticals to treat bacteria resistant to current antibiotics. In our 
laboratory we have developed a series of antimicrobial peptides that incorporate unnatural amino 
acids to impart specific physicochemical properties onto these peptides. Circular Dichroism 
(CD), isothermal titration calorimetry (ITC) and calcein leakage assays were conducted and it 
was determined that there are two distinctly different mechanisms of binding occurring between 
this series of peptides and zwitterionic and anionic membrane models. By understanding the 
interactions of various AMPs with different target cell membranes one can develop novel 
analogs with increased potency and selectivity. 
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CHAPTER ONE: INTRODUCTION 
General Background 
Over the past two decades, infections caused by antibiotic-resistant bacteria have 
increased, while the number of new antibacterial agents approved in the United States has 
decreased. 1-3 Approximately 36 new antibacterial drugs were approved in the United States 
since 1988, however, only one new antibacterial drug was approved between 2006 and 2009.1 
The overuse of antibiotics has facilitated an increase in the evolution of resistance of several 
gram-positive and gram-negative pathogens that cause infection particularly in hospital 
environments. In a 2008 report, Rice grouped Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter 
species as the “ESKAPE” pathogens because they were the major cause of infections in hospitals 
in the United States due to their resistance to established antibacterial agents. 3 The Center for 
Disease Control reported that more people die from methicillin-resistant S. aureus (MRSA) 
infections in US hospital than HIV/AIDS and tuberculosis combined. 4 In a testimony by 
Spellberg to the House Committee on Energy and Commerce Subcommittee on Health on behalf 
of the Infectious Diseases Society of America, he stated that nearly 100,000 people die per year 
in the US as a result of antibiotic-resistant infections they acquired in hospitals. This number, 
however, does not take into account the number of deaths caused by infections acquired outside 
of a hospital setting. [Testimony of the Infectious Diseases Society of America (IDSA), entitled 
“Antibiotic Resistance: Promoting Critically Needed Antibiotic Research and Development and 
Appropriate Use (“Stewardship”) of these Precious Drugs” presented by Brad Spellberg, MD, 
FIDSA, before the House Committee on Energy and Commerce Subcommittee on Health, June 
9, 2010] This serious health crisis has lead to the necessity for a new generation of 
2 
 
pharmaceuticals with a novel mode of action against bacterial agents.5 Antimicrobial peptides 
(AMPs), which are found as natural components of the innate immune system of a vast array of 
organisms, have emerged as possible new therapeutic agents to replace traditional antibiotics 
because of their broad spectrum activity against gram positive and negative bacteria, fungi and 
protozoa.5-7 It is believed that by optimizing multiple parameters, including, but not limited to, 
the reduction of mammalian cell toxicity and the susceptibility to proteolytic degradation, AMPs 
have the potential to be developed as drugs to treat drug-resistant bacteria infections.7, 8 
To date, there are over 1,700 naturally occurring peptides obtained from a variety of 
different species that have been identified and their amino acid sequences determined.9 These 
peptides are listed in a database developed by Wang9 and are classified by their biological 
activities such as antibacterial, anticancer, antiviral and antifungal. 9 Naturally occurring AMPs 
have been isolated from various living organisms including humans, 10 amphibians, 11 insects, 
mammals,12 birds, fish and plants.7, 8, 13-15 In addition to these, several thousand new AMPs have 
been engineered and produced synthetically.8 AMPs are a part of the body’s natural immune 
system and they protect the body in the event of exposure to infectious microorganisms5, 14, 16 by 
either killing the microorganism, slowing its growth or aiding the body’s other natural self-
defense mechanisms.7 In general, most AMPs consist of 10-50 amino acid residues and are 
highly positively charged, with a positive charge between +3 and +9, due to the incorporation of 
basic amino acids such as lysine and arginine. Due to their well defined regions of hydrophobic 
and hydrophilic character (~50% hydrophobic),17 they are considered to be amphipathic 
molecules.5, 8, 12, 13 As previously mentioned, AMPs are of great therapeutic interest as many 
AMPs have shown broad spectrum  bioactivity against several different strains of bacteria 
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including Gram positive and Gram negative, mycobacterium, fungi and protozoa 5 while 
exhibiting very low mammalian toxicity.  
AMPs are classified based on their amino acid composition and structure. The focus of 
this research is a class of linear, cationic, α-helical peptides. This subgroup contains  
approximately 290 peptides 7, 18 which are relatively short containing less than 40 amino acid 
residues, lack cysteine residues, and in some cases, contain a kink or hinge in the middle of the 
sequence.7, 18, 19  These particular peptides are disordered in aqueous solutions, exhibiting 
characteristics of random coil conformation, however they adopt an ordered amphipathic 
secondary structure in the presence of a membrane environment, where all or part of the peptide 
is involved in an α-helix  7, 19-23  Generally, these AMPs exhibit minimum inhibitory 
concentrations (MIC) in the low-micromolar range. 7, 13, 14, 24  The MIC value represents the 
concentration of an AMP that will inhibit 50% of the growth for a microorganism.  
 
Modes of Action 
AMPs can be divided into two subclasses based on the mechanism of action by which 
they kill bacteria cells, non-membrane disruptors 16, 25, 26  and membrane disruptors. 7, 24, 25  The 
former, as the name suggests, does not involve the permeation of the cell membrane, but rather 
involves the translocation of peptides into the cytoplasmic area of the cell interrupting and/or 
inhibiting functions such as cell-wall synthesis, protein synthesis and metabolism.7, 25, 27  The 
latter refers to those AMPs that cause cell lysis through the disruption of the integrity of the cell 
membrane. 5, 8, 28  Although the exact mechanism by which the cell is destroyed is not fully 
understood, there is a general agreement that the first target for any class of peptides is the 
negatively charged membranes of bacterial cells.13, 15, 22, 24, 27, 29 
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There are several proposed theories concerning the mechanism of action between 
peptides and membranes, but the attraction and attachment of the peptide to the surface of the 
membrane is the first step in either mechanism of action.22 The positively charged residues of the 
peptide are attracted to the negatively charged phospholipids of the target cell by electrostatic 
interactions.  7, 14, 24  Once the peptide is bound to the surface via electrostatic interactions, the  
hydrophobic side-chains insert into the hydrophobic core of the membrane, anchoring the 
peptide to the membrane, inducing a conformation that maximizes the electrostatic and 
hydrophobic interactions while minimizing the repulsive forces. 17, 26 At low peptide 
concentrations the peptide is believed to align itself parallel to the surface of the membrane 
causing a thinning of the membrane which is a concentration dependent process (Surface or S-
state). Once a particular peptide to lipid ratio is reached, which varies for both peptide and target 
lipid composition, the perpendicularly oriented peptides insert into the bilayer forming 
transmembrane pores (Insertion or I-state).7, 30-32  The exact mechanism involving I-state 
formation could involve one of several accepted theories, including “carpet,”33, 34 barrel stave,7, 
35, 36
  and a toroidal pore mechanism.35, 37, 38 The toroidal pore mechanism (Figure 1.1) is the 
most pertinent to our research. 
The toroidal pore theory is a well understood mechanism for pore formation. As a peptide 
comes into contact with the membrane, it will orient itself in such a way as to adopt an α-helical 
conformation and align itself parallel to the surface (S-state).16, 39 The hydrophobic residues of 
the bound peptide will cause local displacement of the lipid polar head groups introducing a 
strain onto the surface that will ultimately lead to thinning, displacement of head groups leading 
to a decrease in thickness of the bilayer, and destabilization of the membrane surface.  As the 
concentration of peptide increases they aggregate to form complexes of 4-6 units, in a way such 
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that their polar residues are no longer exposed to the hydrocarbon chains and only associate with 
the polar head groups of the lipids.16, 37 The peptides then change their orientation from parallel 
to perpendicular relative to the membrane surface.7, 13, 40  Due to the destabilization caused by the 
membrane thinning, the oligomers are able to insert into the bilayer, forming a toroidal 
arrangement of peptides.39 As the helical oligomers insert into the membrane, the polar head 
groups of the phospholipids are pulled into the pore inducing a continuous bending of the lipid 
monolayer through the pore. 
 
 
Figure 1.1: Schematic diagram of toroidal pore mechanism. Liposome surrounded by free 
peptide in bulk solution (top left). Peptide is pulled to membrane via electrostatic interactions 
and binds to the surface (bottom left). Peptides aggregate on the surface of the membrane, 
causing the disruption and rearrangement of lipid polar head groups (top right). Peptides insert 
into bilayer, pulling polar head groups into the pore (bottom right). Figure was adapted from 
Brogden.7 
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Because the hydrophobic side-chains are buried in the bilayer, the pore becomes lined 
with the hydrophilic faces of the peptides, as well as, the polar head groups of the monolayer that 
were pulled in. Finally, the outer and inner monolayers bend into each other becoming fused 
together causing a continuous bend from top to bottom. 7  Once the transmembrane pore is 
formed, the intracellular components can leak out or, upon disintegration of the pore, some of the 
peptides can enter the cytoplasmic leaflet of the membrane and target the intracellular 
components. Both result in cell lysis and death.16  The main difference between this mechanism 
and that of the barrel stave model is that in the toroidal model, the peptides are always associated 
with the polar head groups of the monolayers, even when inserted into the core of the bilayer.7, 16 
Membrane-disrupting peptides can be further classified as being cell-selective or non-cell 
selective.41 The therapeutic usefulness of a peptide as a pharmaceutical agent is dependent upon 
its ability to differentiate between a bacterial cell and a mammalian host cell. While non-cell 
selective AMPs are toxic to both bacterial and mammalian cells, cell-selective AMPs are of high 
interest as they exhibit potent activity against bacterial cells while exhibiting much less activity 
against mammalian cells.28, 41, 42The first step of any binding mechanism is the attraction of the 
peptide to the membrane surface and it is believed that the driving force behind this affinity is 
the composition of the target cell’s membrane.8, 12, 14, 17, 24  The chemical composition of the 
membrane of mammalian red blood cells is very different from the chemical composition of 
membranes of bacterial cells.  In general, mammalian red blood cells contain zwitterionic 
phospholipids having an overall neutral charge, while bacterial cell membranes contain a high 
percentage of anionic phospholipids having an overall negative charge.43 The composition of 
bacterial cell membranes also varies between different strains. Gram-positive bacteria 
membranes are covered by a porous layer of peptidoglycan and are considered to be the easiest 
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membrane to penetrate. The membranes of Gram-negative bacteria are slightly more complex 
consisting of two lipid membranes containing lipopolysaccharides and porins.14, 44  The 
bacterium with the most complex bacteria membrane, and therefore the hardest to penetrate and 
kill, is that of the mycobacterium which has a thick mycolate-rich outer coat. 16, 45  
 
Important Characteristics of AMPS 
There are several physicochemical characteristics of AMPs that can affect antimicrobial 
activity and specificity. 7, 19, 46 They include size, charge, hydrophobicity, conformation, 
amphipathicity and polar angle where the charge, hydrophobicity, amphipathicity and 
conformation are closely related.16 If the peptide is not long enough, it may be unable to span the 
width of the bilayer, making it impossible to form pores. Most active peptides range from as few 
as 10 amino acid residues to as many as 50. Shorter peptides offer a simpler synthesis, although, 
the truncation of a peptide to fewer than 20 amino acid residues results in an α-helical peptide 
that is unable to span a lipid bilayer. 24, 47 From a mechanistic perspective, this would explain the 
loss of activity. However, possessing the ability to span a bilayer is not a necessity as there are α-
helical peptides with as few as 13 residues that retain antibacterial activity.24, 48  In one study it 
was determined that 12-18 residues were the required length for activity, with optimal 
antibacterial/hemolytic properties ratio found at 14 residues.18 
The importance of the sequence is not in the types of amino acids, but rather the patterns 
in distribution of the different types of residues within the sequence to give a variation of 
physicochemical properties. 18 Hydrophobic and charged residues are two major types of 
residues that play a major role in the activity of a peptide. The peptides focused on in this 
research are highly positively charged from +4 to +6 with the incorpotation of lysines, arginines 
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or other basic amino acids residues, as are most AMPs. The positive charges of basic amino 
acids are the driving force of the electrostatic interactions that attract the AMPs to the negatively 
charged surfaces of the bacterial cell membrane, thus, playing a major role in the activity and 
specificity of the AMP.16 Several studies have shown a correlation between charge and 
potency.12, 18, 49 Increasing the charge can increase both antibacterial and hemolytic activity, 50 
however, a large increase in charge could also decrease the activity as it would prevent the 
peptide from adopting a structure which would promote binding.51 Magainin studies showed that 
with an increase in charge, smaller, less stable and short lived pores are formed with a faster 
translocation across the membrane, thus causing an increase in hemolytic activity and a loss of 
antibacterial activity.16 The suggested optimal charge for maximal lytic activity is +4.52  
The overall percentage of hydrophobic residues in an active AMP, natural or synthetic, is 
approximately 50% and includes the incorporation of residues such as alanine, leucine, 
phenylalanine or tryptophan.16, 18 The net hydrophobicity of the peptide is very important to the 
activity as it governs the attachment of the peptide to the surface and the extent of insertion into 
the bilayer.16  However, an increase in hydrophobicity has been correlated to increased 
hemolysis and a decrease in cell selectivity.53 
As previously mentioned, this class of AMPs adopts amphipathic α-helical conformations 
upon interaction with the surface of a target cell’s membrane. The extent of the amphipathic 
helicity influences the peptides activity as well as its selectivity and reflects the relative 
abundance and placement of the charged and hydrophobic residues.16 Approximate ratios of 1:1 
to 1:2 of charged residues to hydrophobic residues appear optimal for such a structure.18 It has 
been shown that by having the charged or hydrophobic residues confined to the N- or C-terminal 
segments, respectively, the peptide is inactive. For activity, a transversal amphipathic 
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arrangement of the residues is necessary, for example, polar and nonpolar regions running along 
the length of the peptide.18 As the peptide is attracted to the surface of the membrane via 
electrostatic interactions, an amphipathic α-helix is adopted with polar residues dominating one 
face of the helix and the hydrophobic residues the other.18 Such a conformation maximizes the 
attractive interactions while minimizing the repulsive interactions with the surface of the 
membrane.  
The polar index, more commonly referred to as the polar angle, is the ratio of the polar to 
nonpolar regions of a peptide folded into an amphipathic helix. For example, for an α-helical 
peptide that contains two defined regions, one polar and the other nonpolar, the polar angle 
would be 180o. By decreasing the segregation of these regions, the polar angle would be 
decreased in a proportional manner. Several studies have been conducted to investigate the role 
that the polar angle plays in the interaction of peptides with membranes. An increase in the 
hydrophobic surface area of the peptide, and therefore a smaller polar angle, resulted in an 
increase in the peptides ability to permeabiate membranes.53-55 Although peptides with smaller 
polar angles induced greater membrane permeability, translocation and pore formation rates, 
these pores were also less stable. These studies lead to the conclusion that the hydrophilic and 
hydrophobic components of the peptide play very significant roles in the interaction and 
disruption of membranes.16, 54 All of the above mentioned characteristics play an important role 
in the activity and selectivity of AMPs. Many of these parameters are very closely related and 
modifying any one of them, no matter how small, could result in a significant change in another 
parameter. As high helicity, high hydrophobicity and high amphipathicity have all been 
correlated to high hemolytic activity, 17, 56, 57 care should be taken when making any 
modifications as there are limits.7 
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Magainin 
The magainin class of AMPs  are secreted from the skin of the African clawed frog 
Xenopus laevis and have been classified as linear amphipathic α-helical AMPs.39, 58 The 
magainins were of therapeutic interest as a broad-spectrum antibiotics because they are 
bactericidal, exhibiting potent activity against Gram-positive and Gram negative bacteria, 
fungicidal and virucidal, while exhibiting little mammalian toxicity.8, 13, 39, 58 Although active in 
vitro, magainins were only effective in animal models at very high doses, greatly reducing their 
therapeutic usefulness. However, magainins have been extensively studied so as to gain a better 
understanding of their interactions with bacterial and mammalian cells in an effort to develop 
useful therapeutic agents.59 Magainins consist of 21-26 amino acid residues with an overall 
positive charge of +3 to+5 and are soluble at high concentrations in aqueous solutions at 
physiological pH. The amino acid sequences for three of the most studied analogues of magain 
are given in Table 1.1. When interacting with membrane models, magainins adopt α-helical 
structures possessing a large hydrophobic moment; in other words, have a high probability of 
forming an amphipathic structure.39, 60, 61 This class of AMPs has a broad nonpolar face and a 
narrow polar face with the positive charges of the lysine residues clustered together at the border 
of these two faces, characterizing magainins as well-defined α-helical amphipathic AMPs. It is 
believed that that their cytotoxic effects arise from the permeabilization of the negatively 
charged membrane by the toroidal mechanism previously mentioned.39, 62-64 
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Table 1.1: The amino acid sequences of the three most studied analogues of magainin. 
Compound Amino Acid Sequence
Magainin 1 G-I-G-K-F-L-H-S-A-G-K-F-G-K-A-F-V-G-E-I-M-K-S
Magainin 2 G-I-G-K-F-L-H-S-A-K-K-F-G-K-A-F-V-G-E-I-M-N-S
(Ala8,13,18)magainin-2-amide G-I-G-K-F-L-H-A-A-K-K-F-A-K-A-F-V-A-E-I-M-N-S-NH2
 
 
 
The binding interactions of magainins and their analogues with model membranes have 
been extensively studied via NMR,7, 65, 66 molecular modeling,67  ITC,39, 53, 58  CD,65, 68 Neutron 
diffraction 69, 70 and fluorescence spectroscopy.71, 72 Solid-state NMR spectroscopy has the 
capability of characterizing the secondary structure of an AMP as well as its orientation and 
penetration into lipid bilayers. NMR studies of magainin have determined that they are 
positioned parallel to the plane of the lipid bilayer at low peptide concentrations.7, 20 Hicks and 
coworkers previously tested the hypothesis that the membrane’s physicochemical surface 
interactions with the physicochemical surface of the AMP define organism selectivity using 2D 
NMR and molecular modeling.67 Dodecylphosphocholine (DPC) micelles were used to mimic a 
simple model for zwitterionic cell membranes and sodium dodecylsulfate (SDS) micelles for 
anionic lipids. According to their 2D NMR and molecular modeling studies, (Ala8,13,18)magainin-
2-amide adopts different conformations when in different membrane environments.  In the 
presence of DPC micelles, an α-helical structure is adopted at residues 2-16 with four C-terminal 
residues converging to a loose β-turn like structure. For the SDS membrane, the α-helical 
structure involves residues 7-18 allowing for greater flexibility with C- and N-terminal residues. 
These conformational differences are attributed to the difference in electrostatic and hydrophobic 
interactions with the surfaces of the micelles. The SDS and DPC configurations determined by 
NMR were used to calculate Molecular Electrostatic Potential (MEP) maps to observe how the 
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electrostatic potential surface is affected by changes in conformation. The orientation of the 
peptide varied between membrane models, supporting the conclusion that magainin is cell-
selective.67 
As determined by ITC, the titration of the anionic lipid membrane model POPC/POPG 
into solutions of magainin 2-amide (M2a) can be divided into at least two steps.39 The first step 
is the electrostatic attraction of the peptide to the membrane which increases the concentration of 
peptide immediately above the surface. This is followed by the hydrophobic adsorption of the 
peptide into the lipid bilayer. There is the presence of an endothermic enthalpy component with 
the first few injections of lipid into the peptide, low lipid-to-peptide ratios (L/P), which has been 
attributed to the transition from M2a pore formation to the disintegration of the pore. As the 
concentration of liposomes increases, resulting in an increase in the L/P ratio, the pore ↔ 
monomer equilibrium is shifted toward the M2a monomer phase, and the pore will disintegrate. 
The disintegration of a pore is an exothermic event and it compensates for the enthalpy 
consumed during pore formation.39 
According to CD spectroscopy, magainin exhibits a random coil structure in aqueous 
buffer, but adopts an α-helix in the presence of an anionic membrane model. Using oriented CD 
and NMR spectroscopy, it was determined that at high L/P concentrations, the peptides are 
parallel in helical conformations on the surface of the membrane, but as the ratio decreases, the 
peptide becomes oriented perpendicular to the surface.39, 73 Neutron diffraction coupled with 
fluorescence spectroscopy studies have shown that at high peptide concentration, pores are 
formed by bundles of helical peptides. The peptides of each pore are separated by lipids 
concluding that magainin causes membrane disruption through the formation of toroidal pores.53, 
70
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Novel AMPs 
The broadband activity of magainin coupled with the in-depth understanding of its 
binding interactions with membrane models were the reasons it was used as a reference for the 
design of a new class of novel AMPs developed in the Hicks laboratory in the Department of 
Medicinal Chemistry, Division of Experimental Therapeutics at the Walter Reed Army Institute 
of Research in Silver Springs, Maryland.13 These new compounds were designed to mimic the 
physicochemical properties of the magainins, more specifically their electrostatic surface 
potential maps. Although naturally occurring AMPs are of great therapeutic interest, there are 
several serious limitations to their therapeutic usefulness. Some of these factors include their 
rapid in vivo degradation, high production costs and their reduced activity in physiological 
conditions, as was the case with magainin.29, 74 Efforts to overcome these problems while also 
retaining the biological activity of these peptides has resulted in the use of unnatural amino acids 
that mimic the residues incorporated in the natural pepties.29  
The basic skeleton of each peptide synthesized in the Hicks  lab is similar, containing 
between 15 and 21 natural and unnatural amino acid residues. Tic and Oic (Figure 1.3 – red) are 
unnatural amino acids that were incorporated into the backbone as a dipeptide unit. Together 
these two unnatural amino acids induce a semi rigid conformation onto the peptide backbone.13 
Kyle and co-workers 75 used NMR to determine that placing the dipeptide unit D-Tic-L-Oic in 
positions i+1 and i+2 of a four amino acid sequence induces a β-turn. By strategically placing 
three of these unnatural dipeptide L-Tic-L-Oic units throughout the peptide and connecting them 
with amino acid spacers of defined properties of charge and hydrophobicity, it was believed that 
the 3D physicochemical properties of the peptide could be controlled.76  
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Figure 1.2: Diagram of the basic skeleton of AMPs containing three Tic-Oic dipeptide units 
developed in our laboratory. 
 
 
 
 
In doing so, peptides could be designed with well-defined physicochemical properties in regards 
to acid/base properties, water solubility, and stereochemistry among others that maintain their 
conformational flexibility so as to allow them to adopt different conformations for different 
membranes.  
In our lab, compound 23 (Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK-
CONH2) was chosen as the reference because of its high in vitro activity against different 
bacteria strains and low hemolytic activity. Different modifications were designed to test the 
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significance of the Tic-Oic units, the distance between separate Tic-Oic units (Figure 1.3 – 
spacer #1 in blue), the distance between the positive charge and the peptide backbone (Figure 
1.3 – spacer #2 in gold), the distance between the last Tic residue and the C-terminal Lys 
residues (Figure 1.3 – spacer #3 in green), the need for a hydrophobic residue (Figure 1.3 – 
purple) as well as the number and placement of a cluster of positive charge at either terminus.  
The newly designed AMPs exhibited a broad range of antibacterial activity as well as 
hemolytic activity in cell culture. There were two sets of bacteria assays tested. The first set 
included Salmonella typhimurium  (ATCC 13311) as the gram-negative and Staphylococcus 
aureus ME/GM/MTC (ATCC 33592) as a gram-positive screen. Mycobacterium ranae (ATCC 
110) is a commercially available screen for mycobacterium and it is believed that it can provide 
insight into activity against tuberculosis.10, 13, 17 Bacillus subtillis (ATCC 43223) was used as a 
screen for Bacillus anthraces.10 Most of the observed MICs for these new peptides were as low 
as, if not lower, than those reported for other AMPs. The second series of bacteria assays 
consisted of several gram negative bacteria strains including Acinetobacter baumanii (ATCC 
19606), clinical drug resistant isolate from Walter Reed  Acinetobacter baumanii WRAIR, 
Staphylococcus aureus MRSA (ATTCC 33591), and the select agents Yersinia pestis (CO92), 
Brucella melitensis (16M),  Brucella abortus (2308), Brucella suis (ATCC 23445), Bacillus 
anthracis AMES, Francisella tularensis (SCHU-S4), Burkholderia mallei (ATCC 23444) and 
Burkholderia pseodomallei (BURK003 1026b). 77 The exact results for each peptide will be 
discussed further in their corresponding sections. 
To determine the role the Tic-Oic unit played, compounds were synthesized that either 
deleted the Tic or Oic units completely or replaced them with glycine, or the less 
conformationally restrained phenylalanine.13 Spacer #1 refers to the amino acid residues between 
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the Tic-Oic unit and the following positively charged or hydrophobic amino acid residues. They 
were systematically substituted with natural and unnatural amino acids to lengthen the peptide 
backbone in an attempt to investigate the effects of varying the distance between functional 
groups on selectivity and potency for the different bacterial strains. Compound 23 incorporated a 
one carbon spacer, glycine, in the backbone. Unnatural amino acids including β-alanine (βAla), 
γ-aminobutyric acid (Gaba) and 6-aminohexanoic acid (Ahx) were used to replace glycine in 
order to lengthen the chain from a one-carbon atom to two, three and five, respectively. Because 
the spacers control the distance between the Tic-Oic units as well as the distance between the 
positive and hydrophobic residues, they play a major role in determining the conformational 
flexibility of the peptide. An increase in spacer length adds conformational flexibility to the 
backbone, while the absence of a spacer causes a decrease in flexibility, inducing a helical 
conformation onto the peptide.  
The positively charged amino acid of the peptide is referred to as spacer #2. It defines the 
distance from the side chain terminal amine group, the positive charge, to the peptide backbone. 
Analogues were synthesized to test the importance of this distance by incorporating the unnatural 
amino acids ornithine (Orn), diaminobutyric acid (Dab) and diaminopropionic acid (Dpr) to 
decrease the number of methylene groups from four, as with lysine in compound 23, to three, 
two and one, respectively. Another possibility is the incorporation of arginine (Arg) which 
contains a guanidinium group at the end of its side-chain. In this planar group the positive charge 
is delocalized over two different nitrogen atoms, therefore allowing the positive charge to 
disperse more compared to the localized positive charge on the one nitrogen of the Lys side 
chain amino group. 78, 79   
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Positively charged residues, as previously mentioned, are placed throughout the peptide 
backbone as Spacer #2, but there is also a cluster of positive charge at the C-terminus in our 
parent compound. For compound 23, there are four lysine residues concentrated at the C-
terminus. The positive charges are the driving force behind moving the peptide from the bulk 
solution to the surface of the membrane, thus, several analogues were synthesized changing the 
number of lysines grouped together as well as their location to help determine their significance. 
Analogues with 3 and 5 lysines at the C-terminus were synthesized, as well as an analog with 
four lysines at the N-terminus. 
Spacer #3 refers to an amino acid between the last Tic residue and the lysine cluster at the 
C-terminus. This residue is not always included, but when it is included it usually consists of the 
same amino acid residue as Spacer #1. This particular spacer provides molecular flexibility 
between the last conformationally restrained dipeptide and the cluster of positively charged 
amino acid residues located at the C-terminus.   
Most present day antibiotics kill bacteria via target:receptor interactions. For a peptide to 
interact with a receptor it must adopt a specific conformation with a specific stereochemistry that 
meets the special physicochemical requirements of the receptor. To insure that our peptides are 
not involved in a receptor mediated event and indeed kill the bacteria by disrupting the cell 
membrane two analogues were synthesized incorporating D-amino acids. By incorporating (D)-
amino acids into the peptide backbone, we are changing the orientation of the peptide. If the 
peptide were to exhibit its antibiotic activity via a receptor mediated event, the change in 
stereochemistry and conformation would result in a loss in activity. However, these analogues 
exhibited the same activity as compound 23 which contains all (L)-amino acids,13 proving they 
do not bind to a receptor. 
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Table 1.2: Amino acid sequences of previously synthesized peptides containing three               
Tic-Oic dipeptide units that are pertinent to this research 
Compound Amino Acid Sequence
14 Ac-GK-Tic-Oic-GLGKE-Tic-Oic-GLGK-Tic-Oic-ELMGER-CONH2
23 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK-CONH2
29 Ac-Gaba-F-Tic-Oic-Gaba-K-Tic-Oic-Gaba-F-Tic-Oic-Gaba-K-Tic-KKKK-CONH2
34 Ac-GF-G-Oic-GK-G-Oic-GF-G-Oic-GK-G-KKKK-CONH2 
36 Ac- βAla-F-Tic-Oic-βAla-K-Tic-Oic-βAla-F-Tic-Oic-βAla-K-Tic-KKKK-CONH2
37 Ac- Ahx-F-Tic-Oic-Ahx-K-Tic-Oic-Ahx-F-Tic-Oic-Ahx-K-Tic-KKKK-CONH2
39 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKKK-CONH2 
43 Ac-GF-Tic-Oic-G-Orn-Tic-Oic-GF-Tic-Oic-G-Orn-Tic-Orn-Orn-Orn-Orn-CONH2
45 Ac-GF-Tic-Oic-G-Dpr-Tic-Oic-GF-Tic-Oic-G-Dpr-Tic-Dpr-Dpr-Dpr-Dpr-CONH2
46 Ac-βAla-Fpa-Tic-Oic-βAla-Dpr-Tic-Oic-βAla-Fpa-Tic-Oic−βAla-Dpr-Tic-Dpr-Dpr-Dpr-Dpr-CONH2
50 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-βA-KKKK-CONH2
51 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-Gaba-KKKK-CONH2
52 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-Ahx-KKKK-CONH2
53 Ac-GF-Tic-Oic-G-Dab-Tic-Oic-GF-Tic-Oic-G-Dab-Tic-Dab-Dab-Dab-Dab-CONH2
56 Ac-GF-Tic-Oic-GR-Tic-Oic-GF-Tic-Oic-GR-Tic-RRRR-CONH2
61 Ac-KKKK-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-CONH2
64 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKK-CONH2
 
 
 
 
Instrumentation 
Circular Dichroism 
Circular Dichroism spectroscopy measures the differential absorbance of right- and left-
circularly polarized light by a substance.80, 81 The presence of an asymmetric chromophore is 
required for optical activity. For peptides, this chromophore is the amide bond. A chiral molecule 
interacts differently with right- and left-circularly polarized light at certain wavelengths due to 
differences in the extinction coefficients of the two polarized rays giving way to both positive 
and negative spectral components.68, 81 It is the three-dimensional spatial orientation of the amide 
chromophores, which affects the spectrum of the peptide.68  Circularly polarized light is obtained 
by the superposition of two perpendicular plane-polarized waves of equal amplitude and 
wavelength, but are 90o out of phase. When the waves are 90o out of phase, one wave is at its 
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peak when the other one is just crossing the zero line. When viewed along the direction of 
propagation, or looking toward the light source, the electric vector will appear to be following a 
circular path as the magnitude of the oscillation remains constant and the direction oscillates.  If 
the electric vector is rotating in a clockwise direction, the light is said to be right-circularly 
polarized and for a counter-clockwise direction, left-circularly polarized.81, 82 
Circular dichroism has been used to aid in the characterization of changes in the 
secondary structures of peptide in different membrane environments.83, 84   Some of these 
secondary structures include α-helix, β-sheet, β-turn and random coil. These structures give 
characteristic spectra that, in an ideal situation, can be used to determine the percentage of each 
structure in other compounds.81  However, due to the incorporation of un-natural amino acids 
and the lack of knowledge regarding these residues, quantifying the secondary structures of our 
peptides has proven to be difficult. We have, consequently, used CD as more of a qualitative tool 
and compared the overall changes in the spectra in comparison to each other. For instance, 
peptides that exhibit activity in the presence of bacteria cells, but show little to no activity in the 
presence of mammalian red blood cells should, theoretically, adopt different secondary structures 
in the presence of anionic and zwitterionic membrane models. Thus, we should observe different 
CD spectra in the presence of anionic and zwitterionic membrane models. 
 
Isothermal Titration Calorimetry 
Isothermal titration calorimetry (ITC) is a thermodynamic technique that monitors any 
chemical reaction initiated by the addition of a binding component and has been the method of 
choice for characterizing biomolecular interactions.39, 58, 85-87 An isothermal titration calorimeter 
is a system with two identical cells, a reference and reaction cell, surrounded by an adiabatic 
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jacket to ensure that no heat is gained or lost to the system. The reference cell is filled with water 
or buffer and the reaction cell will contain the macromolecule solution. The two cells are 
equilibrated at the same temperature before the experiment starts. In general, a liquid solution of 
a “ligand” is titrated into the reaction cell which is filled with a liquid solution of the 
“macromolecule,” in our case peptide and liposomes, respectively. The ligand is titrated using a 
syringe that continuously spins in order to ensure proper mixing and distribution of ligand, 
(Figure 1.4) There is a temperature change associated with the binding of the ligand to the 
macromolecule.88  
 
Figure 1.3: Schematic diagram of an ITC instrument.  Figure adapted from Pierce et. al88, 89 and 
the MicroCal User’s Manual.88 
 
 
 
 
The direct observable measured is the time-dependent input of power required to 
maintain equal temperatures in the cells. For an exothermic reaction, heat is evolved causing the 
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temperature in the sample cell to increase. The heat created by the reaction provides the heat 
needed to keep the cells the same temperature, thus, the feedback power is deactivated and a 
negative peak is produced.88, 89 Exothermic reactions occur when components come together and 
bind, such as the electrostatic interactions of peptides on the membrane surface. For endothermic 
reactions, heat is absorbed and the reverse will occur. The feedback circuit will increase power to 
the sample cell to maintain equal temperatures and produces a positive peak. Examples of 
endothermic processes include the disruption of electrostatic interactions or liposome stability.88, 
89
 Due to the fact that the differential power (DP) has units of power, the time integral of the 
peak yields a measurement of thermal energy, ∆H. The heat that is released or absorbed is 
directly proportional to the amount of binding that takes place between the ligand and 
macromolecule. As the amount of available macromolecule diminishes, so does the heat signal. 
Once the macromolecule solution becomes saturated the only signal observed is that of the heat 
of dilution.88 
There are three different types of heat observed that contribute to the overall heat of 
reaction that should be accounted for. These observed heats include contributions from the 
dilution of the titrant and macromolecule, as well as a small contribution from stirring. Control 
experiments to account for the heats of dilution are performed by titrating peptide into a sample 
cell containing only buffer and vice versa. Identical control experiments should be performed 
with liposomes and buffer as well. The small contribution from stirring is taken into account 
automatically by the instrument.89 The calorimeter has a long equilibration that takes place 
before the experiment starts. During this equilibration time, the syringe generates heat while 
stirring continuously. The calorimeter compensates for this heat.88 
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In an ideal case, one can obtain three pieces of thermodynamic data from a single 
experiment, the binding constant (Kb), the reaction stoichiometry (n), and the enthalpy (∆H) of 
the binding association from one ITC experiment (Figure 1.5).88, 90   
 
Figure 1.4: An ideal ITC experiment for the titration of lipid into peptide. The top panel shows 
the baseline-smoothed raw data plotted as mcal/sec versus against time. The bottom panel 
represents the integrated heat for each injection versus the molar ratio. The molar ratio for the 
experiment is the concentration of the lipid (titrant) compared to the concentration of the peptide 
(cell). Figure was adapted from Grossoehme et al.91 
 
 
 
 
By using some simple equations and the experimentally determined enthalpy and binding 
constant, it is possible to determine the Gibbs free energy (∆G) and entropy (∆S) of the reaction. 
Using the binding constant (Kb) and the following Equation 1.1, one can calculate ∆G89, 90: 
∆G = -RTln(55.5K)      (1.1) 
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where R is the gas constant (1.987 cal·K-1·mol-1) and T is the temperature in Kelvin. The factor 
55.5 is the molar concentration of water and is incorporated to correct for the cratic 
contribution.5, 92, 93 Now that ∆G is known, it’s possible to calculate ∆S from the Equation 1.2 
below89, 90: 
∆G = ∆H – T∆S               (1.2) 
Gibbs free energy can help predict how favorable or unfavorable a reaction is, whether it will 
proceed spontaneously or not. If ∆G > 0, the forward reaction is energetically unfavorable and 
the reverse reaction is therefore energetically favored and will proceed spontaneously. If ∆G = 0 
the system is at equilibrium and there is no further change without external stimulus. If ∆G < 0 
then the forward reaction is energetically favorable and will proceed spontaneously. The 
enthalpy of a reaction, ∆H, is the heat evolved or absorbed by the reaction. A positive ∆H means 
the reaction is endothermic, absorbs heat, and is unfavorable. Endothermic reactions give off 
heat resulting in a negative ∆H and a favorable reaction. The second law of thermodynamics 
states that no process will occur spontaneously unless it is accompanied by an increase in the 
entropy of the universe. Entropy refers to the disorder of a system. A positive ∆S and a favorable 
reaction will go towards a more disordered outcome, for example, NaCl dissociating into Na+ 
and Cl-. The reverse of this reaction, the creation of salt, would be an unfavorable reaction with a 
negative ∆S.94 
In order to obtain thermodynamic information mentioned above, the data must be fit to a 
model and there are two different models to consider. One model does not take into account the 
electrostatic interactions between the peptide and membrane surface, while the second does.58, 86 
The former model is the simpler of the two and involves the partitioning of the peptide between 
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the aqueous phase and the lipid membrane, if one assumes the following Equation 1.3 from 
Wieprecht and Seelig 86 is a linear relationship: 
Xb = Kpcf              (1.3) 
where Xb is the molar ratio of membrane-bound peptide per lipid, cf is the concentration of free 
peptide in solution and Kp is the partition coefficient. The Xb and cf can be calculated using the 
following equations. The standard molar reaction enthalpy, ∆H0, is determined from the 
experimental data and Equation 1.4.72, 86    
   ∑=∆
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where δhi are the raw heats of each injection  in µcal after the heats of dilution have been 
subtracted, also known as the corrected heats, 0pepc  is the total peptide concentration (mol/mL) 
and Vcell is the volume of the calorimeter cell (1.4602 mL). Once the reaction enthalpy has been 
calculated, the binding isotherm is derived. After i injections, the fraction of peptide bound to 
lipid vesicles, )(
,
i
bPX  can be found using the Equation 1.5 below:
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δ is the sum of the first k reaction heats in µcals. The 
concentration of free peptide remaining in the bulk solution, )(ifc , after each injection is calculated 
by using Equation 1.6  below72, 86 
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where )(idilf  is the dilution factor. It takes into account the increase in volume after each  
 
injection of lipid vesicle72, 86 and is defined by Equation 1.7. 86 
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injV  is the volume of each injection. The degree of binding, Xb , can then be defined as  
 
the fraction of bound peptide (mmol) per mole of total lipid in the cell and can is  
 
determined using Equation 1.8 From Wieprecht and Seelig72, 86 
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 where 0Lc is the concentration of the lipid stock solution that is injected into the calorimeter cell. 
A plot of Xb versus cf should yield a linear curved that would fit the binding isotherm model 
described by Equation 1.3. However, this is not the case for our peptides as we observe a 
bending in the curves. Our peptides are positively charged and electrostatic interactions should 
be accounted for, which they are not using this particular model.  
The second model, however, does consider electrostatic interactions. As mentioned, our 
peptides carry a positive charge and the net charge of the liposomes may be neutral or negative 
depending on if the model is zwitterionic or anionic making this model more relevant for our 
analysis. The negative charges of the membrane attracts the positively charged residues of the 
peptide resulting in increased peptide concentration at the surface of the membrane, cm, in 
comparison to the bulk solution, cf. 90 This being said, the following Equation 1.9 86, 95-97  is 
more appropriate for the analysis of our data 
  Xb = Kcm      (1.9) 
26 
 
For  negatively charged membranes, as the concentration of peptide at the surface 
increases, the surface potential and the electrostatic attractions between the membrane and 
peptide consequently decreases, resulting in a decrease in the degree of binding, Xb, and the 
downward-bending of the isotherm.92, 95-97 A similar effect can be seen for neutral membranes. In 
the absence of peptides, the membrane surface potential is essentially zero. The binding of 
positively charged peptide on the surface of a neutral membrane causes the surface potential to 
become positively charged. This results in the repulsion of other peptides which becomes 
stronger as the peptide concentration on the surface increases, hence cm < cf.86, 98, 99 In order to 
account for the electrostatic effects, the surface concentration cm must be calculated. This value 
depends on the free peptide concentration in the bulk solution (cf), the charge of the peptide (z) 
and the membrane surface potential (ψ0) and it can be calculated using the following Boltzmann 
distribution (Equation 1.10).  
  cm = cf exp (-zF0ψ0/RT)          (1.10) 
where F0 is the Faraday constant and RT is the thermal energy (J/mol). Unfortunately,  the 
membrane surface potential, ψ0, cannot be measured directly and must be calculated based on its 
connection to the surface charge density, σ. The surface charge density for the binding of the 
electrically neutral POPC membrane with positively charged peptides can be calculated as 
follows according to Equation 1.11.97, 99-101  
)]/(1/[()/( 0 LPbLbp AAXAXez +=σ       (1.11) 
where zp is the effective valency of the peptide (+6 with 6 lysines), e0 is the elementary 
electric charge (1.60218 x 10-16 mC), and AL is the average surface area of a POPC  
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molecule (estimated to be 68 Å.)97, 99-101  The cross-sectional area of the peptide, AP, varies with 
peptide and can only be approximated from inspection with molecular modeling. The Ap for 
compound 23 was used for each of the peptides studied in these investigations. The ratio of 
AP/AL takes into account the possibility of penetration of the peptide into the membrane.101 The 
surface charge density is linearly related to the extent of binding Xb, and once it has been 
calculated, the surface potential, ψ0, can be calculated using the Gouy-Chapman theory described 
by Equation 1.12. (for reviews see Aveyard102, and  McLaughlin 103, 104)         
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In Equation 1.12, ci refers to the concentration of the ith electrolyte in the bulk aqueous phase, 
including buffer, peptide, and negatively charged phospholipids, and zi is the signed valency 
associated with the ith species. The remaining symbols are constants. ε0 is the electric 
permittivity of free space (8.8542 x 10-9mF/m) and εr is the dielectric constant of water. By 
combining Equations 1.8 and 1.9 and calculating the surface charge density from the 
experimentally obtained Xb, the membrane surface potential can be calculated using a number of 
computer programs such as Maxima, as used for our calculations. Once ψ0 is known, cM can be 
calculated. Plotting Xb versus cm, the K can finally be obtained as it is the slope of the line. With 
the experimentally obtained ∆H and the calculated binding constant, K, ∆G and ∆S can be 
calculated using Equations 1.1 and 1.2.89, 90 
 
Calcein Leakage Assays 
Fluorescence is a spectrochemical method of analysis where the molecules of an analyte, 
or fluorophore, are excited by irradiation at a certain wavelength and emit radiation of a different 
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wavelength.  The fluorophore for our research is calcein, which is encapsulated by liposomes at 
self-quenching concentrations. The solution of liposomes is treated with an AMP solution and 
the resulting fluorescence is measure as the calcein leaks out.  
Calcein is self-quenching at very high concentrations, in other words, the fluorescence 
decreases with increasing calcein concentration. As can be seen in Figure 1.6, when at self-
quenching concentrations, calcein is red and does not fluoresce. Once the liposomes are treated 
with peptide and leakage is induced, the calcein is diluted in the surroundings. Once the calcein 
is diluted below self-quenching concentrations and fluoresces. It is the increase in this 
fluorescence that is measured over a period of time. 
 
 
Figure 1.5: Schematic of peptide-induced calcein leakage from liposomes. Peptides bind to 
liposomes filled with calcein at self-quenching concentrations (left). As the peptide concentration 
increases, the membrane begins to disrupt (middle). At high peptide to lipid concentrations, the 
peptides insert into the bilayer causing calcein to leak into its surroundings (right). As the calcein 
is diluted, the concentration is decreased below self-quenching concentrations and fluoresces.  
 
 
 
 
The AMP-induced leakage of fluorescent dyes entrapped in LUVs of different phospholipid 
compositions, such as calcein, is a widely used method for assessing the relative potency of 
peptides for disrupting the integrity of the lipid bilayer membranes and thus for predicting their 
antimicrobial and hemolytic activities.  12, 15, 105-110 
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CHAPTER TWO: MATERIALS AND METHODS 
 
 
Materials 
 
Monobasic and dibasic sodium phosphate, EDTA and sodium chloride (NaCl) were 
purchased from Fischer Scientific. Bis-tris and SDS (Figure 2.1 – top) were obtained from 
Sigma-Aldrich. All chemicals were of analytical or reagent grade and used without further 
purification. POPC (Figure 2.2 – bottom), POPG (Figure 2.2 – top) and DPC (Figure 2.1 – 
bottom) were purchased from Avanti Polar Lipids (Alabaster, AL).  High purity calcein (Figure 
2.3) was purchased from Invitrogen and used as obtained without further purification. All buffers 
and solutions were prepared using distilled water. Some peptides were purchased from the 
Peptide Core Facility in the School of Medicine of the University of North Carolina at Chapel 
Hill, Chapel Hill, NC. Other peptides were synthesized by the Division of Experimental 
Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland.  
 
 
Figure 2.1: Chemical structures of lipids used for micelle membrane models. SDS (top) was 
used as a simple anionic model and DPC (bottom) was used as a simple zwitterionic model. 
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Figure 2.2: Chemical structures of lipids used for micelle membrane models. POPG (top) was 
used as the anionic component for the bilayer membrane models and POPC (bottom) was used as 
the zwitterionic component. 
 
 
 
 
Figure 2.3: Chemical structure of calcein. 
 
 
 
 
Biological Testing 
 
Biological assays for the following bacteria strains were tested by MDS Pharma: 
Salmonella typimurium (ATCC 13311), Staphylococcus aureus ME/GM/MTC resistant bacteria 
(ATCC 33592), Mycobacterium ranae (ATCC 110) and Bacillus subtillis (ATCC 43223). 
Biological assays for the following select agents and other drug resistant bacteria were tested by 
the Division of Bacterial and Rickettsial Diseases at Walter Reed Army Institute of Research: 
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Acinetobacter baumanii (ATCD 19606), Acinetobacter baumanii (WRAIR), Staphylcoccus 
aureus-MRSA (ATCC 33591), Yersinia pestis (CO92), Brucella melitensis (16M), Brucella 
abortus (2308), Brucella suis (ATCC 23445), Bacillus anthracis (AMES), Francisella tularensis 
(SCHU-S4), Burholderia mallei (ATCC 23444) and Burkholderia pseudomallei (BURK003). 
 
Preparation of Liposomes 
 
 
POPC and 4:1 POPC/POPG Liposomes for CD and ITC experiments 
 
For POPC LUVs, a defined amount of dried lipid was weighed and suspended in buffer 
(40 mM sodium phosphate, pH = 6.8) and spun for 30 minutes. The 4:1 POPC/POPG (mol to 
mol) LUVs were prepared by first dissolving a defined amount of POPC and POPG, separately, 
into chloroform. The lipids in chloroform were then mixed at a molar ratio of 4:1, vortexed and 
dried under a steady stream of nitrogen. Once dried, the mixed liposomes were suspended in the 
phosphate buffer and spun for 30 minutes. The liposomes used for CD and ITC were prepared by 
extrusion via a Mini-Extruder (Avanti Polar Lipid Inc).1-3 The lipid solutions were passed 21 
times through a stack of 4 polycarbonate support filters, with a 100 nm pore size polycarbonate 
membrane in the middle. Kennedy and co-workers4 have previously reported that passing the 
liposome solution through the membrane 21 times as described resulted in a homogeneous 
population of LUVs with >95% of the particles falling into the size range of 70-100 nm.4 The 
final lipid concentration was calculated based on the weight of the dried lipid.5-10 
 
 
POPC and 4:1 POPC/POPG Liposomes for Dye Release Experiments 
 
High purity calcein was dissolved in buffer (10 mM Bis-Tris, 150 mM NaCl, 1 mM 
EDTA, pH = 7.1) at self-quenching concentrations (70 mM). Once hydrated, the pH of the 
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calcein-containing buffer was adjusted using 3 mM NaOH. A defined amount of dried lipid was 
hydrated with the calcein-containing buffer to give a starting concentration of 35 mM and 
vortexed for one minute. POPC LUVs were used as obtained. The 4:1 POPC/POPG liposomes 
were made as described above. Both LUV solutions were prepared by the same extrusion process 
as described above and the final volume after extrusion was noted, approximately 300 µL. 
Unencapsulated calcein was removed by gel filtration on a Sephadex G50 column (eluent: buffer 
10 mM Bis-Tris, 150 mM NaCl, 1 mM EDTA, pH = 7.1). Once the sample was added to the 
column, the fraction with the calcein-encapsulated liposomes separated out first as a band that 
was light orange in color. The unencapsulated calcein, along with liposomes containing no 
calcein, formed three bands, two yellow bands with a red one in the middle, Figure 2.4.  
The fraction of calcein-encapsulated LUVs was collected and retained for fluorescence 
studies, taking note of the final volume. The final lipid concentration was calculated based on 
dilution by the column using the volumes before and after separation. To ensure self-quenching 
efficiency (Q) of each lipid solution, the following equation was used: Q = [1- (F0/FT)] x 100% 
where F0 and FT are the fluorescences before and after treatment with 10uL of 10% Triton X, 
respectively.  The minimum Q value used was 80%.5-9, 11-14 
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Figure 2.4: Gel filtration for the separation of calcein-encapsulated LUVs using a G50 Sephadex 
column (eluent: buffer 10 mM Bis-Tris, 150 mM NaCl, 1 mM EDTA, pH =7.1). 1) A clean 
column before the separation process has begun. 2) Recently extruded solution of calcein-
encapsulated LUVs is added all at once to the top of the column. 3 – 5) Fraction containing only 
calcein-encapsulated LUVs separates out as an orange band. Free calcein and LUVs not 
containing calcein remain in yellow and red bands. 6) Separation is complete and fraction 
containing only calcein-encapsulated LUVs is collected.   
 
 
 
 
Circular Dichroism 
 
 
CD Parameters 
All CD spectra were obtained by acquiring 8 scans from 260 to 178 nm on a Jasco J-815 
spectrometer (equipped with Jasco SOFTWARE V) using a 0.1 mm pathlength cylindrical quartz 
cell (Starna Cells, Atascadero, CA) at a speed of 20 nm/min, a 1 nm bandwidth, a data pitch of 
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0.2 nm, response time 0.25 sec and 5 mdeg sensitivity at room temperature (~25ºC) in a 
continuous scanning mode. Contributions due to LUVs were eliminated by subtracting the lipid 
spectra of the corresponding peptide-free suspensions.6, 7 All analysis of CD spectra were 
conducted after smoothing (Means-movement with convolution width of 5-25) and conversion to 
molar ellipticity using the JASCO Spectra Analysis program.1, 14, 15 
Due to the high percentage of unnatural amino acids that are incorporated into our 
peptides, no quantitative estimation of secondary structural features is possible.  Analysis of CD 
spectra will be limited to qualitative comparisons highlighting differences in the spectra of this 
series of compounds.  Reference to α-helical or β-turn structures are based on comparisons with 
published CD spectra of peptides and are used only as a qualitative discussion.   
 
Peptide in buffer and micelle environments 
 
Conformations of the peptides were studied in several different environments. First, 
peptides were weighed and dissolved in 40 mM phosphate buffer (pH = 6.8) to give a final 
concentration of 1 mg/mL in order to observe their natural states.  Binding studies were 
conducted by hydrating dried peptide with either 80 mM SDS or DPC micelles in 40 mM 
phosphate buffer (pH = 6.8) to give an overall peptide concentration of 1 mg/mL.  
 
Peptide in LUV environments 
 
 Binding studies in the presence of LUVs were conducted by hydrating dried 
peptide with either 1.75 mM POPC or 4:1 POPC/POPG LUVs in 40 mM phosphate buffer (pH = 
6.8). LUVs (100 nm liposomes) were selected instead of small unilamellar vesicles (SUVs) 
because they are considered to be more closely related to biological membranes. LUVs are not 
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subject to the increased curvature stress associated with SUVs 6, 16 resulting in metastability and 
an increase in irregular peptide binding.16, 17 The exact concentrations of peptide used for these 
experiments are given in Table 2.1.  
Table 2.1: The concentration (µM) used for each peptide of the different series for the 
interactions with POPC and 4:1 POPC/POPG LUV membrane models as studied by CD. 
Compound POPC 4:1 POPC/POPG
23 200 200
23 75 100
36 75 100
29 75 100
37 75 100
23 75 200
43 100 200
53 100 200
45 100 200
56 100 200
23 75 200
50 100 200
51 100 200
52 100 200
23 75 100
39 100 100
64 100 100
61 100 100
23 200 100
14 200 100
34 200 75
23 75 100
46 100 100
All Unnatural Amino Acids
Parent
Spacer 1
Spacer 2
Spacer 3
Placement of Lys
Negative Control 
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 The HT [V] values and UV spectra of compound 23 in the presence of 1.75, 7.0 and 10.5 
mM POPC (left) and 4:1 POPC/POPG LUVs (right) are given in Figures 2.5 and 2.6, 
respectively. Compound 23 serves as the reference for interference caused by LUVs in CD 
studies. CD spectra should maintain a high tension (HT) voltage below 600 V for the study of 
peptides to ensure that the detector is not saturated. Also, work of Ladokhin and co-workers has 
shown that undistorted CD studies can be obtained in the presence of up to 3 mM LUVs above 
200 nm and in the presence of 7 mM LUVs above 215 nm as long as the absorbance of the 
uncorrected (without subtraction of buffer) spectra remained below 1.5 AU.16 Clearly the 
uncorrected (no subtraction of buffer etc.) absorbance at all three LUV concentrations remained 
below 1.5 AU at a wavelength above 200 nm which based on the work of Ladokhin and co-
workers allows for a qualitative comparison of the CD spectra.16 However, for the purpose of our 
studies in the presence of a constant LUV concentration, we will use 1.75 mM to ensure 
qualitative data below 200 nm.16 
 
Figure 2.5: Representative HT [V] values of 75 µM compound 23 in POPC (left) and 100 µM 
compound 23 in 4:1 POPC/POPG LUVs (right).  
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Figure 2.6: Representative optical density, absorbance values, of 75 µM compound 23 in POPC 
(left) and 100 µM compound 23 in 4:1 POPC/POPG LUVs (right).  
 
 
 
 
CD “pseudo” titration experiments 
 
CD spectra were recorded for separate peptide samples with increasing concentrations of 
liposomes using the parameters previously discussed. 2, 8 Stock solutions of peptide (150 – 400 
µM) and liposomes (35 mM) were prepared. Separate samples were prepared by first, taking 100 
µL of the peptide stock solution and diluting it with varying amounts (0-100 µL) of 40 mM 
sodium phosphate buffer, pH = 6.8. Corresponding volumes of the liposome stock solution were 
then added to give a final sample volume of 200 µL resulting in an overall peptide concentration 
that was half the concentration of the stock solution. A sample calculation chart of the “pseudo” 
titration samples can be seen below in Table 2.2. The final concentrations for each peptide used 
in the “pseudo” CD titrations are given in Table 2.3.  
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Table 2.2: Sample calculation chart for the composition of samples used for the “pseudo” CD 
titration experiments. 
Sample Total Vola Pep Volb Lip Volc Buf Vold [Pep]e [Lip]f L/Pg
0 200 100 0 100 0.1 0 0
1 200 100 5 95 0.1 0.875 8.75
2 200 100 10 90 0.1 1.75 17.5
3 200 100 20 80 0.1 3.5 35
4 200 100 30 70 0.1 5.25 52.5
5 200 100 40 60 0.1 7 70
Total 1200 600 105 495
 
a
 Total volume (µL) of sample. b Volume (µL) of peptide. c Volume (µL) of 35 mM lipid 
solution. d Volume (µL) of 40 mM phosphate buffer, pH = 6.8. e Final concentration (mM) of 
peptide in sample. f Overall concentration (mM) of lipid in sample. g Lipid to peptide ratio. 
 
 
 
Table 2.3: The final peptide concentration (µM) used for the “pseudo” CD titration studies with 
POPC and 4:1 POPC/POPG LUV membrane models.  
Compound  POPC 4:1 POPC/POPG
23 200 200
36 75 100
29 75 100
37 75 200
43 100 200
53 100 200
45 200 200
56 100 100
50 100 200
51 100 200
52 100 200
39 100 100
64 100 200
61 100 100
14 100 100
34 200 75
46 100 100
All Unnatural Amino Acids
Parent
Spacer 1
Spacer 2
Spacer 3
Placement of Lys
Negative Control 
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Isothermal Titration Calorimetry 
 
ITC Parameters 
 
Data was acquired using a Microcal VP-ITC calorimeter (Microcal, Norhampton, MA). 
All experiments were run in 40 mM sodium phosphate buffer, pH = 6.8, and at a temperature of 
25 ºC with a stirring speed of 220 rpm. All solutions were degassed for approximately 10 
minutes under vacuum before running the experiments.   
 
Full Titration Experiment 
 
Full titrations refer to the ITC experiments that are carried out until only the heat of 
dilution was observed and all of the peptide is assumed bound. Experiments included 15 µL 
injections of 35 mM liposomes into excess peptide (50 – 200 µM). The exact peptide 
concentrations used are listed in Table 2.4. Injection durations were 30 s with 700-800 sec 
spacing between individual injections to ensure complete equilibration. The heat of dilution was 
determined by injecting LUV solutions into peptide-free buffer. This heat was subtracted from 
the heat evolved from the interactions between the liposomes and peptide. Data was analyzed 
with the Origin® software (version 7). ITC experiments were duplicated to ensure 
reproducibility.1, 5, 6, 8, 9, 11, 18, 19  
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Table 2.4: The concentration of each peptide (µM) used during the full ITC titration studies.  
The reaction cell was filled with the peptide solutions and titrated with either 35 mM POPC or 
4:1 POPC/POPG LUVs in buffer. 
Compound POPC 4:1 POPC/POPG
23 200 200
36 50 50
29 100 100
37 50 200
43 200 200
53 200 200
45 200 300
56 100 100
50 50 200
51 100 200
52 100 200
39 200 200
64 100 200
61 100 200
14 100 100
34 200 50
46 100 200
All Unnatural Amino Acids
Parent Compound
Spacer 1
Spacer 2
Spacer 3
Placement of Lys
Negative Control
 
 
 
 
 
Single Injection Experiments 
 
 Data from the full injection experiments with 4:1 POPC/POPG LUVs could not be fit to a 
current model, therefore, we were unable to obtain quantitative thermodynamic information. 
However, by performing single injection experiments we were able to determine the ∆H values 
that correspond to the two extremes of the peptide and lipid interaction, binding and membrane 
disruption and should not be confused with ∆H0, the enthalpy of the entire reaction. 
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To determine the ∆H of binding at very high L/P ratios, dilute solutions of peptide (100 – 
200 µM) were titrated into solutions of excess liposomes (15 – 30 mM). Single injection 
experiments were also performed in the opposite direction. Dilute solutions of liposomes (5 – 20 
mM) were titrated into solutions of excess peptide (300 – 400 µM) to determine the ∆H of 
membrane disruption.11, 19-24  The exact concentrations used for each experiment are included 
with the figure in the body of the text. 
 
Calcein Leakage Assays  
 
Peptide-induced calcein leakage was investigated using an ISS PC1 photon counting 
spectrofluorometer (ILC Technology) at an excitation wavelength of 494 nm and an emission 
wavelength of 518 nm. An aliquot of 1.0 mM peptide (10 – 50 µM) in buffer (10 mM Bis-Tris, 
150 mM NaCl, 1 mM EDTA, pH = 7.1) was added to the cell (1.0 cm quartz cuvette) containing 
2.5 mL of liposomes (36.6 µM) to give an overall peptide concentration of 4-20 µM. The 
intensity, FI, was measured every minute for the first 20 minutes of the experiment and every 10 
minutes after until the emission intensity leveled off, approximately 90 minutes. One hundred 
percent leakage, FT, was determined with the addition of 10 µL of 10% (v/v) Triton X. The 
apparent percent leakage was calculated using the following equation: % leakage = [(FI- F0)/FT)] 
x 100 %, where F0 and FT are the fluorescence before introduction of peptide and after the 
addition of Triton X, respectively.1, 5, 7, 12, 13, 25  Representative emission spectra as the time 
increases is given in Figure 2.7. 
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Figure 2.7: Representative spectra of peptide-induced calcein leakage as time increases. At 0 
minutes (black), only calcein-encapsulated 4:1 POPC/POPG LUVs were present. An aliquot of 
the peptide stock solution was added. The fluorescence was measured every minute for the first 
20, then every 10 minutes for a total of 90 minutes. The intensity increased with time.  
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CHAPTER THREE: COMPOUND 23 
 
Introduction 
 As mentioned in Chapter 1, we chose compound 23 with the amino acid sequence Ac-
GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK-CONH2 as the reference peptide due to its 
previously reported high antibacterial activities against Salmonella typhimurium, Staphylococcus 
aureus, Mycobacterium ranae and Bacillus subtillis (Table 3.1).1 Compound 23 was also tested 
in several select agent assays where it showed activity against Acinetobacter baumanii and 
Bacillus anthracis (Table 3.2).2 This peptide also exhibited a therapeutically acceptable 
maximum tolerated dose of 125 mg/kg in a standard mouse toxicity model. 1 The parent 
compound, 23, has been extensively studied via CD, ITC and fluorescence spectroscopy in the 
presence of anionic and zwitterionic micelle and bilayer membrane models.3 
 
Table 3.1: Minimum inhibitory concentration (µM) and hemolytic activity of selected bacteria 
strains1 
Compound Salmonella 
typhimurium
Staphylococcus aureus 
ME/GM/TC resistant
Mycobacterium 
ranae
Bacillus 
subtillis
% hemolysis 
100/25 µM
23 10 3 10 1 14%
 
 
 
 
AMPs are known to exist in many different conformers depending on their local chemical 
environment.4, 5 In the presence of membrane model systems these conformers include 
monomeric peptides in solution as well as surface bound (S-state) and membrane inserted (I-
state) oligomers, the latter being associated with pore formation.6-8 Previous computational 
studies conducted by Bhonsle and co-workers 9 has shown that compound 23  adopts a back to 
back turn conformation in the gas phase with an overall shape similar to a loose helical structure. 
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It is therefore reasonable to assume that compound 23 will adopt an ordered structure when in 
the presence of micelles or LUVs. In an effort to understand the observed biological cell 
selectivity and to improve the selectivity and potency of these peptides CD, calcein leakage 
assays and ITC were conducted to investigate the mechanisms of lipid binding of compound 23 
to zwitterionic and anionic liposomes. 
Table 3.2: Minimum inhibitory concentrations (µM) of specific Gram negative and other drug 
resistant bacteria strains.2 
 
Compound 23
Acinetobacter baumanii 
ATCC 19606 3.2
Acinetobacter baumanii 
WRAIR 3.2
Staphylococcus aureus 
ATCC 33591 205
Yersinia pestis CO92 205
Brucella melitensis 16M 205
Brucella abortus 2308 205
Brucella suis 23444 205
Bacillus anthracis AMES 12.8
Francisella tularensis 
SCHUS4 100
Burkholderia mallei 205
Burkholderia pseudomallei 205
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Results and Discussion 
 
 
Structural Investigations of the Conformational Capacity of the Peptides 
 
 
 Importance of the order and stereochemistry of dipeptide unit. Three different tetra 
peptides were synthesized to observe the role of the Tic-Oic dipeptide unit in the secondary 
structures of the AMP developed in our laboratory. The amino acid sequences investigated were 
Ac-Ala-Tic-Oic-Ala-NH2, Ac-Ala-D-Tic-Oic-Ala-NH2, and Ac-Ala-Oic-D-Tic-Ala-NH2, and 
their CD spectra are given in Figure 3.1. The CD spectra of the tetra peptide Ac-Ala-Tic-Oic-
Ala-NH2 (black) exhibited an ordered turn as indicated by the double minima at about 205 and 
220 nm with a maximum at approximately 195 nm, which is consistent with the presence of β-
turn and helical conformers. 10-12 The tetra peptide Ac-Ala-D-Tic-Oic-Ala-NH2 (red) exhibited an 
ordered turn containing secondary structure as indicated by the double maxima in the CD 
spectrum at about 195 and 205 nm, and a minimum at 220 nm, which is consistent with the 
presence of possible β-turn conformers. 10-12 This observation is consistent with the NMR finding 
by Kyle and co-workers that when Tic and Oic are placed in positions i+1 and i+2 in a four 
sequence unit, a β-turn is induced. 13   The tetra peptide Ac-Ala-Oic-D-Tic-Ala-NH2 (blue) 
exhibits a maximum in the CD spectrum at about 220 nm, and a minimum at about 198 nm, 
which is consistent with random coil conformers. 10, 12 These three CD spectra served as 
experimental evidence that given the proper stereochemistry the Tic-Oic dipeptide unit can serve 
as a turn inducing unit. The dipeptide L-Tic-L-Oic induced a predominately α-helical 
conformation while the inversion of the stereochemistry of the Tic residue from L to D induced a 
β-turn. When the order of the Tic-Oic dipeptide is reversed, the dipeptide no longer induces turn 
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or helical structures proving that the order and stereochemistry of the Tic-Oic dipeptide is 
important in stabilizing a stable secondary structure on the larger peptide. 
 
Figure 3.1: CD spectra of tetrapeptides (1 mg/mL) in 40 mM phosphate buffer (left), pH = 6.8, 
and their corresponding HT values (right). The sequences were Ac-Ala-Tic-Oic-Ala-NH2 
(black), Ac-Ala-D-Tic-Oic-Ala-NH2 (red), and Ac-Ala-Oic-D-Tic-Ala-NH2 (blue).  
 
 
 
 
 TFE studies. All of the peptides in this investigation contain three Tic-Oic dipeptide units 
and to evaluate the order inducing capacity of these peptides, a series of CD spectra of 
compound 23 in trifluoroethanol (TFE) were collected. TFE is an organic solvent which induces 
maximum helicity for short polypeptides.14-17  Figure 3.2 displays the CD spectra observed when 
Compound 23 (1 mg/mL) is dissolved in varying ratios of TFE in 40 mM phosphate buffer (pH = 
6.8), ranging from 100% buffer (black) to 100% TFE (light blue).  The CD spectrum of 
Compound 23 in 100% phosphate buffer exhibits the most intense double minima
 
at 210 and 220 
nm, but the least intense below 200 nm, suggesting a mixture of β-turn and helical structures.  As 
the % of TFE increases, the intensity of the two minima above 200 nm decreases while the 
opposite occurs below 200 nm. The increase of intensity below 200 nm coupled with the shift 
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from ~196 nm in 100% buffer to ~193 nm in TFE suggests that the percentage of α-helical 
conformers in solution is also increasing.   This observation supports our hypothesis that the Tic-
Oic dipeptide unit, in an order inducing environment such as TFE, will induce conformational 
changes to obtain a stable secondary structure.   
 
Figure 3.2: Far-UV Circular Dichroism spectra of Compound 23 (1 mg/mL) dissolved in 
varying ratios of 40 mM phosphate buffer (pH = 6.8) and TFE, from 0% (black) to 100% TFE 
(light blue). 
 
 
 
 
Investigations of Secondary Structures Adopted by Compound 23 
 
Compound 23 in buffer and micelle environments. The CD spectra of compound 23 in 40 
mM phosphate buffer, and in the presence of 80 mM DPC in buffer and 80 mM SDS in buffer 
are shown in Figure 3.3.  In buffer, compound 23 exhibited a characteristic double minimum at 
about 210 and 220 nm which is consistent with the presence of helical and β-turn conformers.10, 
18
  The CD spectra of compound 23 in the presence of DPC micelles displayed a shift in λmax 
from approximately 195 to 190 nm and a shift in one of the minima from 210 to 203 nm. Also, 
59 
 
there was an increase in intensity at approximately 195 and 203 nm. The CD spectra of 
compound 23 in the presence of SDS and DPC micelles were very similar. However, there was a 
significant increase in intensity at the λmax and the double minima in SDS as compared to DPC 
suggesting an increase in α-helical components of the peptide. Both of the CD spectra in DPC 
and SDS micelles were different from the spectrum in buffer indicating they do interact with the 
micelle surfaces. The observed differences intensity of the CD spectra indicate that S-state bound 
conformations of these peptides to SDS and DPC micelles were different, as expected.   
 
 
Figure 3.3: CD spectra of compound 23 (1 mg/mL) in 40 mM sodium phosphate buffer, pH = 
6.8 (black), 80 mM DPC in buffer (red) and 80 mM SDS in buffer (blue). 
 
 
 
 
 Importance of anionic phospholipid concentration. All of the peptides were investigated 
in the presence of  zwitterionic and anionic membrane model systems. As previously mentioned 
in Chapter 2, LUVs were chosen because they are not prone to the curvature stress and 
metastability issues that are common for SUVs.18, 19  It has been documented that the extent of 
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the interaction between the peptides and the membrane model depends on the composition of the 
membrane. 20, 21 To confirm this hypothesis, spectral data was collected of compound 23 in the 
presence of 10 mM mixed POPC/POPG liposomes at various ratios of POPC and POPG. POPC 
vesicles were used to represent zwitterionic membranes, a simple model for eukaryotic 
membranes 22-24 and POPG was used as the anionic component of the model membranes for this 
study.24, 25 The percent composition of the membrane model was varied from 100% POPG (black 
CD spectrum) to 100% POPC (light blue CD spectrum) in 10% increments (Figure 3.4).   The 
CD spectra shown in Figure 3.4 also confirmed our hypothesis that the total percentage of 
anionic lipid plays a major role in defining the membrane’s physicochemical surface properties 
thus affecting the conformations and interactions. Changes in the anionic to zwitterionic 
phospholipid ratios in the membrane model result in different surface potentials, inducing 
different conformations onto the peptide so as to allow for binding. 
 
Figure 3.4:  Far-UV CD spectra of compound 23 (1 mg/mL) in the presence of 10 mM  
POPC/POPG liposomes with varying ratios dissolved in 40 mM phosphate buffer (pH = 6.8). 
The percent composition of the liposomes is varied from 100% POPG (black CD spectrum) to 
100% POPC (light blue CD spectrum) in 10% increments, with the highest POPG ratios on the 
left and highest POPC ratios on the left. 
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Compound 23 in LUV environments. The CD spectra of 75 µM compound 23 and 100 
µM compound 23 in the presence of 1.75 mM POPC and 4:1 POPC/POPG LUVs are given in 
Figure 3.5, along with their corresponding HT values and absorbance for the uncorrected spectra 
(without subtraction of buffer).  As previously discussed in Chapter 2, HT values should remain 
below 600 V and UV absorbance below 1.5 AU in order to exhibit undistorted CD spectra for 
qualitative comparison.19  The spectra in the different membrane environments were different 
from the spectrum observed for this AMP in buffer leading to the conclusion that there is some 
interaction between the AMP and model membrane systems. 
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Figure 3.5: Far-UV CD spectra (top left) of 75 µM compound 23 in 1.75 mM POPC LUVs (red) 
and 100 µM compound 23 in 40 mM phosphate buffer (black), pH = 6.8, and 1.75 mM 4:1 
POPC/POPG LUVs (blue). Corresponding HT [V] (top right) and absorbance spectra (bottom) 
were included. 
 
 
 
 
For POPC LUVs, the increase in the intensity of the maximum at approximately 195 nm 
suggests that compound 23 adopts some type of β-turn or β-sheet like conformation. 10, 18  The 
CD spectra of compound 23 in POPC LUVs is also very different from the CD spectrum 
observed for this AMP in the presence of zwitterionic DPC micelles, particularly in regards to 
the absence of the positive maxima below 200 nm. This is expected since the CD spectrum in the 
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presence of POPC LUVs should include some I-state contribution while that of the spectra in 
DPC micelles should only consist of S-state conformations, thus, their spectra should be 
different. 
 The CD spectrum of compound 23 in the presence of anionic LUVs was different from 
the spectrum of the compound bound to the zwitterionic LUVs.  These differences clearly 
indicated that this compound was adopting different conformations when interacting with the 
two different LUVs.  The λmax between 190 and 195 nm suggests that compound 23 is adopting 
some combination of α-helical and β-turn components in this environment.10, 18 Therapeutically, 
this characteristic would allow for the design of analogs with greater selectivity for a particular 
membrane composition The CD spectra of this AMP in the presence of 4:1 POPC/POPG LUVs 
was also very different from the spectrum observed in the corresponding micelle membrane, 
SDS, more specifically, in the absence of the positive maxima below 200 nm.  This was 
expected, as was the case with zwitterionic DPC and POPC, since in the presence of 4:1 
POPC/POPG LUVs some contribution of the I-state will be observed in the CD spectra.  
 
“Pseudo” CD titrations. It has been well document that the lipid to peptide ratio, L/P, 
plays a major role in determining pore formation. 26-28 In order to better understand the 
mechanism of action for this peptide, CD spectra of compound 23 were recorded at various 
liposome concentrations while maintaining a constant peptide concentration to determine 
conformational information regarding these structures. In the analysis of any data concerning a 
peptide binding to a liposome, it must be remembered that a large number of different possible 
states for the peptides are in equilibrium. These states vary from bulk solution, to surface bound, 
aggregating oligomers consisting of a various number of peptides and pore formation as well as 
any states corresponding to reverse processes.  
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The logic behind these experiments was to span the concentration range from low L/P 
ratios to high L/P ratios. When the peptide concentration is much higher than that of the 
liposome, a combination of peptide in bulk solution and pore forming peptides is favored, i.e. the 
peptide concentration is such that the resulting equilibrium of the liposome bound peptides 
would favor pore formation.  At the other end of the liposome concentration range, high L/P, the 
peptide concentration would be low enough that the equilibrium would favor monomeric peptide 
or clusters of peptides that are too small to form pores on the surface of the liposome.   
The CD spectra of compound 23 with increasing POPC concentrations is shown in 
Figure 3.6.  The concentration of compound 23 was held constant at 200 µM and the POPC 
LUV concentration increased from 0.8 mM to 17 mM.  In the presence of POPC LUVs, even at 
the lowest L/P ratio, dramatic changes were observed in both the shape and intensity of the CD 
spectra compared to the spectrum of the peptide in buffer alone. The CD spectrum of 23 in buffer 
exhibited a double minimum at about 210 and 220 nm, 10, 18  but upon addition of POPC LUVs 
this double minimum disappeared. As can be seen from the CD spectra, the shape and intensity 
remain relatively constant as the LUV concentration increased implying the adopted 
conformations and membrane interactions were not concentration dependant. As expected based 
on the work of Ladokhin and co-workers 19  the spectra at the higher POPC concentrations were 
distorted (i.e. increased noise) at the lower wavelengths, but were still very similar even at the 
highest POPC concentrations above 200 nm.   
 The similarity of the CD spectra with increasing POPC LUV concentrations suggests that 
all possible peptide states were in equilibrium and there was not a predominate state.  This 
assumption is based on the dramatically different conformations observed in conformation in the 
presence of increasing anionic LUVs (Figure 3.7). Only two sets of conformers were observed, 
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peptide in bulk solution and the surface bound state (S-state), suggesting that for POPC LUVs, 
the S-state is dominant with a low probability of I-state formation. This observation is consistent 
with the reports by Marrink and co-workers 29 who conducted molecular dynamics simulations 
of magainin analog interactions with model membranes 29 indicating that the controlling factors 
for spontaneous pore formation was a critical peptide concentration and the propensity of the 
peptides to aggregate. 29 Since the CD spectra in the presence of POPC LUVs were essentially 
unchanged, regardless of the concentration of liposome, one can assume the conformations also 
remain relatively constant.  This observation indicates that peptide oligomerization was not 
occurring on the surface of the zwitterionic LUVs as the oligomerization of peptides would result 
in changes in conformation. 
 
 
Figure 3.6: Far-UV CD spectra for separate samples of 200 µM compound 23 with increasing 
concentration of POPC LUVs. 30, 31 New samples were prepared at each LUV concentration in 
40 mM sodium phosphate buffer; pH = 6.8. The numbers in the legend refer to the L/P ratios. 
Color intensity increases with liposome concentration.  
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 Unfortunately, this did not allow for a conclusion to be made concerning the binding 
mechanism of compound 23 with POPC LUVs. This data suggests that there were no major 
changes in the peptide conformation occurring with increased POPC LUV concentration.  It is 
impossible to characterize the exact conformations adopted by compound 23 upon binding to 
POPC LUVs due to the incorporation of the unnatural amino acids and the distortion below 200 
nm; however, it was possible to make a few therapeutically important conclusions. One, it can be 
concluded that these peptides do interact with POPC LUVs in some manner because there were 
observable differences in the CD spectra in buffer and in the presence of POPC LUVs. Secondly, 
the interaction with POPC LUVs did not appear to be concentration dependant as the spectra did 
not change significantly with an increase in lipid concentrations.26-28 
 The introduction of 20% anionic lipids into the membrane model (4:1 POPC/POPG) 
resulted in large differences in the CD spectra of compound 23 compared to the CD spectrum in 
buffer and in the presence of varying concentrations of POPC liposomes. These differences were 
due solely to small changes in the electrostatic surface potential of the liposomes. This fact is 
highlighted by the CD data as shown in Figure 3.4. These representative spectra clearly show 
that conformers of the peptide in buffer are different from all spectra of the peptide in various 4:1 
POPC/POPG LUV concentrations. The most interesting feature of this figure is the presence of 
three sets of spectra, indicative of three different conformational profiles.  
 At  low L/P ratios, (Figure 3.7 – spectra in blue) the negative molar ellipticity of the 
peaks at 210 and 220 nm gradually decrease toward a ‘critical point’ (Figure 3.8) which occurs 
at a L/P molar ratio of approximately 39:1 (Figure 3.7 – spectrum in green). Having reached the 
‘critical point,’ the decreasing pattern reverses and the negative intensities of both peaks 
gradually increase (Figure 3.7 – spectra in red). Clearly, in the case of compound 23 interacting 
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with 4:1 POPC/POPG LUVs there were dramatic concentration dependant conformational 
changes occurring. 
 
Figure 3.7: Far-UV CD spectra for separate 200 µM compound 23 samples in the presence of 
increasing concentrations of 4:1 POPC/POPG LUVs30, 31 at low L/P ratios (left) and high L/P 
ratios (left). New samples were prepared at each liposome concentration in 40 mM sodium 
phosphate buffer, pH = 6.8. The numbers in the legend refer to the L/P ratios. Color intensity 
increases with liposome concentration.  
 
 
 
 
In Figure 3.8 the molar ellipticity intensity of the minima at 210 and 220 nm versus L/P 
ratios were plotted. Clearly, compound 23 interacts with 4:1 POPC/POPG LUVs in a dramatic 
concentration dependant manner. A maximum change in molar ellipticity occurred at a L/P ratio 
of approximately 39:1. With POPC LUVs, there was no concentration dependence observed in 
the molar ellipticity intensity of the minima at 210 and 220 nm. A similar decrease in the molar 
ellipticity for the antibacterial peptide PGLa with increasing lipid concentration to an end point 
of minimal intensity has been reported by Wieprecht and coworkers. 32  At this concentration 
they proposed that the peptide was completely bound to the liposome.32 This observation is 
consistent with our hypothesis. Having reached the “critical point”, at a L/P ratio of 
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approximately ~39:1, the pattern reversed and the negative intensities of both peaks gradually 
increased (Figure 3.8 – right). 
 
Figure 3.8: Plots of CD intensity at 210 and 220 nm versus L/P ratios for compound 23 in the 
presence of POPC (left) and mixed 4:1 POPC/POPG LUVs (right). 
 
 
 
 
Although it was difficult to obtain quantitative data from the CD spectra due to the 
incorporation of unnatural amino acids, the groups of spectra may be attributed to different 
conformations adopted by the peptide in three different states. We postulated that at low L/P 
ratios, the relative concentration of peptide was such that essentially each liposome was saturated 
with peptide, thus the resulting spectra represents the peptide predominantly in two 
environments, namely solution state and the I-state. As the lipid concentration increases the free 
peptide concentration in bulk solution becomes negligible. This is the ‘critical point’ discussed 
earlier, which we hypothesize is predominantly I-state and this spectrum is un-ordered which is 
unexpected.  However, previous molecular dynamics simulations 29 showed that for a magainin 
analog, the conformation of the peptides in the pore are not highly structured. Furthermore, 
Sengupta and co-workers predicted that the interaction of melittin with 
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dipalmitoylphosphatidylcholine bilayers resulted in disordered toroidal pores. 33 These 
observations are consistent with our data as we see an increase in disordered conformers close to 
the ‘critical point’. Beyond the ‘critical point,’ as the lipid concentration increases further, a L/P 
ratio is reached such that the I-state is no longer statistically favored and various forms of the S-
state dominate.    
 The differences in CD spectra of compound 23 in the presence of the two membrane 
models clearly indicate there are definitive “steps” in the mechanism of liposome binding to 4:1 
POPC/POPG LUVs that are not observed for interaction with POPC liposomes.  By exhibiting 
different interactions, these observations lead to two conclusions. One, compound 23 interacted 
with POPC and 4:1 POPC/POPG LUVs via different binding mechanisms suggesting some level 
of membrane selectivity. Secondly we can use these three individual “steps” to investigate in 
greater detail the overall mechanism of binding to 4:1 POPC/POPG LUVs.  
 
 
ITC Studies 
 
 
 Full titration experiments. The use of isothermal titration calorimetry to study peptide-
membrane interactions is a well documented technique. 30, 34, 35 As previously mentioned in 
Chapter 1, the titration of lipid into peptide would allow for the complete analysis of the 
thermodynamic parameters associated with the interaction, in an ideal case.  These parameters 
include the binding constant (Kb), the enthalpy (∆H), free energy (∆G), the entropy (∆S) and any 
heat capacity changes (cp). 34, 36 
 At the beginning of a full titration experiment, there is an excess of peptide in the cell. 
Small aliquots of LUVs are titrated into the cell and are saturated with peptide, removing some 
peptide from bulk solution. With a decrease in the peptide available for binding, the heats 
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involved with each injection will decrease until all of the peptide is removed from the bulk 
solution. Once the peptide is removed from the bulk solution, the only heat observed will be the 
heat of dilution. A schematic of the full titration experiment can be seen in Figure 3.9. 
 
 
 
Figure 3.9: Illustrative schematic of the full titration experiment for the titration of lipid into 
peptide 
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The initial comparison of the thermograms obtained from the full titration experiment of 
the two different liposomes into compound 23 (over the same liposome concentration range as 
that used in the CD investigations) clearly revealed reproducible differences. The titration of 23 
with 4:1 POPC/POPG LUVs (Figure 3.10 – right) displayed a complex isotherm exhibiting two 
distinct phases. An endothermic phase was observed at low L/P ratios. This phase was followed 
by an exothermic component as the LUV concentration increased. Although this particular 
behavior is not very common it has been observed with other peptides. 24 Andrushchenko and co-
workers37 reported similar thermograms for mixed liposomes with the tryptophan-rich 
cathelicidin antimicrobial peptides, tritrpo4 and tritrpo6. 37 The behavior at low L/P ratios, an 
endothermic phase, has been attributed to processes such as pore formation, 32 peptide 
aggregation, 37 and changes in the phase properties of the lipids. 38 The isolated process of 
peptide binding to the liposome surface is thought to occur at high L/P ratios and was exhibited 
by the exothermic component. 39 
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Figure 3.10: ITC data for the titration of 35 mM POPC (left) and 4:1 POPC/POPG LUVs (right) 
into 200 µM compound 23.  
 
 
 
 
There were also two other intriguing features of this thermogram. One was the point 
observed when the net heat flow is zero, in other words, where the isotherm crosses the x-axis. 
When the overall enthalpy of the reaction is zero, all of the contributions from the endothermic 
processes precisely balance out all of the contributions from the exothermic processes.  Also, it is 
at this point in the titration that all of the free peptide is removed from bulk solution and assumed 
to be 100% bound. 40 
 The second notable feature was the most exothermic point in the titration that occurred at 
a L/P ratio of ~40:1. This molar ratio corresponds to the CD spectra that bridge the two phases, 
which we attributed to the predominance of the I-state.  It is important to note that this critical 
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point is absent from the thermogram and CD data for compound 23 in POPC LUVs. The 
exothermic heat changes associated with increasing concentrations of lipid after this point 
decreased until the heat of dilution was observed.  This decrease in heat corresponded to the 
second set of spectral groupings observed in the 4:1 POPC/POPG LUVs CD studies (Figure 3.7) 
and indicated, what we believe to be, a shift of peptides from a predominantly I-state to various 
S-state configurations. It was because of the complexity of these competing interactions during 
the course of each titration that we were unable to fit our ITC data for mixed liposomes to 
current existing models, which would allow for the complete determination of thermodynamic 
parameters. 24, 37  
 The titration of POPC LUVs into compound 23 (Figure 3.10 – left) produced a relatively 
simple thermogram exhibiting a single endothermic phase.413 Previous ITC studies have noted 
that a combination of several events can attribute to an endothermic phase. These events may 
include electrostatic interactions between the peptide and the membrane surface, disruption of 
polar head groups accompanied by the reorganization of lipids on the surface of the membrane, 
disruption of the solvation spheres on the surfaces of both the peptide and membrane and other 
less understood phenomena. 42 
 A binding isotherm for compound 23 was developed as described previously in chapter 1. 
The plot of Xb versus cf yielded a nonlinear binding isotherm for the binding of compound 23 to 
POPC LUVs (Figure 3.11 – left) and did not fit the model presented by Equation 1.3. Because 
compound 23 is a positively charged peptide, electrostatic interactions should be accounted for. 
Therefore, the concentration of peptide at the surface of the membrane, cm, was plotted against 
Xb, which yielded a linear binding isotherm (Figure 3.11 – right) allowing for the binding 
constant K to be determined.25, 39, 43 For compound 23, ∆H0 was determined experimentally and 
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the binding constant K was derived mathematically. From these two pieces of information a 
complete set of thermodynamic data was calculated for compound 23 using the Equations 1.1 
and 1.2, previously discussed. The results for the thermodynamic analysis of compound 23 with 
POPC LUVs are given in Table 3.3.  
 
 
Figure 3.11:  The degree of binding, Xb, of Compound 23 plotted against the concentration of 
free peptide in bulk solution, cf, (left) and near the surface of the membrane, cm (right).  
 
 
 
 The results for the thermodynamic analysis of compound 23 in the presence of POPC 
LUVs suggest a weak interaction. Although the ∆G and ∆S values were favorable, the ∆H and 
binding constant were not. The low value of the binding constant as compared to M2a suggests 
minimal binding. From a therapeutic standpoint, this is a very desirable quality. 
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Table 3.3: Thermodynamic data for a representative titration of 35 mM POPC into compound 23 
at 25°C as derived from the equations discussed previously.  
Compound ∆H0,a  (kcal/mol) Kb  (M-1) ∆Gc  (kcal/mol) ∆Sd  (cal/mol·K)
23 0.7 211.0 -5.5 20.8
M2ae
-15.9 2000.0 -7.0 -29.4
 
a
 ∆H0 values are directly measured binding enthalpies and calculated using Equation 1.4. 
b
 Binding constants were generated from the lipid-into-peptide titrations using the model as 
described in the text. 
c
 Free energies were calculated using Equation 1.1. 
d
 Entropy was calculated using Equation 1.2.  
e
 Thermodynamic parameters for Magainin analogue M2a as presented by Wieprecht et. al.41 
 
 
 
 Single injection experiments. The membrane selectivity between the different membrane 
models of compound 23 were further highlighted by the single injection ITC experiments, the 
titration of dilute samples of peptide into excess lipid and vice versa.25, 44-46 By titrating relatively 
low concentrations of peptide into excess LUVs, we are able to determine the enthalpy of 
binding.39, 44-46 At the beginning of this experiment, the reaction cell is filled with a large amount 
of liposome and a dilute sample of peptide is titrated into the cell resulting in high L/P ratios. 
Due to the excess liposomes under these conditions, the surface state, or S-state, predominates 
and it is assumed that all of the peptide binds to the liposome after each injection, leaving only 
peptide-free and bound lipid. These injections thus produce identical heats which are averaged to 
provide the ∆H for binding. A schematic of the single injection experiment for the titration of 
peptide into lipid is given below in Figure 3.12. 
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Figure 3.12: Schematic illustration of single injection experiments associated with the titration 
of dilute peptide solutions into excess liposome to determine the ∆H of binding. 
 
 
 
 
The binding enthalpy obtained for the titration of compound 23 into POPC LUVs was 
+2.13  kcal/mol (Figure 3.13 – left) and enthalpically disfavored.  This was in contrast to the -
1.02 kcal/mol obtained for the titration of the peptide into the 4:1 POPC/POPG LUVs  (Figure 
3.13 – right) which indicated an enthalpically favored event. There are several possible factors 
that could contribute to the observed enthalpies of binding to both POPC and 4:1 POPC/POPG 
LUVs.  These factors may include attractive and repulsive electrostatic interactions, 
conformational changes of the peptide, changes in Van der Waals contacts due to dehydration of 
both the peptide and membrane surfaces and the disruption of polar head groups on the surface 
of the liposome.37, 39, 42 The major difference between the two membrane systems was the 
introduction of a greater negative charge on the surface of the mixed liposomes.  The net charge 
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of compound 23 is highly positive (+6). We believe that the attractive electrostatic forces 
between the positive charges of the peptide and the negative charges of the 4:1 POPC/POPG  
LUVs contributed favorably to a net enthalpy of -1.02 kcal/mol.   
 
 
Figure 3.13: Single injection ITC data for the titration of 200 µM compound 23 into 15 mM 
POPC LUVs (left) and 15 mM 4:1 POPC/POPG LUVs (right). The data in red were discarded.  
 
 
 
 
 Reversing the direction of the single injection experiments for binding, and titrating 
dilute samples of LUVs (10 - 20 mM) into excess peptide (300 - 400 µM), allowed for the 
isolation of the heat associated with any membrane disrupting processes that may be taking place 
at low L/P ratios. 47 Only a few unbound liposomes were titrated into the cell at a time, thus, 
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becoming saturated with peptides which would exist predominantly in bulk solution and in the I-
state.   Each injection of liposomes would produce essentially identical heats which were 
averaged to provide the ∆H of the membrane disrupting processes associated with 4:1 
POPC/POPG and POPC LUVs. An illustrative schematic of the single injection titration of dilute 
solutions of liposomes into excess peptides is given below in Figure 3.14. 
 
 
 
 
Figure 3.14: Illustrative schematic of single injection experiments associated with the titration of 
dilute LUV solutions into excess peptide to determine the ∆H of membrane disrupting processes. 
 
  
 
 Single injection experiments to determine the ∆H values associated with membrane 
disruption for compound 23 in the presence of POPC (left) and 4:1 POPC/POPG LUVs is given 
in Figure 3.15.  The enthalpy obtained for titration of POPC (left) into compound 23 was +0.042 
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kcal/mol and three times less than the +0.143 kcal/mol obtained for the 4:1 POPC/POPG LUVs 
(right).  This series of single injection experiments involved several possible processes including 
binding, peptide conformational changes and aggregation, followed by possible pore formation.  
Our studies indicated that for compound 23 in both types of LUV models, the sum of these 
processes was endothermic and enthalpically disfavored.  We attributed the larger endothermic 
enthalpy observed for the 4:1 POPC/POPG LUV to pore formation which is a highly 
endothermic process 39 and absent in the zwitterionic LUVs. All of the single injection data is 
summarized in Table 3.4. 
 
Figure 3.15: Single injection ITC data for the titration of 20 mM POPC (left) and 20 mM 4:1 
POPC/POPG LUVs (right) into 300 µM compound 23. The data in red was discarded.  
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Table 3.4: ∆H (kcal/mol) values for the binding and membrane disruption of 4:1 POPC/POPG 
and POPC LUVs as determined by single injection ITC experiments. 
Compound Compound into 4:1 POPC/POPG
4:1 POPC/POPG 
into Compound
Compound 
into POPC
POPC into 
Compound
23         -1.0 ± .04 0.14 ± .03 2.1 ± .04 0.04 ± 0
 
 
 
 
 The ITC data further supports the hypothesis that there were two different mechanisms of 
interaction for POPC and 4:1 POPC/POPG LUVs. This is consistent with the observed 
selectivity of compound 23 for bacterial cells versus mammalian red blood cells determined 
previously through in vitro testing. 1  
 
 
Calcein Leakage Studies 
 
It has been documented that compound 23 exhibits low micromolar antibacterial activity 
as well as activity against human red blood cells. 1 Peptide-induced calcein leakage monitored 
through fluorescence is well documented as a technique for probing AMP activity 37, 48 Leakage 
studies were conducted to evaluate the potential for compound 23 to induce leakage or form 
pores in POPC or 4:1 POPC/POPG LUVs.49, 50 The data obtained from the fluorescence 
experiments of compound 23 and POPC LUVs (Figure 3.16 – left) supports our earlier 
statement that the mechanism of interaction is not concentration dependant, as it can be observed 
that the calcein leakage from POPC LUVs is relatively low and appears to be insensitive to 
peptide concentration. The most likely cause of calcein leakage in the case of POPC LUVs is the 
rearrangement of the membrane lipids and polar head groups due to peptide binding and not pore 
formation, consequently resulting in the thinning of the surface of the membrane. 41 51  
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Figure 3.16: The time-dependent release of calcein from POPC (left) and 4:1 POPC/POPG 
(right) LUVs by increasing concentrations of compound 23 as measured by fluorescence.52-54 
 
 
 
 
 For 4:1 POPC/POPG LUVs, however, the magnitude of calcein leakage measured via 
fluorescence was much higher than that observed for POPC LUVs. Furthermore the induced 
calcein leakage for 4:1 POPC/POPG LUVs also appeared to be directly correlated with peptide 
concentration (Figure 3.16 – right), as the peptide concentration increases so did the leakage.  
This concentration dependence may be explained in terms of a pore forming mechanism.  The 
difference in concentration dependencies of compound 23 for the zwitterionic and anionic LUVs 
is highlighted when the maximum amount of leakage induced is plotted against the peptide 
concentration (Figure 3.17). As can be seen in the figure, the slope of the plot for POPC LUVs 
remains relatively constant while that of 4:1 POPC/POPG  LUVs increases with increasing 
peptide concentration.  
 The increase of calcein leakage as the peptide concentration increases coupled with the 
leveling off of fluorescence over time suggests the formation of a transient pore as observed in 
earlier studies involving dynorphins and magainin. 51, 55, 56 This type of behavior is best explained 
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by the formation of transient pores during the initial bilayer insertion step, which then undergo a 
nucleation step followed by ‘transient re-stabilization’ of the lipid-peptide structure.  51  The net 
result is a leveling off of the observed leakage. 51, 57 
 
 
 
Figure 3.17: The total time-dependent release of calcein from POPC (black) and 4:1 
POPC/POPG (red) LUVs  by increasing concentrations of compound 23 as measured by 
fluorescence.  
 
 
 
 
Conclusions 
 
 The conclusion that compound 23 interacted via different mechanisms with POPC and 
4:1 POPC/POPG LUVs was supported by spectroscopic, thermodynamic and calcein leakage 
assay data. This peptide appeared to predominately interact with the surface of zwitterionic 
POPC LUVs (S-state), while all of the evidence supports the conclusion that a toroidal pore 
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mechanism dominates the interaction with 4:1 POPC/POPG LUVs (I-state).  This study shows 
that a rational approach may be utilized to design biologically active and selective AMPs.  
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CHAPTER FOUR: SPACER # 1 
 
 
Introduction 
Circular Dichroism, isothermal calorimetry and calcein fluorescence leakage experiments 
were conducted to provide insight into the mechanisms of binding for a series of antimicrobial 
peptides containing unnatural amino acids to zwitterionic and anionic lipids and micelles. The 
basic skeleton of the Tic-Oic dipeptide based AMP was previously given in Figure 1.2 of 
chapter 1.  Spacer #1, denoted by blue in Figure 1.2, defines the distance between successive 
Tic-Oic dipeptide units as well as the distances between the preceding Tic-Oic dipeptide units to 
either the following hydrophobic or positively charged residue. Spacer #1 is involved in defining 
the flexibility of any induced turn or helical structure.   
One of the main advantages of incorporating unnatural amino acids into the peptide 
sequence is having the ability to maintain more control of the conformational flexibility.  
Incorporation of the conformationally restrained amino acids Tic and Oic in our compounds 
reduces the local flexibility of the peptide backbone, consequently reducing the total 
conformational freedom of the peptide during lipid binding. Incorporating different unnatural 
amino acids as Spacer #1 increases the number of methylene groups in the peptide backbone. By 
combining both conformationally restrained and conformationally flexible amino acids into the 
peptide backbone, it is possible to create regions of high and low molecular flexibility resulting 
in a semi-rigid peptide backbone with specific regions of hydrophobicity and charge. These 
modifications resulted in dramatic changes in the physicochemical surface properties within this 
series of AMPs on lipid binding.  
The amino acid sequences for the peptides used to investigate the role played by Spacer 
#1 are given Table 4.1. Compound 23 contains the one-carbon spacer glycine with a distance of 
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2.46 Å between the carbonyl carbon atom and the amide nitrogen atom. Compound 36 contains a 
two carbon spacer, β-alanine, with average distance of 2.94 Å. Gaba in compound 29 is a three 
carbon spacer with average distance 4.68 Å and compound 37 contains the five carbon spacer, 
Ahx, with the longest average distance of 6.91 Å. The average distances were calculated using 
ChemDraw 3D version 10.0 
 
 
Table 4.1: Amino acid sequences of the peptides used to study the role played by Spacer #1.1  
 
Compound Amino Acid Sequence
23 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK-CONH2
29 Ac-Gaba-F-Tic-Oic-Gaba-K-Tic-Oic-Gaba-F-Tic-Oic-Gaba-K-Tic-KKKK-CONH2
36 Ac- βAla-F-Tic-Oic-βAla-K-Tic-Oic-βAla-F-Tic-Oic-βAla-K-Tic-KKKK-CONH2
37 Ac- Ahx-F-Tic-Oic-Ahx-K-Tic-Oic-Ahx-F-Tic-Oic-Ahx-K-Tic-KKKK-CONH2
 
 
 
 
 
These modifications to Spacer #1 have shown to play a role in bacteria strain selectivity 
and potency. All four compounds exhibited very good in vitro MIC activity against Salmonella 
typhimurium (ATCC 13311), Mycobacterium ranae (ATCC 110), Bacillus subtillis (ATCC 
43223), and Bacillus anthracis AMES. Compounds 23, 36 and 37 exhibited very good in vitro 
MIC activity against Staphylococcus aureus ME/GM/TC resistant (ATCC 33592) while 
compound 29 was much less active  (Table 4.2).1  
However, as seen in Table 4.3 compounds 23, 36 and 29 exhibit much lower activity 
against several Gram Negative strains of bacteria except Acinetobacter baumanii (ATCC 19606), 
and Acinetobacter baumanii (drug resistant strain isolated at the Walter Reed Army Institute of 
Research).2 Compound 37, on the other hand, exhibited good to very good in vitro MIC activity 
against Yersinia pestis, Brucella melitensis, Brucella abortus, Brucella suis and Francisella 
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tularensis.2 The observed differences in the in vitro activity of these AMPs support our 
hypothesis that the physicochemical surface properties presented by the AMP to the target cell 
can be engineered to obtain organism potency and selectivity.  The most significant change that 
can be seen is the 2-3 fold differences in the hemolytic activity for these compounds, which 
implies changes in how these peptides interact with zwitterionic lipids.1    
 
 
Table 4.2:  Minimum inhibitory concentration (µM) of selected bacteria strains and hemolytic 
activity.1  
 
Compound Salmonella 
typhimurium
Staphylococcus aureus 
ME/GM/TC resistant
Mycobacterium 
ranae
Bacillus 
subtillis
% hemolysis 
100/25 µM
23 10 µM 3 µM 10 µM 1 µM 14%
36 10 µM 10 µM 1 µM 1 µM 24.4/ 7.4%
29 10 µM 100 µM 10 µM 1 µM 10.8/ 1.0%
37 10 µM 10 µM 3 µM 1 µM 44.7/ 26.6%
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Table 4.3: Minimum inhibitory concentration (µM) of specific Gram negative and other drug 
resistant bacteria strains.2  
 
Compound 23 36 29 37
Acinetobacter baumanii 
ATCC 19606 3.2 1.5 3.1 5.9
Acinetobacter baumanii 
WRAIR 3.2 6.2 3.1 2.9
Staphylococcus aureus 
ATCC 33591 205 200 196 187
Yersinia pestis CO92 205 200 196 23
Brucella melitensis 16M 205 200 196 95
Brucella abortus 2308 205 200 196 12
Brucella suis 23444 205 200 196 47
Bacillus anthracis AMES 12.8 25 12.5 1.5
Francisella tularensis 
SCHUS4 100 100 196 23.4
Burkholderia mallei 205 200 196 187
Burkholderia 
pseudomallei 205 200 196 187
 
 
 
 
 
Results and Discussion 
 
 
CD Studies 
CD spectroscopy is very sensitive and its use to monitor conformational changes in 
peptides and proteins is well documented.3, 4  This investigation was divided into two phases.  
The first phase focused on surface binding (S-state) by only using SDS and DPC micelles.   The 
second phase focused on membrane insertion (I-state) using liposomes membrane models.   
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The observed CD spectrum of a peptide, as previously mentioned, represents the linear 
combination of all of the different spectra due to conformers or states present in the sample 3, 5 
including the peptide in the bulk solution, the surface bound and insertion states. Each of these 
states could exhibit a diversity of conformations. A change in shape and/or intensity of a CD 
spectrum for a peptide in the presence of micelles or liposomes implies that the peptide is 
adopting different conformations. This conformational change is a direct result of the different 
physicochemical interactions that are occurring between the AMP and the membrane model. As 
mentioned in chapter 2, any reference to secondary structures is used only for qualitative 
purposes due to the high percentage of unnatural amino acids.   
 
CD spectra of Spacer #1 peptides in buffer and micelle environments. The CD spectra of 
compounds 23, 36, 29 and 37 in buffer are shown in Figure 4.1.  Compound 23 exhibited a 
characteristic double minimum at approximately 210 and 220 nm, which is consistent with the 
presence of helical and β-turn conformers.4, 6 Compounds 29, 36, and 37 exhibited a clear 
minima between 206 and 209 nm with a slight second minimum at approximately 222 nm 
suggesting the presence of α-helical components.7, 8  The larger magnitude of the minima 
between 206  and 209 nm strongly suggests that, in buffer, these compounds also adopt a 
relatively high percentage of both unordered and β-turn structures4, 9. In addition, the maximum 
between 190 and 200 nm suggests a mixture of some β-sheet and α-helix.10   
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Figure 4.1: Far-UV CD spectra of compounds 23, 36, 29 and 37 (peptide concentration 
approximately 400 µM) dissolved in 40 mM phosphate buffer, pH = 6.8.  
 
 
 
 
The CD spectra of these compounds in the presence of SDS micelles (Figure 4.2 – left) 
showed an increase in the intensity of the λmax at approximately 190 nm and the two minima at 
205 and 220 nm suggesting a shift from a mixture of β-turn, α-helical and unordered features in 
buffer to a more dominate α-helical structure in SDS.10, 11 The intensity of the maximum and 
minima decreased as the length of Spacer #1 increased indicating a reduction in α-helical 
components of the peptides.4, 7, 8, 12  
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Figure 4.2: Far-UV CD spectra of compounds 23, 36, 29 and 37 in the presence of 80 mM SDS 
(left) and 80 mM DPC (right) micelles in 40 mM phosphate buffer, pH = 6.8.  
 
 
 
 
The CD spectra of these compounds in the presence of DPC micelles (Figure 4.2 – right) 
did not exhibit a clear trend as they did in SDS. In regards to changes in intensity, compounds 29 
and 36, with 3 and 2 carbon spacers, respectively, were very similar in intensity with the 
exception of the λmax below 200 nm. Compound 36 exhibited a higher intensity than compound 
29 below 200 nm. Compound 23 exhibited the greatest intensity below 200 nm but the least 
above 200 nm, with the exception of compound 37. Although there was not a discernable trend 
between the intensities of the maxima below 200 nm and the spacer length, all four peptides 
decreased in intensity as compared to their corresponding spectra in SDS. This decrease in the 
intensity of the maxima below 200 nm is indicative of a reduction in the α-helical components of 
the peptide.7, 8, 12 The intensity of the two minima above 200 nm varies, but unlike the case with 
SDS micelles, the intensity of the peaks in DPC micelles does not correlate directly with the 
length of the spacer. For compounds 23, 36 and 29 the intensity of the peaks increased with 
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increasing spacer length. However, compound 37, with the longest Spacer # 1 and therefore the 
most flexible peptide had the least intense maximum below 200 nm and the two minima above 
200 nm. It is possible that this peptide is so flexible it can adopt many different conformations.   
There are also shifts in wavelengths when the peptides are in the DPC environment as compared 
to the buffer and SDS. The most significant shifts occur with the λmax below 200 nm. As 
previously stated, the peptides consisted of mixture of β-turn and α-helical components in buffer 
due to the maxima at approximately 197 nm. These maxima shifted to approximately 190 – 192 
nm for the four compounds suggesting an increase in the α-helical presence in DPC for all of the 
peptides. Also, one of the minima shifted from approximately 207 nm to approximately 202 nm 
in buffer and DPC, respectively. The shift to a lower wavelength for this minimum suggests a 
change from α-helical components to more unordered characteristics.9 This observation coupled 
with the decrease in the intensity supports the conclusion that there was a decrease in the α-
helical character of these peptides as compared to the buffer.7, 8, 12 The observed differences in 
the shape and intensity of the CD spectra clearly indicated  that the S-state bound conformations 
of these peptides in the presence of SDS and DPC micelles were, as expected, very different.   
However, the CD spectrum of each peptide in the same environment was similar in shape. The 
only notable difference within each series was the overall intensity of the individual spectrum 
indicating that the AMPs adopt similar binding conformations.   
 
CD spectra of Spacer #1 peptides in LUV environments. The CD spectra of compounds 
23, 36, 29 and 37 in the presence of 1.75 mM POPC liposomes are given in Figure 4.3 (left) 
with their corresponding HT values (right). A LUV concentration of 1.75 mM does not produce 
an absorbance above 1.5 AU as discussed in Chapter 2 and 3. As such, the distortion caused by 
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this LUV concentration is minimal and does not interfere with qualitative comparisons of the 
data.13 The four CD spectra in POPC LUVs were very similar in shape to their corresponding 
spectra in buffer with minimal shifts in their maximum and minima
 
leading to the conclusion that 
if they were interacting with the POPC LUVs, it was a very weak interaction as shifts in the 
peaks are indicators of conformational change.14, 15 The CD spectra of these peptides did exhibit 
some characteristics similar to each other. For instance, compounds 36 and 37 were similar in 
intensity and shape. All four compounds were similar in shape above 200 nm, but varied in their 
intensities. In most cases, however, the intensity of the minima at approximately 208 and 222 nm 
increased in the presence of POPC LUVs  suggesting an interaction,12 however, these intensities 
cannot be correlated to the length of Spacer #1.  
 
Figure 4.3: Far-UV CD spectra of 75 µM solutions of compounds 23, 36, 29 and 37 (left) in the 
presence of 1.75 mM POPC LUVs dissolved in 40 mM phosphate buffer (pH = 6.8) and their 
corresponding HT values (right). 
 
 
 
 
  The CD spectra of compounds 23, 29, 36 and 37 in the presence of 1.75 mM 4:1 
POPC/POPG LUVs are given in Figure 4.4 (left) with their corresponding HT values (right).  
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The CD spectrum of the compounds in this series in the presence of anionic liposomes were very 
different from their spectra  in zwitterionic liposomes clearly indicating that these compounds 
adopt different conformations when interacting with the two different liposomes.14-16  The 
intensity of the minima at approximately 205 nm can be correlated with the length of Spacer #1. 
The intensity of this peak decreases with an increase in the number of methylene groups in the 
spacer. Compound 23, with no methylene groups, exhibited a greater intensity than compound 36 
which contains one methylene group. Compounds 29 and 37 exhibited even less intense spectra. 
The overall shape and λmax of the compounds were very similar to each other with the exception 
of compound 37. This compound not only exhibited the weakest intensity, but had a completely 
different shape indicating that it adopts a different conformation than the other peptides when in 
the presence of 4:1 POPC/POPG LUVs.15, 16    
 
 
 
Figure 4.4: Far-UV CD spectra of 100 µM solutions of compounds 23, 36, 29 and 37 in the 
presence of 1.75 mM 4:1 POPC/POPG LUVs (left) dissolved in 40 mM phosphate buffer (pH = 
6.8) and their corresponding HT values (right).  
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The CD data for compounds 23, 36, 29 and 37 clearly indicated there was a difference, as 
expected, in the conformations observed for these peptides on interacting with zwitterionic and 
anionic liposomes. The changes in λ max were relatively small although the changes in molar 
ellipticity could be large indicating a change in the degree of secondary structure present. 
 
“Pseudo” CD Titrations. The conclusion that these AMPs interact differently with POPC 
and 4:1 POPC/POPG LUVs was further proven with “pseudo” titration experiments of 
increasing liposome concentrations as previously described. By preparing separate, but identical, 
samples of peptide and adding varying amounts of liposomes, we were able to observe the 
conformational changes associated with the transition from low L/P to high L/P ratios. As we 
previously reported, there was a dramatic difference in the CD behavior for compound 23 in the 
presence of POPC and 4:1 POPC/POPG liposomes.17 Increasing the concentration of POPC 
LUVs while holding the concentration of the peptide constant resulted in very similar CD 
spectra. As can be seen in Figure 4.5, the CD spectra of these peptides did not vary much with 
the introduction of POPC LUVs suggesting that the interaction was not concentration dependent. 
Even at high L/P ratios, the spectra were very similar to the samples associated with low L/P 
ratios proposing an overall weak interaction with the membranes.10 
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Figure 4.5: Far-UV CD spectra of separate samples of 200 µM compound 23 (top left) and 75 
µM solutions of compounds 36 (top right), 29 (bottom left) and 37 (bottom right) with increasing 
concentrations of POPC LUVs.18, 19 
 
 
 
 
However, vastly different CD spectra resulted from samples with increasing 
concentrations of 4:1 POPC/POPG LUVs  (Figure 4.6).  Increasing the anionic LUVs 
concentration yielded CD spectra that were very different in both intensity and shape from their 
corresponding spectrum in buffer. As the L/P ratio increased, the intensity decreased until a ratio 
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was met that exhibited an intensity of a constant-level. We refer to this as the “critical point” and 
it was at this point that all of the peptide was assumed to be bound. The L/P ratio that 
corresponds to this point was unique to each peptide. For compound 23 this ratio was 
approximately 39, for compound 36 it was 105, for compound 29 it was 70 and for compound 37 
it was approximately 52.  Once this “critical point” was reached, the trend of decreasing intensity 
was reversed and the intensity of the spectra increased. 
The titration of 4:1 POPC/POPG LUVs into the peptide solutions resulted in three 
separate groupings of CD spectra.  The first group yielded decreasing spectral intensity as the 
LUV concentration increased.   At low L/P ratios, the relative concentration of peptide was such 
that each liposome was saturated with peptide. The resulting spectra represented the peptide free 
in solution and in the I-state (blue spectra).17 The second group, which seemed to be limited to 
the transition point, consisted of 1 or 2 spectra which were very similar to each other and 
exhibited the lowest intensity. As the LUV concentration was increased, the amount of free 
peptide in bulk solution decreases and becomes negligible. We believe this corresponds to the 
‘critical point’ discussed earlier, and hypothesize it is predominantly I-state (green spectra). The 
third and final grouping refers to the spectra after the “critical point” that continue to increase in 
intensity with increasing liposome concentration.  17 Beyond the ‘critical point,’ as the LUV 
concentration increases further, a P/L ratio is reached such that the I-state is no longer 
statistically favored and various forms of the S-state dominate (red spectra).17  
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Figure 4.6: Far-UV CD spectra of separate samples of 200 µM solutions of compound 23 (top 
left) and 37 (bottom right) and 100 µM solutions of compounds 36 (top right) and 29 (bottom 
left) with increasing concentrations of 4:1 POPC/POPG LUVs. 18, 19  
 
 
 
ITC Studies      
Anionic LUVs. ITC investigation for the titration of 4:1 POPC/POPG LUVs into 
compounds 23 (Figure 4.7 – top left), 36 (Figure 4.7 – top right), 29 (Figure 4.7 – bottom left) 
and 37 (Figure 4.7 – bottom right) produced complex 2-phase thermograms. Each peptide 
displayed an endothermic heat event followed by an exothermic event. With the exception of 
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compound 36, as the spacer length increased, the magnitude of the endothermic heat event 
increased while the exothermic heat event subsequently decreased. Endothermic heat events are 
associated with several processes including the desolvation of the peptide and of the membrane 
surfaces, disruption of the polar lipid head groups and lipid:lipid interactions as well as the 
release of the water molecules from inside the vesicle.20-23  With an increase in the length of the 
spacer, the conformational flexibility of the peptide and the overall space that the peptide 
occupies also increases. Consequently, the larger the space occupied by the peptide, the more 
disruption there is on the surface of the membrane. This increased disruption therefore increases 
the positive ∆H contributions. The magnitude of the cumulative endothermic heat components 
for compounds 23, 29 and 37 were +0.80, +1.00 and +2.30 kcal/mol, respectively. Compound 36 
absorbed the least amount of heat with +0.42 kcal/mol.22-25  
Exothermic heats correspond with a process that favors binding. Processes that contribute 
to a negative ∆H include, but are not limited to, attractive electrostatic interactions, hydrogen 
bonding due to conformational changes of the peptide, increase in Van der Waals forces due to 
binding of the peptide to the membrane and the reorganization of the polar head groups and 
lipid:lipid interactions after binding.11, 19, 21-23, 26  The exothermic component of the thermograms 
reached a maximum ∆H before subsequently decreasing into the heat of dilution for each 
peptide. As the length of the spacer increased, the maximum value that was reached by the 
exothermic component decreased. When the spacer length increases, the overall hydrophobic 
character of the peptide backbone also increases, thus allowing the peptide to associate more 
strongly through Van der Waal interactions with the hydrophobic core of the membrane bilayer. 
With stronger associations, the peptides are less likely to disassociate from one liposome in order 
to bind to another one. The process of leaving one liposome to bind with another resulted in the 
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exothermic component of the thermogram; therefore a decrease in this process would ultimately 
result in the decease of the magnitude of the exothermic component. The cumulative exothermic 
heat events released for compounds 23, 29 and 37 were, respectively, -0.40, -0.17 and -0.05 
kcal/mol.22, 23, 25, 27 Compound 36, as with the endothermic heat event, was an exception to this 
trend and produced -0.16  kcal/mol. 
 
Figure 4.7: Full titration ITC experiment for the titration of 35 mM 4:1 POPC/POPG LUVs into 
200 µM compound 23 (top left), 50 µM compound 36 (top right), 100 µM compound 29 (bottom 
left) and 200 µM compound 37 (bottom right).  
 
104 
 
Another intriguing feature of these pepties was the correlation between the most 
exothermic point of the ITC and the “critical point” of the CD titrations studies. The molar ratios 
obtained at each point were the same and were indicative of a transition from peptides in 
predominately I-states to those in S-states.   These ratios are different for each peptide in this 
series, and decrease with increasing spacer length, with the exception of compound 36. 
As with compound 23, we were unable to fit this data to known models so as to obtain a 
full set of thermodynamic data. However, single injection ITC experiments were conducted to 
determine the enthalpy (∆H) values for the binding interaction as well as membrane disruption.11, 
22, 23, 25, 26, 28
  These ∆Hs should not be confused with ∆H0, the enthalpy of the entire reaction, as 
they focus on the two extremes of the isotherm: binding and membrane disruption. To determine 
the ∆H of binding, dilute solutions of compounds 23, 36, 29 and 37 were titrated into 
concentrated solutions of  4:1 POPC/POPG LUVs  (Figure 4.8)  25 to isolate the processes 
associated with high L/P ratios where the surface state, or S-state, predominates. An illustrative 
schematic can be seen in Figure 3.12.  The ∆H for the binding of compounds 23, 36, 29 and 37 
to anionic LUVs were -1.02, + 0.46, +1.2 and +1.8 kcal/mol, respectively. Compound 23 
exhibited the most favorable enthalpic process of the peptides in this study while compounds 36, 
29 and 37 exhibited endothermic processes.  These endothermic heat events can be explained in 
large part by the desolvation of the structured water molecules on the surfaces of the peptide and 
membrane. As the non-polar residues partition into the membrane, attaching the peptide to the 
surface, the water spheres surrounding both the peptide and membrane are disrupted. 26 As 
previously discussed with the full titration experiments, the increase in the length of the spacer 
for compounds 36, 29 and 37 results in larger peptides which will cause more disruption on the 
surface of the membrane.  
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Figure 4.8: Single injection ITC experiments to determine the ∆H of binding. A dilute solution 
of 200 µM compound 23 (top left) was titrated into 15 mM 4:1 POPC/POPG LUVs. Dilute 
solutions of  250 µM compound 36 (top right), 200 µM compound 29 (bottom left) and 100 µM 
compound 37 (bottom right) were titrated into concentrated solutions of 20 mM 4:1 
POPC/POPG LUVs to give high L/P ratios.29  
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Titrating dilute samples of lipid into excess peptide allowed for the isolation of heat 
associated with any membrane disrupting processes. In general, this process includes the 
saturation of the membrane surface followed by pore formation for 4:1 POPC/POPG LUVs. The 
LUVs were saturated upon injection into the reaction cell containing excess peptide so as to 
achieve L/P ratios where the peptide was present in two possible environments, bulk solution or 
the inserted state (I-state). An illustrative schematic can be seen in Figure 3.14. Single injection 
experiments for the titration of 4:1 POPC/POPG LUVs into the peptides (Figure 4.9) yielded 
enthalpy values ranging from +0.10 and +0.60 kcal/mol. These endothermic values can be 
explained in large part by the loss of water molecules on the surface of the peptide and 
membrane as the peptide inserted into the bilayer as well as the release of water molecules from 
the inside of the liposome due to the formation of a pore.23 Also, the disruption of the lipid:lipid 
interactions of the bilayer upon insertion would contribute further to the endothermic heat 
event.20, 23 All of the single injection data for the interactions between compounds 23, 36, 29 and 
37 are summarized in Table 4.5. 
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Figure 4.9: Single injection ITC experiments to determine the ∆H of membrane disruption. 
Dilute solutions of 20 mM 4:1 POPC/POPG LUVs were titrated into 300 µM solutions of 
compound 23 (top left) and 36 (top right). A 15 mM solution of 4:1 POPC/POPG LUVs was 
titrated into 300 µM compound 29 (bottom left) and 10 mM 4:1 POPC/POPG LUVs into 300 
µM compound 37 (bottom right). 
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Zwitterionic LUVs. Full titrations of 35 mM POPC LUVs into compounds 23 (Figure 
4.10 - top left), 36 (Figure 4.10 - top right), 29 (Figure 4.10 - bottom left) and 37 (Figure 4.10 - 
bottom right) resulted in a single endothermic phase.30 Previous ITC studies have reported 31 that 
an endothermic phase would be attributed to a combination of several events including 
electrostatic interactions between the peptide and the membrane surface, disruption of polar head 
groups accompanied by reorganization of lipids on the surface of the membrane, disruption of 
the solvation spheres on both the peptide and the membrane surfaces, and other less understood 
phenomena.31 All of the titrations with POPC LUVs resulted in a continuous decrease of heat as 
the experiment progressed until only the heat of dilution was observed. The subsequent decrease 
of heat was due to the fact that with each addition of lipid, peptide became bound to the vesicles 
and removed from the bulk solution, thus, decreasing the amount of peptide available for 
binding. This process continued until no peptide was available for binding and thus was assumed 
to be 100% bound. The only heat observed after this point was the heat from dilution of lipid.11, 
19, 22-24, 28, 32
 There were two observations of the thermograms that were indicative of weak 
binding between our peptides and POPC LUVs. One, there was minimal heat evolved upon 
titration of the peptide solutions with lipid.31, 33 Also, weak binding was indicated by the high 
L/P molar ratios observed for complete binding of the peptides.19, 22-24, 28  High ratios, ~120, 275, 
250 and 300 for compounds 23, 36, 29 and 37 respectively, were required before all of the 
peptide was removed from the bulk solution. 
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Figure 4.10: ITC experiment for the titration of 35 mM POPC LUVs into solutions of 200 µM 
compound 23 (top left), 50 µM compound 36 (top right), 100 µM compound 29 (bottom left) and 
50 µM compound 37 (bottom right).  
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Although we were unable to obtain thermodynamic data for the titration of 4:1 
POPC/POPG LUVs into peptides, this was not the case for the titration with POPC LUVs. A plot 
of the degree of binding, Xb, against cf, that concentration of free peptide in bulk solution, 
yielded nonlinear binding isotherms compounds 23, 36, 29 and 37 in the presence of 35 mM 
POPC LUVs at 25°C (Figure 4.11).  
 
 
Figure 4.11: Plot for the degree of binding, Xb, as a function of the peptide concentration in bulk 
solution, cf. The binding isotherms were derived from the titration of 35 mM POPC LUVs into 
compounds 23 (top left), 36 (top right), 29 (bottom left) and 37 (bottom right). Xb and cf were 
calculated as described in chapter 1 of the text.21, 26 
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The nonlinear plots were due to the fact that the model, Xb = Kpcf, does not account for 
the electrostatic interactions between the positively charged peptide and the localized regions of 
negative charge on the membrane surface. This results in an increase of peptide concentration at 
the surface of the membrane, cm in comparison to the bulk solution, cf.26 Therefore, the more 
sophisticated surface partition equilibrium model, Xb = Kcm, from Equation 1.9 in Chapter 121, 
32, 34, 35
 is more appropriate for the analysis of our data. By plotting Xb versus cm (Figure 4.12), 
the binding constant K can be obtained as it is the slope of the line. Knowing Kb allowed for the 
calculation of other thermodynamic data, including free energy (∆G0) and entropy (∆S) from the 
Equations 1.2 and 1.3 discussed earlier: ∆G0 = –RTln(55.5K) and ∆G0 = H – T∆S. 
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Figure 4.12:  Plot for the degree of binding, Xb, as a function of the surface concentration of 
peptide, cm. The binding isotherms were derived from the titration of 35 mM POPC LUVs into 
compounds 23 (top left), 36 (top right), 29 (bottom left) and 37 (bottom right). Xb and cm were 
calculated as described in chapter 1 of the text.21, 26 
 
 
 
 
Upon plotting cm against Xb, a unique relationship was revealed between the binding 
constants and the spacer length. As seen in Figure 4.12 one line was observed with compound 
23, where two intersecting lines were observed for compounds 36, 29 and 37. This intriguing 
observation has been attributed to the fact that compounds 36, 29 and 37 contain unnatural amino 
acid spacers. Consequently, two sets of thermodynamic data were calculated for compounds 36, 
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29 and 37, one at lower peptide concentration and one at higher peptide concentration. The 
results for the thermodynamic analysis of compounds 23, 36, 29 and 37 with POPC liposomes 
are given in Table 4.5. As can be seen in Table 4.5, there is no discernable trend in ∆H0, K or 
∆G with regard to the length of Spacer #1. However, there is an obvious trend with the ∆S of the 
interactions as the entropy increases with the length of the spacer. The ∆S values become more 
positive as the spacer length increases.  
 
 
Table 4.4: Thermodynamic data for a representative titration of 35 mM POPC into the peptides 
at 25°C as derived from the equations discussed previously. 
Compound ∆H0,a  (kcal/mol) Kb  (M-1) ∆Gc  (kcal/mol)         ∆Sd  (cal/mol·K)
23 na    na     na na
36 0.04 265.2 -5.7 19.2
29 0.49 146.9 -5.3 19.5
37 0.19 309.0 -5.8 20.0
23 0.67 211.0 -5.5 20.8
36 0.59 412.2 -5.9 21.9
29 0.95 262.7 -5.7 22.2
37 1.63 479.0 -6.0 25.7
M2a -15.9 2000.0 -7.0 -29.4
Higher Peptide Concentration
Lower Peptide Concentration
Magainin-2-amidee
 
a 
∆H values were calculated using Equation 1.4 from chapter 1 using the binding enthalpies 
measured directly from the experiment.  
b K values were generated from the lipid-into-peptide titration using the calculations as described 
in chapter 1.  
c
 ∆G values were calculated using Equation 1.1 from chapter 1. 
d
 ∆S was calculated using Equation 1.2 from chapter 1.  
e
 The thermodynamic parameters for the magainin analogue M2a as presented by Wieprecht et. 
al. 20, 30 
 
 
 
The increasing entropy can be explained by the molecular volume of the peptide. As the 
spacer length increases, the conformational flexibility and degrees of freedom for each peptide 
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also increases thereby causing the conformational space available to the peptide to increase 
dramatically. The magnitude of disruption caused on the surface of the membrane increases as 
the conformational space available for the peptide to sample increases. Association of the peptide 
with a membrane results in the desolvation of structured water molecules on both surfaces, 
contributing to the positive component of ∆S.23, 36-38 Other positive ∆S contributors include the 
interruption of the polar head groups on the surface as well as the disruption of the lipid-to-lipid 
interactions upon binding.23 Consequently, as the concentration of peptide increases so do the 
processes that disrupt the membrane surface, thus resulting in an increase of ∆S.11, 19, 20, 23, 37, 39  
Traditional binding isotherms for peptides containing α-amino acids, such as compound 
23 with a glycine spacer, exhibit straight lines.11, 22, 26 However, for the peptides 36, 29 and 37 
which incorporate unnatural amino acids containing additional methylene groups in peptide 
backbone, resulted in two distinct intersecting lines. At this point, we have not been able to 
locate similar behavior in the literature. This unique observation could be due to the fact that β- 
peptides (compound 36), γ-peptides (compound 29) and ε-peptides (compound 37) have 
expanded hydrogen bond ring sizes 40 which allow them to take on additional conformations that 
the α-amino acids such as the glycine of compound 23, can not adopt. The longer the amino acid 
backbone the more flexible the peptide will be, thus allowing it to occupy a larger space.40 The 
second line in the binding isotherm may represent a conformational transition un-available to α-
amino acid containing peptides. 
Examining the processes occurring in the full titration experiments could possibly offer 
an explanation for the observed behavior. As previously discussed, there is an excess of peptide 
in the cell at the beginning of the titration experiment. Small aliquots of liposomes were titrated 
into the cell and saturated with peptide, removing peptide from bulk solution with each titration. 
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As the peptide available for binding decreases, so do the heats associated with each injection 
until all of the peptide is removed from the bulk solution.23 Low L/P ratios were observed at the 
beginning of the titration as the liposomes were saturated with peptide after each injection. At the 
end of the titration high L/P ratios were observed. An illustrative schematic can be seen in 
Figure 3.9. Depending on the L/P ratio, there are two types of conformational changes that the 
peptide may undergo. One involves the binding of peptide to a saturated liposome while the 
other involves a peptide-free liposome. As LUVs were titrated into the peptide solution, the 
peptides immediately adopt conformations to fit around the charged polar lipid head groups. At 
this point, the surface potential of the membrane becomes more positive resulting in the second 
type of conformational change which corresponds to the binding isotherm at higher peptide 
concentrations. With a change in the surface potential, the peptide must change conformation 
while in the bulk solution so as to bind with a liposome surface which is already saturated. As 
the L/P ratio increases, the peptides only undergo the conformational changes associated with 
binding to a peptide-free membrane surface. This process corresponds to the binding isotherm at 
lower peptide concentrations.  Even though both processes occur with the binding of α-amino 
acids, we feel that the lack of conformational space available to α-amino acids relative to the 
others causes the two processes to be indistinguishable from each other.  
Single injection experiments were also performed for the POPC liposomes in order to 
obtain representative ∆H values for low and high L/P ratios for the interaction between the 
peptides and zwitterionic models. Titrating minimal peptide into excess POPC lipid allowed for 
the isolation of the heat associated with the initial binding.  For an illustrative schematic refer to 
Figure 3.12. For each of these peptides, this particular ∆H was endothermic with no obvious 
trend associated with an increase in spacer length. Compound 37 absorbed the most heat at +3.9 
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kcal/mol followed by compound 23, 36 and 29 with +2.1, +1.6 and +1.1 kcal/mol, respectively 
(Figure 4.13). The fact that ∆H was positive rather than negative as observed in most “binding” 
events can be attributed to several processes including the desolvation of the water molecules on 
the surfaces of both the membrane and peptide, displacement of polar lipid head groups upon 
interaction with the peptide, disruption of the lipid:lipid interactions as the hydrophobic side 
chain inserted into the bilayer and any repulsive interactions between the positively charged side 
chains and the localized negative charge on the surface. The processes formerly mentioned 
contribute to positive ∆H values and thus counteract the negative ∆H of binding to produce an 
overall endothermic reaction.11, 26, 31, 41  These differences in binding enthalpies reflect the global 
conformational and physicochemical changes that occur during the binding of each peptide to the 
surface of the liposomes.  For example compound 37, with the longest spacer Ahx, exhibited the 
greatest conformational flexibility and thus displayed the largest enthalpy changes.   
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Figure 4.13: Single injection ITC experiments in order to determine the ∆H of binding for POPC 
LUVs. Dilute solutions of 200 µM compound 23 (top left), 36 (top right) and 29 (bottom left) 
were titrated into 15 mM solutions of POPC LUVs. A dilute solution of 100 µM compound 37 
(bottom right) was titrated into 15 mM POPC LUVs to give high L/P ratios.29  
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The heat associated with membrane disruption was isolated by titrating dilute samples of 
POPC LUVs into excess peptide.   Generally for the case of our peptides with POPC LUVs, this 
process includes the saturation of the membrane surface consequently causing leakage. Due to 
the low L/P ratio, the peptide will be observed in one of two possible environments, the bulk 
solution or in the inserted state (I-state). As the surface should be saturated with peptide, the I-
state or other states involved in membrane disruption should predominate, producing injections 
of identical heats that were averaged. For an illustrative schematic refer to Figure 3.14. There 
was no discernable trend for the observed ∆Hs affiliated with membrane disruption for this series 
of peptides and the spacer length. Compound 37 had the highest ∆H with +0.05 kcal/mol 
followed by compound 23 with +0.04 kcal/mol, compound 36 with +0.03 kcal/mol and 
compound 29 absorbed the least amount of heat with +0.02 kcal/mol (Table 4.5). One notable 
feature was the 4-10 fold decrease in the magnitude as compared to the ∆H of membrane 
disruption for 4:1 POPC/POPG LUV membrane models. This observation supports the 
conclusion that these peptides are selective towards anionic membranes over zwitterionic. 
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Figure 4:14: Single injection ITC experiments to determine the ∆H of membrane disruption for 
POPC LUVs. Dilute solutions of 20 mM 4:1 POPC/POPG LUVs were titrated into 300 µM 
solutions of compound 23 (top left), 36 (top right), 29 (bottom left) and 37 (bottom right). 
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The difference in ∆Hs of the two different single injection experiments for POPC LUVs 
can be attributed to exothermic processes counteracting the positive ∆H contributions of the 
endothermic processes. At the low L/P ratios of the membrane disrupting processes, there are 
several peptides binding per lipid, thus increasing the negative ∆H component of the overall 
reaction. An increase in the negative component consequently causes an overall decrease in the 
positive.22  
 
Table 4.5: ∆H (kcal/mol) values for the binding and membrane disruption of 4:1 POPC/POPG 
and POPC LUVs as determined by single injection ITC experiments.23 
Compound Compound into      4:1 POPC/POPG
4:1 POPC/POPG 
into Compound
Compound into 
POPC
POPC into 
Compound
23 -1.0 ± .04 0.14 ± .03 2.1 ± .04 0.04 ± 0
36 0.3 ± .02 0.14 ± .00 1.1 ± .07 0.02 ± 0
29 1.2 ± .02 0.44 ± .01 1.6 ± .05 0.03 ± 0
37 1.8 ± .02 0.62 ± .01 3.9 ± .08 0.05 ± 0
 
 
 
 
 
The different shapes of the anionic and zwitterionic thermograms, two phases versus one, 
are indicative of different mechanisms of action. This observation coupled with the large 
differences in the heats absorbed and/or released during the single injection experiments supports 
the hypothesis that this series of peptides is selective. There are several factors that contribute to 
the binding and membrane disruption enthalpies that are common to anionic and zwitterionic 
membrane models. In addition to changes in Van der Waals interactions due to the desolvation of 
both the peptide and membrane surfaces,26, 31, 42 these factors include both repulsive and 
attractive electrostatic interactions, changes in conformation adopted by the peptide, disruption 
of polar head groups as well as lipid:lipid interactions on the outside and inside of the 
liposomes.11, 19, 20, 22, 23 The only significant difference between the two model membrane 
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systems was the introduction of a greater negative charge on the surface of the 4:1 POPC/POPG 
mixed LUVs. This small increase in negative charge clearly played an important role in the 
interactions of the highly positively charged (+6) peptides and anionic membrane models, thus 
promoting selectivity.   
 
 
Calcein leakage studies 
Monitoring the fluorescence of peptide induced calcein leakage has been well 
documented as a technique for probing AMP activity.42, 43  By introducing different 
concentrations of peptide to solutions of calcein-encapsulated POPC or 4:1 POPC/POPG LUVs, 
it was possible to determine the concentration dependency, if any, for the activity. It can be seen 
in Figure 4.15 that these peptides did not appear to interact with POPC LUVs via a 
concentration dependent mechanism. There is not a significant difference in the leakage 
observed at 4 µM peptide and at 20 µM with any of the four peptides. It is hypothesized that the 
leakage observed was more than likely due to the displacement of the polar head groups as the 
peptides became bound. From the CD and ITC data, it is evident that there was a level of 
interaction taking place. As the peptide concentration increased, the increased displacement of 
polar lipid head groups resulted in the “thinning” of the membrane. Thus, one possible 
explanation for the leakage is due to a modified “carpet” mechanism rather than a pore.20, 44, 45  
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Figure 4.15: The time dependent release of calcein from POPC LUVs induced by increasing 
concentrations of compound 23 (top left), 36 (top right), 29 (bottom left) and 37 (bottom right) as 
measured by fluorescence.  
 
 
 
 
It is evident in Figure 4.16 that these peptides, with the exception of compound 36, 
interact with the anionic membrane models via a concentration dependent manner. As the 
concentration of peptide increased so did the leakage, which maybe explained in the terms of a 
pore forming mechanism. 46-48 More specifically, the increase in leakage followed by a leveling 
off suggests a transient pore mechanism. 46, 49 During the initial insertion of the peptide into the 
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bilayer, the pore undergoes a nucleation step which is followed by a restabilization of the lipid-
peptide structure, 46 consequently resulting in the leveling off of the observed leakage after a 
period of time unique to the peptide.46, 50  The differences in the amount of leakage observed for 
each peptide can be explained by the varying selectivity of each peptide. In vitro data presented 
in Tables 4.2 and 4.3 provided proof that these peptides are in fact selective against different 
gram-negative and other drug resistant bacteria strains.  
 
 
Figure 4.16: The time dependent release of calcein from 4:1 POPC/POPG LUVs induced by 
increasing concentrations of compound 23 (top left), 36 (top right), 29 (bottom left) and 37 
(bottom right) as measured by fluorescence. 
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When comparing the total percent leakage caused by each peptide at the same 
concentration (Figure 4.17), compounds 29 and 37 exhibited a significant increase from POPC 
and 4:1 POPC/POPG LUVs as compared to compounds 23 and 36.  For POPC, this excess 
leakage was most likely due to the larger peptides displacing more polar head groups as they 
bind, thus increasing the extent of membrane thinning allowing leakage of the dye.20, 44, 45  The 
best explanation for the increased leakage in the presence of 4:1 POPC/POPG LUVs at constant 
peptide and LUV concentrations is that compounds 29 and 37 form a larger number of pores. 
The increase in the spacer length results, ultimately in a larger peptide. With larger peptides, 
fewer peptides are needed to form pores capable of leakage. Due to the fact that the number of 
peptides available was held constant and fewer peptides were needed per pore, there were more 
peptides available to make more pores, thus leading to higher leakage. This conclusion was 
supported by the full titration ITC data for the titration of 4:1 POPC/POPG LUVs into the 
peptides. The larger peptides have smaller exothermic components, suggesting that we are 
observing peptides that remain bound to the liposome and do not dissociate from one membrane 
surface to associate with another.   
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Figure 4.17: The total percent of calcein leakage from POPC (left) and 4:1 POPC/POPG LUVs 
induced by increasing concentrations of compounds 23, 36, 29 and 37 as measured by 
fluorescence. 
 
 
 
 
Conclusions 
 
The data presented in this chapter supports the hypothesis that this particular series of 
peptides exhibit selectivity and the lengthening of Spacer #1 does in fact play a role in the 
interactions with model membrane systems. CD spectra of compounds 23, 36, 29 and 37 clearly 
indicate that these peptides interact with zwitterionic and anionic micelles and liposomes 
differently, as expected.   The conclusion that the different conformations adopted by the 
peptides in different membrane models as seen by CD are indicative of different mechanisms is 
supported by the ITC and calcein leakage studies. The change in the mechanism is believed to be 
a result of the changes in the physicochemical properties presented to the liposome surfaces by 
the modifications of spacer #1. 
 The ITC observed for these compounds is very different from the thermodynamic data 
that has been observed for natural AMPs.18, 20-23, 25-27, 35, 41, 42, 51-53 We believe these differences 
are due, in large part, to the fact that our peptides incorporate a high percentage of unnatural 
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amino acids and were designed to have regions of limited conformational flexibility while the 
peptide backbones of most natural peptides are relatively flexible.  As a whole, we believe that 
this group of peptides interacted with POPC LUVs via a modified version of the “carpet” 
mechanism, associating predominately with the surface, while forming pores in the presence of 
4:1 POPC/POPG LUVs. We have also presented evidence suggesting that the peptides with the 
shorter spacers, compounds 23 and 36, require a higher number of peptides to form a leakage 
inducing pore than compounds 29 and 37 with the longer backbones.   
It was shown in Figure 3.2 that compound 23 exhibited different CD spectra depending 
on the percentage of anionic lipids present in the liposomes.  This particular observation supports 
our hypothesis that the chemical composition, and thus the surface physicochemical properties, 
of the lipid membrane plays a very important role in determining the conformation adopted by 
these peptides upon binding to the surface.  Each strain of bacteria has small differences in the 
chemical composition of its cell membrane, thus presenting different physicochemical properties 
to the approaching peptide.  We have provided spectroscopic and thermodynamic evidence 
supporting the conclusion that these peptides, with increasing spacer length, adopt different 
conformations and undergo different mechanisms of action depending on the membrane surface 
they are presented with.   It is therefore reasonable to expect our peptides to be capable of 
interacting specifically with the membranes of various bacteria strains. The observed differences 
in biological activity (MIC values) between the various strains of bacteria as a function of spacer 
length can be explained by these peptides adopting different conformations on the membranes of 
the various bacteria strains. Some of these interactions are more favorable for pore formation 
than others, thus resulting in lower MIC values for that particular bacteria strain.  This is clearly 
the case for compound 37 against the Gram Negative bacteria strains given in Table 4.3. 
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Therefore, it should be possible to design analogs which will exhibit selectivity for specific 
bacteria strains based on the chemical composition of their respective membranes.   
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CHAPTER FIVE: SPACER # 2 
 
Introduction 
This chapter discusses the use of a combination of CD spectroscopy, ITC and calcein 
fluorescence leakage assays to investigate the role played by Spacer #2 (Figure 1.2 – gold). 
Spacer #2 defines the distance between the polypeptide backbone and the positively charged side 
chain amine. The residue is also involved in determining the overall surface charge density of the 
peptide as well as the distance between the membrane surface and the backbone of the peptide.1  
The number of methylene groups in the side chain of Spacer #2 decreases from four with Lys in 
compound 23, to three with Orn in compound 43, to two with Dab in compound 53 and to one 
methylene with Dpr in compound 45. The sequences are given in Table 5.1. These studies were 
designed to provide a better understanding of how the physicochemical properties of the peptide 
influence the mechanism of binding with several zwitterionic and anionic membrane model 
systems. We have already discussed the logic of incorporating un-natural amino acids into the 
peptide sequence of an AMP as there are several advantages over an AMP consisting exclusively 
of naturally occurring amino acids.  Here we will focus on the importance of the positively 
charged amino acid residue. By decreasing the length of the side chain, the positive charge 
density will reside closer to the backbone resulting in less flexibility during binding which is 
more important in binding with zwitterionic lipids than anionic. 
A fifth AMP was included in this particular series. Compound 56 replaces the Lys 
residue of compound 23 with Arg, an amino acid residue containing a guanidinium group, a 
planar group with the positive charge delocalized over two different nitrogen atoms. This 
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delocalization allows for the positive charge to disperse more than the localized positive charge 
of the one nitrogen of the Lys side chain.2, 3  
 
Table 5.1: Amino acid sequences of the peptides used to study the role of spacer #2. 
Compound Amino Acid Sequence
23 Ac-GF-Tic-Oic-G-K-Tic-Oic-GF-Tic-Oic-G-K-Tic-K-K-K-K-CONH2
43 Ac-GF-Tic-Oic-G-Orn-Tic-Oic-GF-Tic-Oic-G-Orn-Tic-Orn-Orn-Orn-Orn-CONH2
45 Ac-GF-Tic-Oic-G-Dpr-Tic-Oic-GF-Tic-Oic-G-Dpr-Tic-Dpr-DprDpr-Dpr-CONH2
53 Ac-GF-Tic-Oic-G-Dab-Tic-Oic-GF-Tic-Oic-G-Dab-Tic-Dab-Dab-Dab-Dab-CONH2
56 Ac-GF-Tic-Oic-G-Arg-Tic-Oic-GF-Tic-Oic-G-Arg-Tic-Arg-Arg-Arg-Arg-CONH2
 
 
The in vitro activity of these peptides against several common bacterial strains1 as well as 
several gram negative and drug-resistant strains4 can be seen in Tables 5.2 and 5.3, respectively. 
The activities of this series of compounds were compared to the activity of compound 23 as it 
has shown broad spectrum activity with minimal hemolysis. Compound 43, with 3 methylene 
groups, had increased activity in 8 of the 15 bacterial assays tested in comparison to compound 
23, and retained similar MIC values in the remaining 7.  The next shortest spacer, compound 53, 
had improved activity in one bacterial assay, lost activity in 4 and retained activity in 10 assays.  
Compound 45 with the shortest chain had decreased activity in 8 of the 15 assays, the same in 5 
and slightly increased activity in 2 concluding that compound 45 is the least active peptide of this 
series. These results lead to the assumption that as the spacer length decreases, so does the 
activity. Compound 56 with the guanidinium group was similar to compound 43 in that they both 
contain three methylene groups. The activity of compound 56, overall, was very similar to that of 
compound 23. 
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Table 5.2: Minimum inhibitory concentration (µM) of selectra bacteria strains and hemolytic 
activity.1  
Compound Salmonella 
typhimurium
Staphylococcus aureus 
ME/GM/TC resistant
Mycobacterium 
ranae
Bacillus 
subtillis
% hemolysis 
100/25 µM
23 10 3 10 1 14%
43 3 3 10 0.3 not tested
45 3 10 100 1 not tested
53 30 10 10 not tested not tested
 
 
Table 5.3: Minimum inhibitory concentration (µM) of specific Gram negative and other drug 
resistant bacteria strains.4  
Compound 23 43 53 45 56
Acinetobacter baumanii 
ATCC 19606 3.2 6.6 3.4 3.6 5.98
Acinetobacter baumanii 
WRAIR 3.2 6.6 3.4 3.6 24
Staphylococcus aureus 
ATCC 33591 205 53 220 114 96
Yersinia pestis CO92 205 26.5 220 228 192
Brucella melitensis 16M 205 106 220 288 192
Brucella abortus 2308 205 106 220 288 192
Brucella suis 23444 205 106 220 288 192
Bacillus anthracis AMES 12.8 0.82 6.8 14.8 5.98
Francisella tularensis 
SCHUS4 100 106 220 228 192
Burkholderia mallei 205 212 220 228 192
Burkholderia 
pseudomallei 205 212 220 228 192
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CD Studies 
CD spectra of Spacer #2 peptides in buffer and micelle environments. CD spectra of 
compounds 23, 43, 53, 45 and 56 can be seen in 40 mM phosphate buffer, pH = 6.8 (Figure 5.1). 
All of the peptides exhibited a characteristic α-helical structure with double minima at 
approximately 208 and 222 nm.5-9 There also appeared to be the presence of some β-turn 
components due to the maxima between 195 and 200 nm.10-12 Overall, the CD spectra of each 
compound in buffer were very similar in shape with varying intensities that appeared to be 
random and not associated with the decrease in the side-chain length of the positive residue. The 
average distances between the side chain amine and the α-carbon of the peptide backbone for 
each of the Spacer #2 amino acid residues were calculated using ChemDraw 3D, Cambridge 
Software and are given in Table 5.4. Although the distance for Arginine is not listed, we 
assumed it to be approximately the same distance as Orn from compound 43 as they both contain 
three methylene groups in their side-chains. 
 
Figure 5.1: Far-UV CD spectra of compounds 23, 43, 53, 45 and 56 (1 mg/mL) in 40 mM 
phosphate buffer, pH = 6.8. 
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Table 5.4: Average distances between the side chain amine and the α-carbon of the Spacer #2 
amino acid residues. 
Peptide ID 23 43 53 45
Residue Lys Orn Dab Dpr
Average distance 4.76 Å 3.55 Å 2.99 Å 2.56 Å
# of carbons in 
side-chain 4 3 2 1
 
 
 
In the presence of the negatively charged SDS micelles (Figure 5.2 – left), all of peptides 
exhibited a shift in λmax from approximately 195 to 190 nm as well as an increase in intensity. 
Both of these observations are indicative of an increase in α-helicity.6, 8, 13, 14 All of the 
compounds, with the exception of compound 45, exhibited the very similar shape with different 
intensities. The compounds with the longer side-chains, 23 and 43, exhibited very similar 
intensities below 200 nm but compound 23 was slightly less intense above 200 nm. Compound 
53 was less intense at the maximum below 200 nm and at both minima indicating less helical 
structure.6, 8, 14 The shift in the minima from approximately 208 to 202 nm suggests an increase 
in the unordered components of the peptides.8, 12, 15 
Compound 45, with the shortest side-chain, exhibited a change in shape from the other 
peptides at approximately 200 nm which suggests a different interaction with the surface of the 
anionic membrane. A loss in the intensity at 190 and 202 nm also suggests a loss in ordered 
structure.6, 8, 13 This could be due to the extremely short side-chain not allowing enough 
flexibility for the peptide to adopt the same secondary structures as the other peptides in this 
series. However, the shape of each spectrum in SDS micelles differed from the corresponding 
spectrum in buffer indicating that these peptides interact with the surface of the anionic micelle 
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membrane as they adopted different conformations.5, 14 This interaction would be expected as the 
peptides are all highly positively charged.  
 
 
 
Figure 5.2: Far-UV CD spectra of compounds 23, 43, 53, 45 and 56 in the presence of 80 mM 
SDS (left) and 80 mM DPC (right) in 40 mM phosphate buffer, pH = 6.8. 
 
 
As seen in Figure 5.2 (left), when in the presence of zwitterionic DPC micelles, the 
shape and intensities of the CD spectra followed the same trend as they did for SDS with shifts to 
190 nm and double minima at approximately 202 and 222 nm. Compounds 23 and 43 were 
essentially identical and very similar to compound 56 which had a slight increase in the 
intensities at 190 and 222 nm. Compound 53 exhibited the same shape, but the intensity of the 
spectra was extremely different. The intensity of compound 45 was similar to that of compounds 
23 and 43, but displayed a different shape. The minimum at the lower wavelength was obscured 
between 205 and 215 nm and not well defined as was the case for the other peptides. As a series, 
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each spectrum in DPC was significantly different from their corresponding spectra in buffer 
concluding some level of interaction was occurring. Although the spectra were similar in shape 
to those in SDS, the intensity was lower, with the exception of compound 53, indicating less 
helical componenents.6, 13, 14  
 
CD spectra of Spacer #2 peptides in LUV environments. The CD spectra of the five 
peptides in the presence of 1.75 mM POPC LUVs, the simple zwitterionic membrane model, are 
presented in Figure 5.3. Minimal changes were observed with regards to the intensity and 
location of the λmax of the spectra in POPC LUVs as compared to buffer. For the double minima 
above 200 nm, there was no significant shift in the wavelengths, but there were observable 
changes in the intensities. For compounds 23, 43 and 53  the intensities increased at 
approximately 208 nm, remained relatively constant for 56, while significantly decreasing for 
compound 45. The second minimum at approximately 222 nm increased in intensity for 
compound 23, remained relatively unchanged for compounds 43 and 53, decreased for 
compound 56 and disappeared for compound 45. The decrease in the intensity of the double 
minima appeared to increase with the increase in spacer length. This increase in ellipticity of the 
two α-helical characteristics is indicative of an increase in the ordered structure.6, 7, 14 As the 
spacer length increased, the peptide becomes more flexible allowing it to adopt such 
conformations. Compound 45, however, does not appear to be ordered as it contains a minimum 
below 200 nm.8, 12, 15, 16 
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Figure 5.3: Far-UV CD spectra of compounds 23, 43, 53, 45 and 56 in 1.75 mM POPC (left) in 
40 mM phosphate buffer, pH = 6.8, and their corresponding HT values (right). 
 
 
When compared to their spectra in the presence of DPC micelles , these compounds had 
obvious similarities and differences depending on the peptide. As a whole, there was a 
significant decrease in the intensity of the maximum below 200 nm suggesting a decrease in α-
helicity.6, 13, 14 However, this observation may be compensated by the shift in minimum from 
approximately 202 nm in the presence of DPC micelles, a combination of unordered and α-
helical components,8, 15, 16 to 208 nm in POPC LUVs, a characteristic of pure α-helicity.6, 8, 9 The 
intensity of both minima increased for compounds 23 and 43, however, decreased for 
compounds 53 and 56. Compound 45 was completely different from its ordered conformation in 
DPC micelles suggesting different S-state and I-state conformations. Also, compound 45 was not 
only different from its own spectra in buffer and DPC micelles, but it was also completely 
different from the spectra of the other peptides. This observation leads to the assumption that 
compound 45 interacts with zwitterionic bilayers via a completely different mechanism. 
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As for the spectra of the peptides in the presence of the anionic membrane models, 4:1 
POPC/POPG LUVs (Figure 5.4), all of the peptides exhibited a downfield λmax shift, as well as 
shifts in the minima from approximately 208 to 200 nm when compared to the spectra in buffer. 
The former suggests an increase in α-helicity7, 17 while the latter is indicative of a combination of 
α-helical and unordered structures.8, 12 Compound 23, as previously discussed, had an overall 
increase in the intensity of the spectra supporting the conclusion that it was adopting α-helical 
characteristics. Overall, the intensity changes of compounds 43, 53, 45 and 56 proved minimal.  
 
 
 
Figure 5.4: Far-UV CD spectra of compounds 23, 43, 53, 45 and 56 in 1.75 mM 4:1 
POPC/POPG LUVs in 40 mM phosphate buffer, pH = 6.8, and their corresponding HT values 
(right). 
 
 
 When compared to the spectra in the presence of SDS micelles, there were significant 
changes in the intensity of the λmax. Each compound exhibited a decrease in the intensity from 
SDS micelles to the POPC/POPG bilayer, proposing a decrease in the helical characteristic of the 
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peptides.6, 14 This could be due to the fact that these peptides were inserting into the bilayer and 
losing some of their α-helical component.  
“Pseudo” CD Titrations. Pseudo titrations of the peptides with POPC LUVs are given in 
Figure 5.5 for compounds 23, 43, 53, 45 and 56. Although the CD spectra for compounds 23 and 
45 in the varying POPC LUV concentrations were clearly different from their spectra in buffer, 
and compounds 43, 53 and 56 were very similar, overall, the CD spectra did not appear to vary 
much in conformation when POPC LUV was added. The lack of variation in conformations 
suggests that the interaction between these peptides and the POPC LUV membrane models was 
not concentration dependent.18-20 The spectra at low L/P ratios were very similar to the samples 
associated with high L/P ratios. 
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Figure 5.5: Far-UV CD spectra of separate samples of 200 µM compound 23 (top left) and 45 
(middle right) and 100 µM solutions of compounds 43 (top right), 53 (middle left) and 56 
(bottom) with increasing concentrations of POPC LUVs.21, 22  
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The “pseudo” titrations of these peptides with 4:1 POPC/POPG LUVs (Figure 5.6) 
yielded a very different outcome. The CD spectra of each peptide changed dramatically in shape 
and intensity from their spectra in buffer with the first introduction of anionic LUVs. The 
intensity of the spectra for each peptide at low L/P ratios (blue spectra) decreased with increasing 
LUV concentration. Intensity continued to decrease until a critical ratio was reached in which it 
became constant (green spectrum). The peptide is assumed to be completely membrane bound at 
this P/L ratio, which is unique to each peptide.23, 24 Intensity of the spectra returned with the 
continuous addition of anionic liposomes (red spectra) and as the L/P continued to decrease. The 
blue group of spectra is associated with low L/P ratios and there for membrane disrupting 
processes while the red spectra correspond with high L/P ratios and binding. 
A different trend, however, was observed for compounds 45 and 56. The CD spectra for 
compound 45 were different from the spectrum in buffer, but the intensity changes of the two 
minima were minimal with no clear spectra associated with the transition from low to high L/P 
ratios, or I-state to S-state. Without this observable transition, it is believed that compound 45 
does not favor pore formation. Compound 56, on the other hand, exhibited several different 
groupings of spectra in comparison to the groups before and after the “critical point” for the 
compounds 23, 43 and 53. There was no discernable increasing or decreasing trend of the spectra 
as the L/P ratio increased before or after the spectra corresponding to the transition from 
predominately I-state to S-state (green spectrum). The complexity of the different processes 
occurring has been attributed to the delocalized positive charge of the guanidinium group, and at 
this point, cannot be described further. 
144 
 
 
Figure 5.6: Far-UV CD spectra of separate samples of 200 µM compound 23 (top left), 43 (top 
right), 53 (middle left) and 45 (middle right) and 100 µM solutions of compound 56 (bottom) 
with increasing concentrations of 4:1 POPC/POPG LUVs.21, 22 
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ITC Studies 
 Anionic LUV environments. Titrating 4:1 POPC/POPG LUVs  into the peptides (Figure 
5.7) resulted in an endothermic reaction followed by a transition to an exothermic reaction.  
Overall, the appearance of the thermograms for compounds 23, 43, 53 and 56 were very similar. 
Endothermic phases have been attributed to a combination of several events including 
electrostatic interactions, the disruption of polar lipid head groups, disruption of the solvation 
spheres and several other less understood phenomena. The previously mentioned processes are 
involved with pore formation.24-27 As the concentration of LUVs continues to increase, the 
thermogram shifts from an endothermic heat event to an exothermic which has been attributed to 
the transition from pore formation to pore disintegration. Due to the increased L/P ratios 
associated with the exothermic phase, the enthalpy of pore disintegration also corresponds to 
binding processes.23, 25, 26 
The exothermic phase of each thermogram exhibited a maximum exothermic heat event 
which was followed by a continuous decrease in ∆H as the L/P ratio increased and the 
experiment progressed.22, 27-30 The L/P ratio at the maximum exothermic injection refers to the 
point in the titration when the processed involved shifts from predominately I-state to S-state9, 22, 
25, 27, 29
  and correlates back to the “critical point” (Figure 5.6 – green spectra) in the “pseudo” 
CD titrations with 4:1 POPC/POPG LUVs. The endothermic heat event corresponds to low L/P 
ratios and the blue spectra from the CD titrations while the exothermic phase refers to high L/P 
and the red spectra.  
Compound 45, with the shortest spacer, exhibited a very different thermogram with the 
shortest and weakest endothermic component followed by a rapid transition into a very strong 
exothermic phase.  Due to the magnitude of the exothermic component of compound 45, it is 
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believed that it favors binding interactions over pore formation.22, 25, 25, 27 This conclusion is 
supported by the single set of CD spectra for the “pseudo” titration and the decreased biological 
activity as compared to the other peptides. 
As per the case for the previously discussed peptides, the complexity of this data made it 
impossible to fit using a current model. However, we were able to make some hypothesis about 
the meaning of the thermograms. Compounds 23 and 43 were very similar. The sums of their 
endothermic components9, 25, 27, 31 had very similar total ∆Hs, as well as the most, with 
approximately +0.80 and +0.90 kcal/mol, respectively, with compound 43 absorbing the most 
heat. Because endothermic components have been associated with pore formation9, 25 coupled 
with the fact that the thermograms did not transition from the endothermic to the exothermic 
component until a L/P molar ratio of approximately 30, suggests that they both favor pore 
formation. Compound 43 had the larger cumulative endothermic component, therefore, was the 
more active of the two. This data coincides with the bioactivity as well as the CD data. In 
addition, both compounds 23 and 43 produced the least amount of heat for the exothermic 
component, supporting the idea that they favor pore formation. 
Compound 53 absorbed approximately +0.65 kcal/mol followed by compound 45 with 
the least at 0.01 kcal/mol. Although the sums of the endothermic components for compounds 53 
and 45 exhibited the least amount of heat, they produced the most exothermic heat. The 
cumulative exothermic heat for compound 53 was approximately -0.57 kcal/mol while 
compound 45 produced the most “binding” heat with -1.44 kcal/mol.22, 25, 26, 32, 33 This 
information coupled with the low molar ratios required to transition from the endothermic to the 
exothermic phase suggests that they favor binding over pore formation for anionic membrane 
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models.27 This conclusion is supported by the bioactivity data as they are less active than 
compounds 23 and 43.   
Compound 56 produced a cumulative endothermic ∆H of less magnitude, with the 
exception of compound 45, than the other peptides with approximately +0.39 kcal/mol, but this 
was compensated with a larger cumulative exothermic component of -0.55 kcal/mol.25, 27 Two 
possible explanations for this suggests two different mechanisms for compound 56, both of 
which are focused on the role of the guanidinium group at the end of the Spacer #2 side-chain. If 
compound 56 were involved in pore formation, the decrease in the endothermic component as 
compared to the other peptides could be attributed to the large positive entity partaking in 
stronger binding through attractive electrostatic interactions.22, 25-27 Stronger binding causes an 
increase in the negative ∆H component, counteracting the positive ∆H produced by pore 
formation, thus decreasing the overall positive ∆H.25 The second theory relates compound 56 
predominately with surface interactions rather than pore formation and suggests that when the 
peptide binds to the surface of the membrane, the polar head groups are displaced farther apart to 
allow for the positively charged guanidinium group.24 Here again, the negative ∆H of binding 
counteracts the positive ∆H associated with the disruption of the polar head groups.25 However, a 
large enough displacement of the head groups could allow for the leakage of the contents via a 
“thinning” mechanism similar to the “carpet” model. 18, 19, 24 
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Figure 5.7: Full titration ITC experiment for the titration of 35 mM 4:1 POPC/POPG LUVs into 
200 µM compound 23 (top left), compound 43 (top middle), and compound 53 (top right) and 
300 µM compound 45 (bottom left) and 100 µM compound 56 (bottom right). 
 
 
Quantitative data was collected regarding the ∆H associated with binding and pore 
formation via the single injection experiments previously discussed.9, 25, 27-29, 33 When titrating 
dilute peptide solutions into excess lipid to determine the ∆H of binding, compound 56 released 
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the highest amount of heat with -2.84 kcal/mol. This could be attributed to the larger positively 
charged side chain which will increase the attractive electrostatic interactions.25, 27, 33 Compound 
43, the most active peptide with regards to bioactivity, produced the second highest ∆H for 
binding. Compounds 53 and 45 were very similar and compound 23 produced the lowest ∆H for 
binding. This could be attributed to the fact that the longer spacer, lysine, allows compound 23 to 
occupy a larger volume. An increased volume would cause more disruption on the surface of the 
membrane, thus producing a larger positive ∆H component to counteract the negative ∆H of 
binding.24, 25, 27 
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Figure 5.8: Single injection ITC experiments to determine the ∆H of binding for 4:1 
POPC/POPG LUVs. A dilute solution of 200 µM compound 23 (top left) was titrated into 15 
mM 4:1 POPC/POPG LUVs. Dilute solutions of  100 µM compounds 43 (top middle), 53 (top 
right), 45 (bottom left) and 56 (bottom right) were titrated into concentrated solutions of 20 mM 
4:1 POPC/POPG LUVs to give high L/P ratios.  
 
 
The titration of these peptides with dilute samples of 4:1 POPC/POPG LUVs proved to 
give very similar results in regards to the ∆H of pore formation (Figure 5.9), with the exception 
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of compound 45. The peptide with the shortest positively charged side chain exhibited the least 
amount of heat, consequently producing injection peaks with both negative and positive 
components. The split injection peaks suggests that pore formation was not the dominate 
interaction for this compound.25, 26  
The guanidinium group of compound 56 also played a large role in the increased ∆H 
associated with the pore formation. Due to the increased size of the positive charge, more 
disruption would be caused to the surface of the membrane and the lipid:lipid interactions upon 
formation of a pore.24, 27 In addition to the disruption of the membrane composition, larger 
enthalpies would be involved with the desolvation of both membrane and peptide hydration 
shells.22, 27, 34, 35 All of the fore mentioned processes are associated with pore formation and 
would contribute to the greater positive ∆H. The single injection data for this series in the 
presence of both zwitterionic and anionic LUVs is summarized in Table 5.6. 
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Figure 5.9: Single injection ITC experiments to determine the ∆H of membrane disruption for 
4:1 POPC/POPG LUVs. Dilute solutions of 20 mM 4:1 POPC/POPG LUVs were titrated into 
300 µM solutions of compound 23 (top left). A 10 mM solution of 4:1 POPC/POPG LUVs was 
titrated into 300 µM solutions of compounds 43 (top middle), 53 (top right), 45 (bottom left) and 
56 (bottom right). 
 
 
Zwitterionic LUV environments. The titration of POPC LUVs into compounds 23, 43, 53 
and 56 (Figure 5.10) resulted in one endothermic reaction which required large L/P molar ratios 
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to reach completion. As POPC LUVs were titrated into the peptide solutions, the peptide will be 
pulled out of solution, decreasing the amount of peptide available left to bind, if binding 
occurs.22, 27-30 The above mentioned compounds all required a L/P molar ratio of approximately 
120 or more before all of the peptide was assumed bound and removed from the bulk solution. 
These high molar ratios suggest weak interaction between these compounds and POPC 
liposomes.9, 22, 25, 27 However, compound 45 (Figure 5.10) reached one hundred percent binding, 
assumed, at a molar ratio of approximately 50 indicating that the shorter spacer interacts more 
effectively with zwitterionic liposomes.27 From a therapeutic perspective, this is undesirable.   
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Figure 5.10: Full titration ITC experiment for the titration of 35 mM POPCLUVs into 200 µM 
compound 23 (top left), 43 (top middle), 53 (top right) and 45 (bottom left) and 100 µM 
compound 56 (bottom right). 
 
 
 Binding isotherms for the titration with POPC LUVs  were developed as previously 
described by Equations 1.3 – 1.12 using the experimentally measured ∆H0 values. With the 
exception of compound 45, the plots for the degree of binding, Xb, against the concentration of 
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peptide free in solution, cf, did not yield linear relationships as the electrostatic interactions were 
not accounted for using the model from Equation 1.9. The downward bend of these plots has 
been attributed to the repulsion of the peptides by the membrane bound peptides as the charge of 
the membrane surface increases.9, 36 As the spacer length decreases, the relationship between Xb 
and cf became more linear suggesting that the compounds were participating in a different 
mechanism. One explanation is that the peptide is pulled so close to the surface of the membrane, 
it is adsorbed into the phospholipid head groups and the positively charged face is not exposed to 
the incoming peptides, thus decreasing the repulsion. The lack of bending for the compounds 
with the shorter side chains further supports this theory. 
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Figure 5.11: Plot for the degree of binding, Xb, as a function of the peptide concentration in bulk 
solution, cf. The binding isotherms were derived from the titration of 35 mM POPC LUVs into 
compounds 23 (top left), 43 (top middle), 53 (top right), 45 (bottom left) and 56 (bottom right). 
Xb and cf were calculated as described in chapter 1 of the text.26, 32  
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 To factor in the electrostatic interactions between the peptides and membranes that cause 
an increase in the concentration of peptide immediately above the membrane surface, cm, the 
more sophisticated surface partition equilibrium model was used.23 The peptide concentration at 
the surface of the membrane was calculated using the equations presented in chapter 1 and a 
maximum peptide cross-sectional area of 342.4 Å2 for each peptide. Plotting Xb against cm 
yielded complex linear relationships with the degree of binding increasing as the length of the 
spacer decreased. As can be seen in Figure 5.12, compounds 23 and 43 exhibited one single line 
while compounds 43, 53 and 56 were divided into two distinct phases. The division of the 
relationship was more distinct with the shorter spacers and compound 56 with the larger positive 
body, suggesting different mechanisms. This observation supports the theory discussed earlier in 
regards to the linearity of the Xb versus cf plots increasing with the decrease in spacer length.  
The phase at the lower peptide concentration could correspond, as suggested with spacer #1, to 
the conformational changes the peptides undergo when binding to a peptide-free liposome. As 
the peptide concentration increases and becomes bound to the surface, the peptides remaining 
free in solution must undergo an additional change in order to maneuver around the bound 
peptides. The binding isotherm at higher peptide concentrations could correspond to this 
additional conformational change. The slopes of the lines were taken as the binding constants, K, 
and were then used in combination with their corresponding ∆H0 values to calculate the ∆G and 
∆S of the interactions (Table 5.5).  
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Figure 5.12: Plot for the degree of binding, Xb, as a function of the membrane surface 
concentration of peptide, cm. The binding isotherms were derived from the titration of 35 mM 
POPC LUVs into compounds 23 (top left), 43 (top middle), 53 (top right), 45 (bottom left) and 
56 (bottom right). Xb and cf were calculated as described in Chapter 1 of the text.26, 32  
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 In the case of POPC LUVs, a therapeutically relevant compound would produce the least 
favorable thermodynamic parameters. For this series of peptides, compound 43 has proven to 
interact the least with zwitterionic membranes, in a thermodynamic matter of speaking. 
Compound 43 exhibited the least favorable ∆G and lowest K and ∆S values. In comparison, 
compound 45 interacted the most favorably with POPC LUVs concluding that it would not be a 
desirable therapeutic agent. Overall, based on the thermodynamic data derived from the binding 
isotherms, the decreasing spacer length has a negative effect on the binding with POPC LUVs. 
Increasing the size of the positive charge increased binding constants and entropy in comparison 
to compound 23 and 43, however, it still exhibited a more favorable interaction than compound 
45, possibly due to electrostatic repulsions. 
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Table 5.5: Thermodynamic data for a representative titration of 35 mM POPC into the peptides 
at 25°C as derived from the equations discussed previously.  
Compound ∆H0,a  (kcal/mol) Kb  (M-1) ∆Gc  (kcal/mol) ∆Sd  (cal/mol·K)
23 na na na na
43 na na na na
53 0.51 211.27 -5.54 20.33
45 0.15 569.50 -6.13 21.09
56 -0.23 304.17 -5.76 18.57
23 0.67 211.00 -5.54 20.84
43 1.26 190.68 -5.48 22.64
53 0.98 296.02 -5.74 22.57
45 0.22 1364.50 -6.65 23.06
56 1.02 561.70 -6.12 23.98
M2ae
-15.9 2000.0 -7.0 -29.4
Higher Peptide Concentration
Lower Peptide Concentration
Magainin 2 amidee
    
a 
∆H values were calculated using Equation 1.4 from chapter 1 using the binding enthalpies 
measured directly from the experiment.  
b K values were generated from the lipid-into-peptide titration using the calculations as described 
in chapter 1.  
c
 ∆G values were calculated using Equation 1.1 from chapter 1. 
d
 ∆S was calculated using Equation 1.2 from chapter 1.  
e
 The thermodynamic parameters for the magainin analogue M2a as presented by Wieprecht et. 
al. 28 
 
 
 
Single injection experiments for the titration of dilute samples of peptide into zwitterionic 
LUVs  (Figure 5.13) yielded ∆H values that became more negative, favorable, as the side-chain 
length decreased. Binding interactions involve both positive and negative contributions to the ∆H 
values, but the more dominant process will be observed.25, 27 The increased negativity of the ∆H 
of binding as the spacer length decreases supports the previous conclusion that the shorter side-
chains allow for more favorable binding with POPC LUVs, a therapeutically unfavorable event. 
This trend could be attributed to the ability for the peptide to position itself closer to the 
membrane surface, thus allowing for the hydrophobic side-chains to insert and bind. 
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Figure 5.13: Single injection ITC experiments to determine the ∆H of binding for POPC LUVs. 
A dilute solution of 200 µM compound 23 (top left) was titrated into 15 mM POPC LUVs. 
Dilute solutions of 100 µM compounds 43 (top middle), 53 (top right) and 45 (bottom left) were 
titrated into 30 mM POPC LUVS. A dilute solution of 100 µM compound 56 (bottom right) was 
titrated into 35 mM POPC LUVs to give high L/P ratios.  
 
 
There was not a significant change in the ∆H associated with membrane disruption for 
POPC LUVs (Figure 5.14), but there was an increase, once again, with the decrease in spacer 
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length. One must remember that every pore forming process is accompanied by a 
thermodynamically counteracting binding process.25 Keeping this in mind, it is quickly realized 
that the ∆H for pore formation would be much greater, especially in the case of compound 45. 
The positive ∆H for pore formation required to overcome the -3.02 kcal/mol associated with 
binding would be very large. The single injection experiment data is summarized in Table 5.6. 
 
 
Figure 5.14: Single injection ITC experiments to determine the ∆H of membrane disruption for 
POPC LUVs. Dilute solutions of 20 mM POPC LUVs were titrated into 300 µM solutions of 
compound 23 (top left). A 10 mM solution of POPC LUVs was titrated into 300 µM solutions of 
compounds 43 (top middle), 53 (top right), 45 (bottom left) and 56 (bottom right). 
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Table 5.6: ∆H (kcal/mol) values for the binding and membrane disruption of 4:1 POPC/POPG 
and POPC LUVs as determined by single injection ITC experiments.  
23 0.14 ± 0.03 -1.00 ± 0.04 0.04 ± 0.00 2.10 ± 0.04
43 0.13 ± 0.00 -2.75 ± 0.18 0.05 ± 0.00 1.23 ± 0.03
53 0.16 ± 0.00 -1.85 ± 0.12 0.07 ± 0.00 -1.21 ± 0.07
45 0.02 ± 0.00 -1.86 ± 0.05 0.09 ± 0.00 -3.02 ± 0.14
56 0.15 ± 0.00 -2.90 ± 0.19 0.04 ± 0.00 -1.66 ± 0.09
4:1 POPC/POPG 
into Compound
Compound into 
4:1 POPC/POPG
POPC into 
Compound
Compound into 
POPCCompound
 
 
Calcein Leakage Studies 
Peptide induced calcein leakage from POPC LUVs was determined and presented in 
Figure 5.15. The leakage of calcein increased with a decrease in spacer length.  Compound 23, 
with the longest spacer, produced the least amount of leakage at a concentration of 20 µM with 
approximately 30%. Compound 43 increased the leakage to approximately 50% followed by 
compound 53 at 70% total leakage. Even at the lowest peptide concentration of 4 µM, compound 
45 induced the maximum leakage for POPC LUVs. As can be seen in Figure 5.15 and further 
highlighted in Figure 5.17 (left), the peptide induced calcein leakage does not appear to be 
concentration dependent, except for possibly compound 45, which appears to significantly 
increase from 8 to 12 µM.  
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Figure 5.15: The time dependent release of calcein from POPC LUVs induced by increasing 
concentrations of compounds 23 (top left), 43 (top right), 53 (middle left), 45 (middle right) and 
56 (bottom) as measured by fluorescence.37-39  
 
 
165 
 
 This trend, however, was not the case for the peptide induced leakage of calcein from 4:1 
POPC/POPG LUVs (Figure 5.16). As the concentration of the peptide increases, the leakage of 
calcein also increases, which is further highlighted in Figure 5.17 – right. Another obvious trend 
was the increase of the leakage as the spacer length decreases. Although this does not support the 
bioactivity data as compounds 23 and 43 were the most biologically active and compound 45 the 
least, there are two possible explanations. One, the liposomes used are very simple models and 
do not mimic the surfaces of all bacterial strains that could be presented to the peptides. Another 
explanation for the increased leakage caused by the compounds which are, biologically, less 
active could involve the distance between the peptide backbone and the membrane surface. With 
shorter side-chains, the peptide must reside closer to the surface in order for the hydrophobic side 
chains to insert, binding the peptide to the liposome. Due to the close proximity, the peptides 
may be adsorbed into the region of phospholipid head groups causing greater displacement. This 
process could cause calcein leakage through a membrane “thinning” mechanism similar to that 
of the “carpet” model,18, 19, 24 rather than actual pores. With the higher degree of binding 
observed by the compounds with shorter spacers, there would be an increase the calcein leakage 
as compared to the other compounds. As for the case of compound 56, the guanidinium group 
requires a larger space, thus forming larger pores and increased leakage as compared to the other 
peptides.  
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Figure 5.16: The time dependent release of calcein from 4:1 POPC/POPG LUVs induced by 
increasing concentrations of compounds 23 (top left), 43 (top right), 53 (middle left), 45 (middle 
right) and 56 (bottom) as measured by fluorescence.37-39 
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Figure 5.17: The total percent of calcein leakage from POPC (left) and 4:1 POPC/POPG LUVs 
induced by increasing concentrations of compounds 23, 43, 53, 45 and 56 as measured by 
fluorescence. 
 
Conclusion 
 It is clear that the CD, ITC and calcein leakage data support the observed in vitro MIC 
activity data and serves as evidence that the length of Spacer #2 plays an important role in 
defining the mechanism of action between this series of peptides and zwitterionic and anionic 
membrane models. We hypothesized that because Spacer #2 defined the distance between the 
peptide backbone and the positively charged amine group, it would determine the overall surface 
charge density of the peptide as well as the distance between the peptide backbone and 
membrane surfaces. The different conformations adopted as observed by CD coupled with the 
different thermodynamic mechanisms studied via ITC support this hypothesis.  
 There is an obvious optimal length of Spacer #2 that promotes antibacterial activity while 
maintaining minimal interaction with zwitterionic membranes. Compound 43, with the carbon 
spacer Orn, exhibited increased antibacterial activity in vitro as well as with the anionic 
membrane models, but showed minimal interactions with the zwitterionic membranes. 
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Compound 45, on the other hand, contained the shortest spacer and also exhibited the greatest 
interaction with zwitterionic membranes, a therapeutically undesirable quality. Knowing the 
effect that the length of the positively charge residue will aid in future design and development 
of novel AMPs as therapeutic agents. 
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CHAPTER SIX: SPACER #3 
 
Introduction 
 
The molecular flexibility and the net positive charge of AMPs play an important role in 
the bioactivity and selectivity as discussed in previous chapters. Here, we focus on increasing the 
flexibility of the positive charge cluster at the C-terminus to determine the effect it has on the 
binding interactions with anionic and zwitterionic membrane models. Figure 1.2 in Chapter 1 
gives the basic skeleton of our AMPs containing three Tic-Oic dipeptide units. Spacer #3, and 
the focus of this chapter, is denoted in green and refers to the amino acid between the last Tic 
residue and the C-terminus lysines. Compound 23 does not contain Spacer #3. The three 
compounds investigated in this chapter are compounds 50, 51 and 52 with βAla, Gaba and Ahx 
incorporated as Spacer #3, respectively. Their amino acid sequences are given in Table 6.1. 
 
Table 6.1: Amino acid sequences of the peptides used to study the role of spacer #3. 
Compound Amino Acid Sequence
23 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK-CONH2
50 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-βAla-KKKK-CONH2
51 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-Gaba-KKKK-CONH2
52 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-Ahx-KKKK-CONH2
 
 
 
 
 
 
 Spacer # 3 provides molecular flexibility to the cluster of positively charged amino acid 
residues located at the C-terminus of the AMP. Due to the correlation between flexibility and net 
charge with the potency and selectivity of AMPs, it was believed that the activity of the 
compounds could be increased if the flexibility of the large positive charge was increased by 
inserting amino acid residues of varying lengths before the positive cluster. However, as can be 
seen in Tables 6.2 and 6.3, the overall activity of compounds 50, 51 and 52 did not increase with 
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the insertion of Spacer #3. Unfortunately, hemolysis data was not collected for these peptides so 
there can be no correlation for the data in the presence of zwitterionic membrane models.  
 
Table 6.2: Minimum inhibitory concentration (µM) of select bacteria strains and hemolytic 
activity.1 
Compound Salmonella Typhimurium
Staphylococcus 
Aureus ME/GM/TC 
resistant
Mycobacterium 
Ranae
Bacillus 
Subtillis
% hemolysis 
100/25 mM
23 10 µM 3  µM 10  µM 1  µM 14%
50 30  µM 30  µM 10  µM not tested not tested
51 30  µM 10  µM 3  µM not tested not tested
52 30  µM 30  µM 10  µM not tested not tested
 
 
 
Table 6.3: Minimum inhibitory concentration (µM) of specific Gram negative and other drug 
resistant bacteria strains.2 
Compound 23 50 52
Acinetobacter baumanii 
ATCC 19606 3.2 6.2 3
Acinetobacter baumanii 
WRAIR 3.2 6.2 6.1
Staphylococcus aureus 
ATCC 33591 205 199 196
Yersinia pestis CO92 205 199 48.9
Brucella melitensis 16M 205 199 196
Brucella abortus 2308 205 199 198
Brucella suis 23444 205 199 196
Bacillus anthracis AMES 12.8 12.4 48.9
Francisella tularensis 
SCHUS4 100 199 196
Burkholderia mallei 205 199 196
Burkholderia 
pseudomallei 205 199 196
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Results and Discussion 
 
 
CD Studies 
 
 CD spectra of compounds in buffer and micelle environments. In buffer (Figure 6.1), all 
the CD spectra of the peptides exhibited a similar shape, but exhibited varying intensities. Each 
spectrum contained a double minimum at approximately 208 and 222 nm, typical of an α-helix.3-
7
 The  maximum at approximately 195 nm was indicative of a combination of β-turn and α-
helical components.3, 8-10  The differences in their intensities suggest varying degrees of ordered 
structures in buffer.4, 5, 11  
 
Figure 6.1: Far-UV CD spectra of compounds 23, 50, 51 and 52 (peptide concentration 
approximately 400 µM)  in 40 mM phosphate buffer, pH = 6.8. 
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 In the presence of SDS micelles (Figure 6.2 – left), there was a shift in the CD spectra of 
these compounds from 195 to 190 nm accompanied with an increase in the intensity. This 
observation is consistent with the increase in α-helical components.4, 7, 12-14 Each compound also 
exhibited a shift from 208 to approximately 202 nm suggesting the combination of α-helical, 
some type of β-turn and random coil conformations.6, 15, 16 Only compounds 23 and 51 observed 
in an increase in intensity for the double minima.  
 The CD spectra in the presence DPC micelles (Figure 6.2 – right) exhibited shapes and 
intensities very similar to those observed in CD spectra in the presence of  SDS micelles. This 
observation leads to the conclusion that the S-state conformations and therefore the binding 
interactions were not greatly affected by the flexibility of the positively charged lysine cluster at 
the C-terminus.3-5 
 
 
Figure 6.2: Far-UV CD spectra of compounds 23, 50, 51 and 52 (peptide concentration 
approximately 400 µM)  in 80 mM SDS (left) and 80 mM DPC (right) micelles in 40 mM 
sodium phosphate buffer, pH = 6.8. 
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 Transitioning from buffer to the zwitterionic POPC LUVs (Figure 6.3 – left) exhibited 
losses in intensity below 200 nm indicating a loss in α-helical characteristics. However, some of 
this loss may have been compensated for with the increase of the minimum at 208 nm which 
suggests an increase in α-helicity. 4, 5, 11 The similarity between the CD spectra of these 
compounds in POPC LUVs and their corresponding spectra in buffer suggests that minimal 
conformational changes occurred on interaction with zwitterionic membrane models.3, 5  
 
Figure 6.3: Far-UV CD spectra of 75 µM compound 23 and 100 µM solutions of compounds 50, 
51 and 52 in 1.75 mM POPC LUVs (left) in 40 mM phosphate buffer, pH = 6.8, and their 
corresponding HT values (right). 
 
 
 
  
 Obvious shifts in wavelengths in the CD spectra from approximately 195 and 208 to 192 
and 202 nm, respectively, are indicative of changes in conformation when in the presence of 
anionic membrane models (Figure 6.4 – left).3-5 The decrease in the intensity of the maximum 
coupled with the shift in wavelength for the minimum at 208 to 202 nm suggests a decrease in α-
helical characteristics. The shift in the maximum and increase in the intensity of the minimum, 
however, suggests an increase. 3, 5, 6 Overall, the conformation of these peptides was different in 
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anionic LUVs as compared to buffer and the zwitterionic models concluding there was a 
different interaction taking place. 5However, there is no discernable trend that suggests the length 
of spacer #3 played a role.  
 
Figure 6.4: Far-UV CD spectra of 200 µM compound 23, 50, 51 and 52 in 1.75 mM 4:1 
POPC/POPG (left) in 40 mM phosphate buffer, pH = 6.8, and their corresponding HT values 
(right). 
 
 
 
 
 “Pseudo” CD titrations of compounds 23, 50, 51 and 52. The spectra of compounds 23 
and 50 with increasing POPC LUV concentrations (Figure 6.5) were very different from their 
corresponding spectra in buffer, but did not vary much, in regards to shape, as the LUV 
concentration increased. Compounds 51 and 52 exhibited similar spectra in POPC LUVs as they 
did with buffer. There were no discernable changes, with the exception of intensity, that would 
associate the conformational changes with the LUV concentration. These CD spectra lead to the 
conclusion that the interaction between these peptides and zwitterionic LUVs was minimal, a 
therapeutically desirable quality.  
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Figure 6.5: Far-UV CD spectra for separate samples of 200 µM solutions of compounds 23 (top 
left) and 100 µM solutions of compounds 50 (top right), 51 (bottom left) and 52 (bottom right) 
with increasing concentrations of POPC LUVs in 40 mM phosphate buffer, pH = 6.8.17, 18  
 
 
 
 
 Different trends were observed for compounds 50, 51 and 52 in the presence of 
increasing anionic LUV concentrations as compared to the previously discussed pattern of 
compound 23 (Figure 6.6). The intensity of the spectra for compound 23 decreased with 
increasing LUV concentration (blue spectra) until a constant level was reached (green spectra) 
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and all of the peptide was assumed to be bound.19, 20 As the LUV concentration continued to 
increase, the intensity of the spectra once again increased (red spectra). As the length of Spacer 
#3 increased, the mechanism associated with changes in the secondary structure conformations 
also changed and the peptides with Spacer #3 incorporated exhibited different trends from 
compound 23. For compound 50 with a βAla inserted, the intensity of the spectra increased 
(Figure 6.6 – top right, blue spectra) with the addition of liposomes until a maximum intensity 
was reached. Once the maximum intensity was reached, subsequent addition of LUVs resulted in 
a spectrum with a complete loss of intensity. As the LUV concentration increased, the intensity 
of the spectra gradually increased. The latter grouping of spectra for compound 50 followed the 
same trend as the second group of CD for compound 23, at higher L/P ratios.  
For compound 51, the first group of CD spectra, at low L/P ratios, followed the same 
trend as those for compound 50 and exhibited an increase in intensity. However, once the 
maximum intensity was reached for compound 51, the intensity of the spectra gradually 
decreased as the L/P ratio increased until the intensity was constant and approximately 0. For the 
compound with the longest Spacer #3, 52, the same pattern as compound 51 was observed, but 
the extent to which the spectra decreased was less.  
It appears that as the spacer length increases, the mechanism of action shifts, with 
compounds 50 and 51 as intermediates between 23 and 52. The pattern for compound 23 was a 
decrease in intensity followed by an increase.  Compound 50 involved two decreasing trends and 
51 an increasing pattern followed by a decrease. The trends for compound 51 were the exact 
opposite of compound 23. The longest spacer, Ahx in compound 52, essentially was the opposite 
of 23 with a less intense second phase and a completely different mechanism. However, the 
mechanisms associated with these changes in conformation did not result in an increase in the 
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biological activity of these peptides in comparison to compound 23, thus concluding that Spacer 
#3 does not play a role in the determination of the biological activity.  
 
 
 
Figure 6.6: Far-UV CD spectra of separate samples of 200 µM solutions of compound 23 (top 
left) and 100 µM solutions of 50 (top right), 51 (bottom left) and 52 (bottom right) with 
increasing concentrations of 4:1 POPC/POPG liposomes in 40 mM phosphate buffer, pH = 
6.8.17, 18  
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ITC Studies 
 
 Anionic LUVs. All four compounds exhibited 2-phase thermograms when titrated with 
4:1 POPC/POPG LUVs (Figure 6.7) which is indicative of pore formation at low L/P ratios 
followed by binding as the LUV concentration increased.19, 21, 22 Endothermic heat is the result of 
several different processes including, but not limited to, disruption of polar lipid head groups and 
lipid:lipid interactions, desolvation of structured water molecules on the peptide and membrane 
surfaces.20-23 These processes coincide with exothermic processes which describe binding. 
Attractive electrostatic interactions between the peptide and membrane, conformational changes 
of the peptide and binding interaction through Van der Waals and hydrogen bonding are a few of 
these processes.18, 22-24 Endothermic and exothermic processes occur simultaneously with the 
more dominate of the two being observed.22   
 At low L/P ratios, pore formation is the dominate interaction as indicated by the 
endothermic phase.22 At these ratios, the peptides are in excess of the lipid, oligomerizing and 
forming pores. As the lipid concentration increases, the pore ↔ binding equilibrium shifts 
towards binding as the ratio shifts to high L/P.19, 21, 22 Each of these peptides favors pore 
formation over binding and their ability to do so increases as the length of Spacer #3 increases. 
The ratio of the cumulative endothermic components to the cumulative exothermic components 
increases with the increased flexibility of the positive charges at the C-terminus. Favorability for 
pore formation in the presence of anionic LUVs suggests these peptides would exhibit some 
biological activity against bacterial cells.  As seen in Tables 6.2 and 6.3, these peptides do 
exhibit biological activity against the common bacterial strains, although no more than 
compound 23 without Spacer #3 incorporated. 
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Figure 6.7: ITC data for the full titration of 35 mM 4:1 POPC/POPG LUVs into 200 µM 
solutions of compounds 23 (top left), 50 (top right), 51 (bottom left) and 52 (bottom right).  
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Each single titration experiment for the titration of peptide into anionic LUVs exhibited 
an exothermic event (Figure 6.8).22, 23, 25, 26 The exothermic processes associated with binding 
are counteracted by corresponding endothermic processes such as desolvation and displacement 
of polar lipid head groups.20, 22, 23 As seen in Figure 6.8, the exothermic processes were favored. 
With the exception of compound 23, the binding enthalpies decreased as the spacer length 
increased. This result could be attributed to the increased disruption of water molecules and polar 
head groups caused by the larger space occupied by the cluster of lysines at the C-terminus due 
to its increased flexibility.22, 23 Because compound 23 does not follow suit, it appears as though 
there is not an obvious trend associating binding enthalpies and the length of Spacer #3. 
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Figure 6.8: Single injection ITC experiments to determine the ∆H of binding. A dilute solution 
of 200 µM compound 23 (top left) was titrated into 15 mM 4:1 POPC/POPG LUVs. Dilute 
solutions of 100 µM compound 50 (top right), 51 (bottom left) and 52 (bottom right) were 
titrated into 20 mM 4:1 POPC/POPG LUVs to give high L/P ratios.22, 26  
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Compound 23 absorbed the largest amount of heat for the single injection experiment of 
4:1 POPC/POPG LUVs into peptide in order to determine the ∆H of membrane disruption 
(Figure 6.9).22, 23, 26 The increase in spacer length did not appear, once again, to have a critical 
impact on the heat associated with pore formation as compounds 50, 51, 52 were similar to each 
other and less than compound 23. Pore formation, which is associated to cell lysis, appears to be 
more favored with compound 23 than the peptides containing Spacer #3, which is supported by 
the bioactivity. 
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Figure 6.9: Single injection ITC experiments to determine the ∆H of membrane disruption. A 20 
mM solution of 4:1 POPC/POPG LUVs was titrated into 300 µM compound 23 (top left). Dilute 
solutions of 10 mM 4:1 POPC/POPG LUVs were titrated into 400 µM compound 50 (top right) 
and 51 (bottom left). A dilute solution of 5 mM 4:1 POPC/POPG LUVs  was titrated into 400 
µM compound 52 (bottom right).22, 26 
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 Zwitterionic LUVs. The full titrations of POPC LUVs into each peptide (Figure 6.10) 
yielded one endothermic phase. High L/P ratios were required for the complete binding of the 
peptide indicating a weak interaction, a therapeutically desirable quality. With the exception 
compound 23, the L/P ratios required for 100% binding decreased with the increase in the length 
of Spacer #3, suggesting that the longer spacers favor binding with POPC LUVs. One 
explanation for this conclusion could be attributed to the flexibility. By incorporating flexibility 
into the positively charged C-terminus, it may be possible for the peptide to maneuver around the 
areas of localized positive charge on the membrane, thus increasing the binding. 
 By fitting the data to known models allowed us to determine some thermodynamic data 
so as to make better conclusions regarding the interactions of these peptides with zwitterionic 
membranes, and thus the role played by Spacer #3, if any. The degree of binding, Xb, and 
concentration of free peptide in bulk solution, cf, were calculated using Equations 1.4 through 
1.8 and the raw data from the experiments. The plots of Xb against cf are given in Figure 6.11. 
Each of the figures exhibited a nonlinear curve which could not be fit by the binding isotherm 
model described by Equation 1.3. The downward bend of the curves have been attributed to the 
decrease of the surface potential and electrostatic attractions between the membrane and peptides 
as the concentration of the peptide on the surface increases.25, 27 This particular model did not 
account for these electrostatic interactions and, therefore, was not the appropriate model to 
describe this data. 
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Figure 6.10: ITC experiment for the titration of 35mM POPC LUVs into 200 µM compound 23 
(top left), 50 µM compound 50 (top right) and 100 µM solutions of compounds 51 (bottom left) 
and 52 (bottom right).  
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Figure 6.11: Plot for the degree of binding, Xb, as a function of the peptide concentration in bulk 
solution, cf. The binding isotherms were derived from the titration of 35 mM POPC LUVs into 
compounds 23 (top left), 50 (top right), 51 (bottom left) and 52 (bottom right). Xb and cf were 
calculated as described in Chapter 1 of the text.21, 24  
 
 
 
 
 A more sophisticated surface partition equilibrium model for determining the binding 
isotherms was employed in order to account for the electrostatic interactions between the 
membrane surface and positively charged peptides. Equation 1.9 from Chapter 1 factors in the 
concentration of the free peptide immediately above the surface of the membrane, cm, as the 
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attractive electrostatic interactions will cause an in case in this concentration as compared to the 
peptide concentration in bulk solution. Using Equations 1.10 through 1.12, it was possible to 
calculate cm. plotting Xb against cm yielded linear curves that could be fit to the binding isotherm 
model described in Equation 1.9. Fitting these curves to straight lines allowed for the 
determination of the binding constant, K, as it was the slope. Knowing K and the experimentally 
determined ∆H0 of the interactions allowed for the determination of ∆G and ∆S using Equations 
1.1 and 1.2, thus providing a full set of thermodynamic data. The data is summarized in Table 
6.4. 
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Figure 6.12.  Plot for the degree of binding, Xb, as a function of the membrane surface 
concentration of peptide, cm. The binding isotherms were derived from the titration of 35 mM 
POPC LUVs into compounds 23 (top left), 50 (top right), 51 (bottom left) and 52 (bottom right). 
Xb and cm were calculated as described in Chapter 1 of the text.21, 24  
 
 
 
 
 Upon examination of the thermodynamic data in Table 6.4, there was not a clear trend 
between the spacer length and degree of the interaction with POPC LUVs. However, there was 
one obvious result; the peptides with Spacer #3 incorporated had increased favorable 
thermodynamic data as compared to compound 23. With the exception of ∆H0, which were 
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overall very similar, compounds 50, 51 and 52 favored the interaction with POPC LUVs more 
than compound 23, in terms of thermodynamics. The binding constants were larger, the ∆G 
values were more negative and the ∆S values more positive, all favorable results. Based on the 
thermodynamic data, one can conclude that by increasing the flexibility of the lysine cluster at 
the C-terminus, the interaction with zwitterionic membrane models is also increased. Increasing 
the flexibility, as mentioned previously, could allow the peptide the mobility to maneuver around 
the positive charges on the surface, thus increasing the binding. Such characteristics are not 
desirable for therapeutic agents. 
 
 
Table 6.4: Thermodynamic data for a representative titration of 35 mM POPC into the peptides 
at 25°C as derived from the equations discussed previously.  
Compound ∆H0,a  (kcal/mol) Kb  (M-1) ∆Gc  (kcal/mol) ∆Sd  (cal/mol·K)
23 0.67 211.00 -5.54 20.84
50 0.88 418.23 -5.95 22.93
51 0.68 394.85 -5.91 22.14
52 0.56 561.41 -6.12 22.41
M2a -15.9 2000.0 -7.0 -29.4
Magainin 2 amidee
   
 
a 
∆H0 values were calculated using Equation 1.4 from chapter 1 using the binding enthalpies 
measured directly from the experiment.  
b K values were generated from the lipid-into-peptide titration using the calculations as described 
in chapter 1.  
c
 ∆G values were calculated using Equation 1.1 from chapter 1.  
d
 ∆S was calculated using Equation 1.2 from chapter 1. 
e
 The thermodynamic parameters for the magainin analogue M2a as presented by Wieprecht et. 
al.19, 20 
 
 
 
 Fitting the data obtained from the full titration of POPC LUVs into the peptides provided 
thermodynamic data concerning the entire interaction between the peptides and LUVs. 
Performing single injection experiments, however, allowed for the isolation of the two extremes 
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of the interaction, binding and membrane disruption. The titration of dilute solutions of peptide 
into excess LUVs isolated the binding interaction as the L/P was very high. As seen in Figure 
6.13, and summarized in Table 6.5, increasing the length of Spacer #3 results in a binding 
enthalpy that becomes more negative, and thus more favorable. This observation supports the 
theory that increasing the length of Spacer #3 consequently increases the flexibility of the 
positive cluster. The added flexibility aids in the binding process as the peptide is able to 
maneuver around the positive charges of the zwitterionic membrane surface.   
 Reversing the single injection experiment and titrating dilute solutions of LUVs into 
excess peptide (Figure 6.14), the ∆H of membrane disruption was determined. None of the 
compounds in this series appeared to favor membrane disruption through pore formation more 
than another, as the ∆Hs were almost identical. Although this would appear to be a favorable 
quality with regards to useful therapeutic agents, pore formation is not the only mechanism by 
which to disrupt the membrane and cause cell lysis. 
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Figure 6.13: Single injection ITC experiments to determine the ∆H of binding. A dilute solution 
of 200 µM compound 23 (top left) was titrated into 15 mM POPC LUVs. Dilute solutions of 200 
µM compounds 50 (top right) and 52 (bottom right) were titrated into 30 mM POPC LUVs. A 
dilute solution of 200 µM compound 51 (bottom left) was titrated into 35 mM  POPC LUVs to 
give high L/P ratios.22, 26 
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Figure 6:14: Single injection ITC experiments to determine the ∆H of membrane disruption. A 
20 mM solution of POPC LUVs was titrated into 300 µM compound 23 (top left). Dilute 
solutions of 10 mM POPC LUVs were titrated into 400 µM compound 50 (top right), 51 (bottom 
left) and 52 (bottom right).22, 26 
 
 
 
 
 
 
 
 
 
 
196 
 
Table 6.5: ∆H (kcal/mol) values for the binding and membrane disruption of 4:1 POPC/POPG 
and POPC LUVs as determined by single injection ITC experiments.23    
23 0.14 ± 0.03 -1.00 ± 0.04 0.04 ± 0.00 2.10 ± 0.04
50 0.08 ± 0.00 -1.77 ± 0.13 0.04 ± 0.00 0.90 ± 0.08
51 0.10 ± 0.00 -1.73 ± 0.08 0.04 ± 0.00 0.80 ± 0.07
52 0.09 ± 0.00 -1.41 ± 0.07 0.04 ± 0.00 -1.02 ± 0.08
4:1 POPC/POPG 
into Compound
Compound into 
4:1 POPC/POPG
POPC into 
Compound
Compound into 
POPCCompound
 
 
 
 
 
Calcein Leakage Studies 
 
 The increase in the fluorescence associated with the peptide induced calcein leakage of 
POPC (Figure 6.15) and 4:1 POPC/POPG LUVs (Figure 6.16) was monitored over time in an 
attempt to determine any concentration dependency for the activities or mechanisms of action.28, 
29
 In the presence of POPC LUVs, with the exception of a slight increase with compound 51, 
these peptides did not appear to interact via a concentration dependent mechanism. In fact, these 
compounds did not appear to interact with the zwitterionic membranes much at all and this is 
further highlight in Figure 6.17 – left. These results lead to the conclusion that the incorporation 
of Spacer #3 may not affect the binding interaction with mammalian red blood cells either.  
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Figure 6.15: The time dependent release of calcein from POPC LUVs induced by increasing 
concentrations of compounds 23 (top left), 50 (top right), 51 (bottom left), and 52 (bottom right) 
as measured by fluorescence.30-32  
 
 
 
 
 The results for the leakage from 4:1 POPC/POPG LUVs presented in Figure 6.16 
exhibited a concentration dependent mechanism. This dependency is further highlighted in 
Figure 6.17 – right. Compound 51 displayed the most concentration dependent leakage as well 
as the most leakage. The increase in leakage as the concentration of peptide increased maybe 
explained by the formation of a pore.33-35Although there was an increase in the overall leakage 
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with the compounds incorporating Spacer #3 as compared to compound 23 without the spacer, 
there did not appear to be a great increase. With the exception of compound 51, which appeared 
to have an optimal spacer length for the interaction with these simple membrane models, there 
was no data to suggest that compounds 50 and 52 would be more biologically active than 
compound 23. This conclusion is supported by the biological data which suggests, overall, the 
activity of the peptides is very similar.  
 
 
Figure 6.16: The time dependent release of calcein from 4:1 POPC/POPG LUVs induced by 
increasing concentrations of compounds 23 (top left), 50 (top right), 51 (bottom left), and 52 
(bottom right) as measured by fluorescence.30-32 
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Figure 6.17: The total percent of calcein leakage from POPC (left) and 4:1 POPC/POPG LUVs 
induced by increasing concentrations of compounds 23, 50, 51, and 52 as measured by 
fluorescence. 
 
 
 
Conclusions 
 
 As suggested by the biological activity, the incorporation of Spacer #3 did not have an 
increased effect on the interactions with anionic membrane models as determined by CD, ITC 
and fluorescence leakage studies. There were changes in the CD spectra that indicate 
conformational changes are needed to compensate for the flexibility of the lysine cluster at the 
C-terminus. ITC and calcein leakage data supported the biological activity data for anionic 
membranes as the results were slightly different from compound 23 but almost identical to each 
other. Again, these results support the findings that the changes in the length of Spacer #3 played 
no role in the biological activity. 
 There was no hemolytic data available for this series of compounds in order to correlate 
the results of the CD, ITC and calcein leakage assays for POPC LUVs. However, we were able 
to hypothesize the interactions based on the studies. CD studies showed that the compounds 
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adopt very similar conformations in the presence of POPC LUVs to those adopted in buffer.  It 
was determined that thes conformations are not dependent on the concentration of the 
zwitterionic LUVs suggesting minimal interactions with the LUVs. Based on ITC data, there 
were indications that the strength of the binding interactions increased with the length of Spacer 
#3. It is probably that the increased flexibility maximizes the attractive electrostatic interactions 
for binding. However, the pore forming capability of the compounds with Spacer #3 appeared 
minimal based on the single injection data and further supported by the calcein leakage studies. 
Based on the spectroscopic and thermodynamic data for the compounds incorporating Spacer #3 
increasing the flexibility of the positively charged C-terminus resulting in increased binding to 
zwitterionic membranes. Although pore formation was not favored, if this modification was 
coupled with another that did increase pore formation, the increased binding would cause in 
increase in hemolysis, an unfavorable characteristic.   
 
 
References  
(1) Hicks, R. P.; Bhonsle, J. B.; Venugopal, D.; Koser, B. W.; Magill, A. J. De Novo Design of 
Selective Antibiotic Peptides by Incorporation of Unnatural Amino Acids. J. Med. Chem. 2007, 
50, 3026-3036.  
(2) Venugopal, D.; Klapper, D.; Srouji, A. H.; Bhonsle, J. B.; Borschel, R.; Mueller, A.; Russell, 
A. L.; Williams, B. C.; Hicks, R. P. Novel antimicrobial peptides that exhibit activity against 
select agents and other drug resistant bacteria. Bioorg. Med. Chem. 2010, 18, 5137-5147.  
(3) Olofsson, A.; Borowik, T.; Gröbner, G.; Sauer-Eriksson, A. E. Negatively Charged 
Phospholipid Membranes Induce Amyloid Formation of Medin via an α-Helical Intermediate. J. 
Mol. Biol. 2007, 374, 186-194.  
(4) Richardson, J. M.; Makhatadze, G. I. Temperature Dependence of the Thermodynamics of 
Helix–Coil Transition. J. Mol. Biol. 2004, 335, 1029-1037.  
(5) Sanavio, B.; Piccoli, A.; Gianni, T.; Bertucci, C. Helicity propensity and interaction of 
synthetic peptides from heptad-repeat domains of herpes simplex virus 1 glycoprotein H: A 
201 
 
circular dichroism study. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 2007, 
1774, 781-791.  
(6) Glukhov, E.; Stark, M.; Burrows, L. L.; Deber, C. M. Basis for selectivity of cationic 
antimicrobial peptides for bacterial versus mammalian membranes. J. Biol. Chem. 2005, 280, 
33960-33967.  
(7) Dathe, M.; Schumann, M.; Wieprecht, T.; Winkler, A.; Beyermann, M.; Krause, E.; 
Matsuzaki, K.; Murase, O.; Bienert, M. Peptide Helicity and Membrane Surface Charge 
Modulate the Balance of Electrostatic and Hydrophobic Interactions with Lipid Bilayers and 
Biological Membranes. Biochemistry (N. Y. ) 1996, 35, 12612-12622.  
(8) Brahms, S.; Brahms, J.; Spach, G.; Brack, A. Identification of beta,beta-turns and unordered 
conformations in polypeptide chains by vacuum ultraviolet circular dichroism. Proc. Natl. Acad. 
Sci. U. S. A. 1977, 74, 3208-3212.  
(9) Ganesh, S.; Jayakumar, R. Circular dichroism and Fourier transform infrared spectroscopic 
studies on self-assembly of tetrapeptide derivative in solution and solvated film. The Journal of 
Peptide Research 2003, 61, 122-128.  
(10) Nomura, K.; Corzo, G. The effect of binding of spider-derived antimicrobial peptides, 
oxyopinins, on lipid membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes 2006, 
1758, 1475-1482.  
(11) Imura, Y.; Nishida, M.; Matsuzaki, K. Action mechanism of PEGylated magainin 2 
analogue peptide. Biochim. Biophys. Acta 2007, 1768, 2578-2585.  
(12) Nielsen, S. B.; Otzen, D. E. Impact of the antimicrobial peptide Novicidin on membrane 
structure and integrity. J. Colloid Interface Sci. 2010, 345, 248-256.  
(13) Jing, W.; Hunter, H. N.; Hagel, J.; vogel, H. J. The structure of the antimicrobial peptide 
Ac-RRWWRF-NH2 bound to micelles and its interacitons with phospholipid bilayers. Journal of 
Peptide Research 2003, 61, 219-229.  
(14) Christiaens, B.; Grooten, J.; Reusens, M.; Joliot, A.; Goethals, M.; Vandekerckhove, J.; 
Prochiantz, A.; Rosseneu, M. Membrane interaction and cellular internalization of penetratin 
peptides. European Journal of Biochemistry 2004, 271, 1187-1197.  
(15) Wang, P.; Bang, J.; Kim, H. J.; Kim, J.; Kim, Y.; Shin, S. Y. Antimicrobial specificity and 
mechanism of action of disulfide-removed linear analogs of the plant-derived Cys-rich 
antimicrobial peptide Ib-AMP1. Peptides 2009, 30, 2144-2149.  
(16) Wieprecht, T.; Beyermann, M.; Seelig, J. Binding of Antibacterial Magainin Peptides to 
Electrically Neutral Membranes: Thermodynamics and Structure. Biochemistry (N. Y. ) 1999, 38, 
10377-10387.  
202 
 
(17) Hunter, H. N.; Jing, W.; Schibli, D. J.; Trinh, T.; Park, I. Y.; Kim, S. C.; Vogel, H. J. The 
interactions of antimicrobial peptides derived from lysozyme with model membrane systems. 
Biochimica et Biophysica Acta (BBA) - Biomembranes 2005, 1668, 175-189.  
(18) Wen, S.; Majerowicz, M.; Waring, A.; Bringezu, F. Dicynthaurin (ala) Monomer Interaction 
with Phospholipid Bilayers Studied by Fluorescence Leakage and Isothermal Titration 
Calorimetry. The Journal of Physical Chemistry B 2007, 111, 6280-6287.  
(19) Wieprecht, T.; Apostolov, O.; Beyermann, M.; Seelig, J. Membrane Binding and Pore 
Formation of the Antibacterial Peptide PGLa: Thermodynamic and Mechanistic Aspects. 
Biochemistry (N. Y. ) 2000, 39, 442-452.  
(20) Wieprecht, T.; Apostolov, O.; Seelig, J. Binding of the antibacterial peptide magainin 2 
amide to small and large unilamellar vesicles. Biophys. Chem. 2000, 85, 187-198.  
(21) Wieprecht, T.; Seelig, J. Isothermal Titration Calorimetry for Studying Interactions between 
Peptides and Lipid Membranes. Current Topics in Membranes 2002, 52, 31-55.  
(22) Wenk, M. R.; Seelig, J. Magainin 2 Amide Interaction with Lipid Membranes: Calorimetric 
Detection of Peptide Binding and Pore Formation. Biochemistry (N. Y. ) 1998, 37, 3909-3916.  
(23) Abraham, T.; Lewis, R. N. A. H.; Hodges, R. S.; McElhaney, R. N. Isothermal Titration 
Calorimetry Studies of the Binding of a Rationally Designed Analogue of the Antimicrobial 
Peptide Gramicidin S to Phospholipid Bilayer Membranes. Biochemistry (N. Y. ) 2005, 44, 2103-
2112.  
(24) Seelig, J. Titration calorimetry of lipid-peptide interactions. Biochim. Biophys. Acta 1997, 
1331, 103-116.  
(25) Nomura, K.; Corzo, G. The effect of binding of spider-derived antimicrobial peptides, 
oxyopinins, on lipid membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes 2006, 
1758, 1475-1482.  
(26) Bastos, M.; Bai, G.; Gomes, P.; Andreu, D.; Goormaghtigh, E.; Prieto, M. Energetics and 
Partition of Two Cecropin-Melittin Hybrid Peptides to Model Membranes of Different 
Composition. Biophys. J. 2008, 94, 2128-2141.  
(27) Seelig, J. Thermodynamics of lipid-peptide interactions. Biochim. Biophys. Acta 2004, 
1666, 40-50.  
(28) Andrushchenko, V. V.; Aarabi, M. H.; Nguyen, L. T.; Prenner, E. J.; Vogel, H. J. 
Thermodynamics of the interactions of tryptophan-rich cathelicidin antimicrobial peptides with 
model and natural membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes 2008, 
1778, 1004-1014.  
203 
 
(29) Medina, M. L.; Bolender, J. P.; Plesniak, L. A.; Chapman, B. S. Transient vesicle leakage 
initiated by a synthetic apoptotic peptide derived from the death domain of neurotrophin 
receptor, p75NTR. Journal of Peptide Research 2002, 59, 149-158.  
(30) Wei, S.; Wu, J.; Kuo, Y.; Chen, H.; Yip, B.; Tzeng, S.; Cheng, J. Solution Structure of a 
Novel Tryptophan-Rich Peptide with Bidirectional Antimicrobial Activity. J. Bacteriol. 2006, 
188, 328-334.  
(31) Wieprecht, T.; Dathe, M.; Schumann, M.; Krause, E.; Beyermann, M.; Bienert, M. 
Conformational and Functional Study of Magainin 2 in Model Membrane Environments Using 
the New Approach of Systematic Double-D-Amino Acid Replacement. Biochemisty 1996, 35, 
10844-10853.  
(32) Tamba, Y.; Yamazaki, M. Single Giant Unilamellar Vesicle Method Reveals Effect of 
Antimicrobial Peptide Magainin 2 on Membrane Permeability. Biochemistry (N. Y. ) 2005, 44, 
15823-15833.  
(33) Hugonin, L.; Vukojević, V.; Bakalkin, G.; Gräslund, A. Membrane leakage induced by 
dynorphins. FEBS Lett. 2006, 580, 3201-3205.  
(34) Matsuzaki, K.; Yoneyama, S.; Miyajima, K. Pore formation and translocation of melittin. 
Biophys. J. 1997, 73, 831-838.  
(35) Benachir, T.; Lafleur, M. Study of vesicle leakage induced by melittin. Biochimica et 
Biophysica Acta (BBA) - Biomembranes 1995, 1235, 452-460.  
 
 
 
 
 
 
 
 
 
 
  
 
 
CHAPTER SEVEN: ROLE PLAYED BY NUMBER AND PLACEMENT OF POSITIVELY 
CHARGED CLUSTER 
 
 
Introduction 
 
 Positive charges are important for the initial attraction of the AMPs to the surface of the 
target cell’s membrane. However, there is an optimal net positive charge that can enhance these 
electrostatic interactions and exceeding that optimal charge can diminish binding to the surface 
of the membrane. If the net positive charge is too low the attractive electrostatic interaction 
between the peptide and the membrane may be insufficient to attract the peptide to the surface of 
the membrane. If the net positive charge is too high, the repulsive electrostatic interactions 
between the incoming peptides and peptides already bound to the surface of the membrane may 
dominate, thus keeping additional peptide away from the surface of the membrane and 
preventing the peptide from reaching the critical concentration necessary for pore formation to 
occur. This chapter focuses on the number of positively charged residues clustered at either end 
of the peptide sequence. Compound 23 has four lysines at the C-terminus following a Tic 
residue. This number is decreased to three in compound 64 and increased to five for compound 
39. The cluster is relocated to the N-terminus in compound 61, preceding a glycine amino acid. 
The amino acid sequences are given in Table 7.1. 
 
Table 7.1: Amino acid sequences of the peptides used to study the rold played by the number 
and placement of the lysine cluster1 
Compound Amino Acid Sequence
23 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK-CONH2
64 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKK-CONH2
39 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKKK-CONH2 
61 Ac-KKKK-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-CONH2
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The in vitro antibacterial activity of these compounds clearly documents the critical role 
played by the placement and number of positively charged residues in defining activity.  The in 
vitro activity of compounds 23, 39 and 61 against common bacterial strains (Table 7.2), are very 
similar. Overall, each compound exhibited low MIC values and their activity is very similar with 
the exception of the decreased activity of compound 61 against Salmonella typhimurium. 
However, in the presence of several Gram negative and Gram positive bacteria strains (Table 
7.3), there appears to be a range of activity for compounds 23, 64 and 61. Compound 23 is the 
least active of the series except in the case of Acinetobacter baumanii. Either compound 64 or 
61, if not both, have increased activity against each strain as compared to compound 23.  
Unfortunately, antibacterial activity against select agents is not available for compound 39, so 
any conclusions made will be based on its activity with the common bacterial strains. 
 
 
Table 7.2: Minimum inhibitory concentration (µM) of select bacteria strains and hemolytic 
activity.1 
Compound Salmonella 
typhimurium
Staphylococcus aureus 
ME/GM/TC resistant
Mycobacterium 
ranae
Bacillus 
subtillis
% hemolysis 
100/25 µM
23 10 µM 3 µM 10 µM 1 µM 14%
39 10 µM 3 µM 3 µM 1 µM 24.9/ 18.9%
61 100 µM 30 µM 3 µM not tested not tested
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Table 7.3: Minimum inhibitory concentration (µM) of Gram negative and other drug resistant 
bacteria strains.2 
Compound 23 64 61
Acinetobacter baumanii 
ATCC 19606 3.2 6.7 12.8
Acinetobacter baumanii 
WRAIR 3.2 3.4 12.8
Staphylococcus aureus 
ATCC 33591 205 54 102
Yersinia pestis CO92 205 27 13.1
Brucella melitensis 16M 205 54 51
Brucella abortus 2308 205 27 51
Brucella suis 23444 205 >216 25.6
Bacillus anthracis AMES 12.8 27 0.4
Francisella tularensis 
SCHUS4 100 0.02 51
Burkholderia mallei 205 0.02 204
Burkholderia pseudomallei 205 0.02 204
 
 
 
 
 
Results and Discussion 
 
CD Studies 
 
CD spectra in buffer and micelle environments. In buffer, the shapes of of the CD spectra 
of compounds 23, 64 and 61 were very similar with some differences in their intensities. The 
maximum at approximately 195 nm was indicative of α-helical components. 1, 3-7 Compound 64 
exhibited the most intense CD spectrum followed by 61 and 23. However, the CD spectrum of 
compound 61 exhibited the most intense double minima suggesting an increase in α-helical 
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character.8-12 The increase in lysines at the C-terminus, compound 39, did not appear to adopt 
any discernable structure in buffer. 
 
 
Figure 7.1: Far-UV CD spectra of compounds 23, 64, 39 and 61 (peptide concentration of 
approximately 400 µM) in 40 mM phosphate buffer, pH = 6.8. 
 
 
 
 
Transitioning from a buffer environment to SDS micelles (Figure 7.2 - left), the CD 
spectra exhibited two obvious changes. A shift from the λmax 195 to 190 nm accompanied by an 
increase in the intensity for each peptide, a minimal increase in intensity was observed for 
compound 39, indicated an increase in the helicity of the peptides.5, 8-10, 12 There was also a shift 
of the λmin at approximately 210 to 202 nm suggesting a decrease in the α-helical component.5, 11, 
13
 However, except for compound 23, the intensities of the minima did not change, although the 
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order of the spectral intensities did. Compound 61 exhibited the most intense spectra followed by 
23 and 64 with similar intensities in buffer. However, in the presence of SDS micelles, 
compound 23 exhibited the most intense spectra followed by 61 then 64. The CD spectrum of 
compound 39 was the least intense in both environments. The CD spectra of all of the peptides, 
except for 39, exhibited shifts in wavelength and changes in intensity in comparison to their 
spectra in buffer, concluding that they were adopting different conformations in the presence of 
anionic micelles.5, 8-10  
Similar shapes were observed in CD spectra of the peptides in the presence of DPC 
micelles (Figure 7.2 - right) as well, although, once again a change in the increase of the 
intensities accompanied the CD spectra. The CD spectrum of compound 23 was the least intense 
in the presence of DPC micelles, decreasing from intensities observed in the CD spectra in SDS 
micelles, but increasing in comparison to its spectra in buffer. The CD spectra of compounds 64 
and 61 were similar below 200 nm and in the intensities of their double minima, with compound 
61 being the most intense. The CD spectrum of compound 39 retained the same shape in both 
DPC and SDS concluding that its S-state interactions, and therefore conformations, do not vary.5, 
9
 Changes in the intensities of the spectra led to the conclusion that the peptides were changing 
the amount of ordered structure when interacting with DPC and SDS micelle surfaces.8, 9, 11, 12 
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Figure 7.2: Far-UV CD spectra of compounds 23, 64, 39, and 61 (peptide concentration of 
approximately 400 µM) in 80 mM SDS (left) and 80 mM DPC (right) in 40 mM sodium 
phosphate buffer, pH = 6.8.  
 
 
 
 
 CD spectra of peptides in LUV environments. Introducing POPC LUVs (Figure 7.3 – 
left) induced significant changes in the shapes and intensities in the CD spectra of all peptides, 
including compound 39. When compared to their corresponding spectra in buffer, there was a 
decrease in the intensity of the λmax at 195 nm. The increase in intensity and varying shifts in the 
λmin from 208 in buffer to 210 nm for compound 23 and 212 nm for compounds 64 and 61 was 
evidence of conformational changes in the presence of POPC LUVs.9-11 As compared to their S-
state conformations in DPC micelles, compounds 23 and 39 were the only peptides which 
increased in their intensity at their minima.  
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Figure 7.3: Far-UV CD spectra of 75 µM compound 23 and 100 µM solutions of compounds 64, 
39 and 61 in 1.75 mM POPC (left) in 40 mM phosphate buffer, pH = 6.8, and their 
corresponding HT values (right). 
 
 
 
 
 The variations in the positively charged clusters had a great effect on the conformations 
observed in the presence of 1.75 mM 4:1 POPC/POPG LUVs (Figure 7.4 – left). Compound 23 
exhibited shifts from approximately 196 and 208 nm to 192 and 202 nm, respectively, suggesting 
an increase in α-helical, β-turn and unstructured components.3, 9, 11, 13 The CD spectrum of 
compound 39 was very similar to compound 23, but with a decrease in intensity suggesting less 
structures.8, 9, 12 Compounds 64 and 61 were very different from their spectra in buffer as well as 
the peptides in this series. The minimum below 200 nm for compound 64 was indicative of a 
random coil conformation.3, 6, 11 Though there is not a component of positive charge at 
approximately 220 nm, which is characteristic of random coil, 8, 9, 11 the disappearance of the 
minimum typical of an α-helix confirms the significant decrease of an ordered structure in the 
presence of anionic LUVs. It has been suggested through molecular modeling that peptides do 
not possess a high degree of ordered structure when inserted into a bilayer as part of a pore.14 
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This observation could explain the unordered appearance of the spectra of compound 64 in the 
presence of anionic membranes. The compound is biologically active as supported by the 
biological data and should in fact, for pores. Compound 61, on the other hand, exhibited a 
minimum at approximately 202 nm with great intensity as compared to the other minimum at 
222 nm. This increased ellipticity coupled with the maximum at approximately 195 nm supports 
the conclusion that compound 61 adopted a conformation containing high amounts of β-turn and 
α-helical components.3, 11, 13, 15   
 
 
 
Figure 7.4: Far-UV CD spectra of 75 µM compound 23 and 100 µM solutions of compounds 64, 
39 and 61 in 1.75 mM 4:1 POPC/POPG LUVs (left) in 40 mM phosphate buffer, pH = 6.8, and 
their corresponding HT values (right). 
  
 
 
 
CD spectra for “pseudo” titrations. The “pseudo” titration of POPC LUVs into these 
peptides did not yield any results that would suggest a concentration dependent interaction, as 
can be seen in Figure 7.5. The number or placement of the lysine cluster does not appear to 
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dramatically change the spectra as the concentration of POPC LUVs increased. Compound 23 
was the only compound that was significantly different from its spectra in buffer. The remaining 
three peptides vary in intensity, suggesting some level of interaction.8, 9, 12  
 
 
Figure 7.5: Far-UV CD spectra of separate samples of 200 µM solutions of compounds 23 (top 
left) and compound 61 (bottom right) and 100 µM solutions of compounds 64 (top right) and 
compound 39 (bottom left) with increasing concentrations of POPC LUVs in 40 mM phosphate 
buffer, pH = 6.8.16, 17 
 
213 
 
 The “pseudo” titrations of compounds 23 and 39 with the anionic liposomes 4:1 
POPC/POPG LUVs (Figure 7.6) yielded the trend that was discussed previously in chapter 3. A 
decrease in ellipticity occurred as the L/P ratio increased until a spectra of leveling intensity was 
reached, followed by an increase. Very different results were observed for the “pseudo” titrations 
with 4:1 POPC/POPG LUVs for compounds 64 and 61. As can be seen from the figure, neither 
compound 64 nor 61 exhibited a spectrum transitioning from decreasing to increasing spectral 
intensity as was observed with other peptides in this series.  This transition spectrum denotes a 
“critical point” or transition from predominately I-state to S-state. Both compounds, however, 
exhibited opposite trends in their changing intensities as compared to compounds 23 and 39. The 
intensity of their spectra initially decreased with the first addition of anionic LUVs and 
proceeded to increase (blue spectra) to a spectra of maximum intensity. At this point, the trend 
reversed and the intensity began to decrease (purple to red spectra). This data was evidence that 
compounds 64 and 61 interact with anionic membranes via different mechanisms than 
compounds 23 and 39, which could support the increased bioactivity.  
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Figure 7.6: Far-UV CD spectra of separate samples of 200 µM solutions of compound 23 (top 
left), 64 (top right), 39 (bottom left) and 61 (bottom right) with increasing concentrations of 4:1 
POPC/POPG LUVs in 40 mM phosphate buffer, pH = 6.8.16, 17 
 
 
 
 
ITC Studies 
Anionic LUVs. Upon first observation of the full titration experiment for 4:1 
POPC/POPG LUVs  into these peptides, noticeable observations included a very small 
exothermic component for compound 39 , and the even smaller, almost undetectable  for 
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compound 64. It would appear that the slight increase and/or decrease of the charge density at 
the C-terminus played an important role in the interaction of the peptide with anionic 
membranes.  We were unable to fit thermodynamic data to an existing model, however, by 
breaking down the thermograms into their separate components, endothermic and exothermic, it 
was possible to make conclusions in regards to the interactions. The cumulative endothermic 
heats decreased as the number of lysines increased.18-21 An endothermic process has been 
attributed to pore formation.20, 22   Formation of a pore encompasses several different processes 
that contribute to positive and negative ∆H values, with the positive components dominating.20 
Positive ∆H contributions include, but are not limited to, the desolvation of structured water 
molecules on the surfaces of the peptides and membrane, disruption of the phospholipid head 
groups and lipid:lipid interactions, as well as the release of the water molecules from inside the 
bilayer model.17, 21, 23-26  Attractive electrostatic interactions, conformational changes, and 
reorganization of the head groups and lipid acyl chains are contributors to the negative ∆H 
associated with the binding process.17, 20, 21  The resulting peaks observed in the thermogram after 
each injection reflect the dominate process, pore formation or binding, and therefore the more 
favorable of the two.20 The decrease in the endothermic cumulative heats as the number of 
lysines decreases, 0.79, 0.78 and 0.75 kcal/mol for compounds 64, 23 and 39 respectively, 
suggests that pore formation is slightly more favorable with less net positive charge. One 
possibility for this result could involve the repulsion that is caused by the binding of peptides that 
are highly positively charged. Accumulation of positively charged peptides on the surface of the 
LUV during binding may causes an increase in the surface charge of the membrane, 
consequently increasing the repulsion of additional peptides.18, 27 In addition, the transition from 
the endothermic to exothermic phases has been attributed to the shift in the formation ↔ pore 
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disintegration equilibrium towards to the right. Pore disintegration corresponds to the exothermic 
phase, and therefore, processes that refer to binding.20, 22, 28 The L/P ratio that corresponds to the 
transition from the endothermic to exothermic phase also refers to the point at which all of the 
peptide is assumed to be bound.17, 20, 21  The low molar ratios required for this transition to occur 
supports the theory that the compounds with less net positive charge favor pore formation.  
The exothermic components refer to the portion of the titrations that favor binding.17, 20, 
24, 29
 As the L/P molar ratios continued to increase, and peptide-free liposomes were added to a 
solution that was assumed to have no free peptide available, a maximum exothermic point is 
reached where the processes transition from predominately I-state to S-state. Previously, the L/P 
ratio corresponding to this transition point could be correlated to the “critical point” in the 
“pseudo” CD titrations with POPC/POPG LUVs, as was the case for compounds 23 and 39. For 
The blue spectra of Figure 7.6 correspond to the endothermic phase and pore formation of the 
full titration ITC thermograms for 4:1 POPC/POPG LUVs. The red spectra, therefore, represent 
the binding and exothermic phases that occur with increased lipid concentration. Compounds 23 
and 39 clearly had both phases as seen in CD and ITC, which was not the case for compound 64. 
ITC exhibited one clear endothermic phase corresponding with pore formation and the “pseudo” 
CD titration supports this data with one grouping of CD spectra. These two experiments 
combined suggest a different mechanism of action for compound 64.  
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Figure 7.7: ITC data for the full titration of 35 mM 4:1 POPC/POPG LUVs into 200 µM 
solutions of compounds 23 (top left), 64 (top right), 39 (bottom left) and 61 (bottom right).  
 
 
Repositioning the cluster of lysines at the N-terminus as in Compound 61 (Figure 7.7 -
bottom right) also exhibited a different mechanism of action which is supported by the full 
218 
 
titration ITC experiment and “pseudo” CD titrations with 4:1 POPC/POPG LUVs. The 
thermogram was very similar in shape to compound 23. Both exhibited clear endothermic and 
exothermic components. Their cumulative endothermic ∆Hs18-21 were however, different with 
780 and 530 cal/mol for compounds 23 and 61, respectively.  Compound 23 may have produced 
more “pore forming” heat, but compound 61 bound all of the free peptide at a L/P ratio of 
approximately 20 compared to 36 for compound 23.17, 18, 20, 21 The sum of their exothermic 
components, however, were very similar in magnitude at approximately -0.37 and -0.38 
kcal/mol, respectively, for compounds 23 and 61. The similarity of these values suggests that 
their abilities to bind to the membrane surface were comparable. Further evidence that the two 
compounds, whose only difference is the position of their lysine cluster, were the L/P molar 
ratios associated with their maximum exothermic component. The maximum exothermic point 
observed in the thermogram for the titration of compound 23 with anionic LUVs corresponds to 
the green spectrum in Figure 7.6 of the CD titration. This particular spectrum refers to the 
transition from predominately I-state to S-state. Compound 61, however, does not have a 
spectrum comparable to that of the transitioning green spectrum observed for compound 23 due 
to the reversed direction of the changes in the intensity of the spectra. For compound 61, the 
intensity of the spectra increased with the first addition of anionic liposomes until a maximum 
intensity was reached and then began to decrease, a completely different trend from that which 
was observed for compound 23. The ITC thermogram of compound 61 supports the CD results 
in that the placement of the lysine cluster plays an important role in the interaction with anionic 
LUVs.  
Both compounds 64 and 61 interacted via different mechanism from the other two 
peptides in this series, as well as each other. This conclusion supports the biological activity 
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(Table 7.3) and the ability for these particular compounds to exhibit activity against several 
different bacteria strains with varying membrane compositions. It is possible that an overall net 
charge of +5, with a concentration of +3 at the C-terminus as in compound 64, is ideal for 
increased activity against Yersinia pestis CO92, Francisella tularensis SCHUS4 and some 
strains of  Burkholderia. The change in mechanism of action for compound 61 could be due to 
the increased flexibility of the lysine tail at the N-terminus versus the C-terminus. The lysine 
cluster precedes a glycine residue when positioned at the N-terminus, but follows a very rigid Tic 
residue at the C-terminus. The neighboring residue in the sequence could play a role in the 
flexibility of the positive cluster that allows it to adopt certain conformations in the presence of 
particular bacteria cell membranes such as Bacillus anthracis AMES and strains of Brucella. 
 
Zwitterionic LUVs. At first inspection of the full titrations of POPC LUVs into 
compounds 23, 64, 39 and 61 (Figure 7.8), their thermograms are very similar. All have 
endothermic components that require very high L/P molar ratios before all of the peptide is 
assumed bound to the LUV. This high molar ratio is indicative of weak interactions with 
zwitterionic LUVs. The degree of binding, Xb, associated with these interactions was calculated 
and plotted against the concentration of peptide free in solution, cf, using the equations described 
previously. These plots are given in Figure 7.9. 
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Figure 7.8: ITC data for the full titration of 35 mM POPC LUVs into 200 µM compound 23 (top 
left), and 100 µM solutions of compounds 64 (top right), 39 (bottom left) and 61 (bottom right).  
 
There were two obvious sets of plots. Compounds 23 and 61 exhibited dramatic 
downward bends at high peptide concentrations. This result has been attributed to repulsion. As 
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the cationic peptides become bound, the surface of the membrane becomes more positively 
charged, thus hindering the binding of other peptides. Compound 61 portrayed a more drastic 
downward bend than compound 23, suggesting an increase in the repulsive interactions. One 
possible explanation for this could be the increased flexibility of the lysine cluster at the N-
terminus due to the increased flexibility of the neighboring glycine versus the rigid Tic residue at 
the C-terminus. With the added flexibility, the peptide has increased mobility to move over the 
surface of the membrane, thus repelling other peptides over a larger area. Compound 23, when 
bound, may remain more or less stationary and does not have the capability to repel over a large 
surface area.  
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Figure 7.9: Plot for the degree of binding, Xb, as a function of the peptide concentration in bulk 
solution, cf. The binding isotherms were derived from the titration of 35 mM POPC LUVs into 
compounds 23 (top left), 64 (top right), 39 (bottom left) and 61 (bottom right). Xb and cf were 
calculated as described in chapter 1 of the text.  
 
 
 
 
Compounds 64 and 39, the analogues of 23 with a decrease and increase in the number of 
lysines in the C-terminus cluster, respectively, do not exhibit a drastic bending of their isotherm. 
The lack of a downward bend is indicative that a different interaction is taking place. This 
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conclusion is supported when a more sophisticated model, surface partition equilibrium, was 
applied to the data to account for the electrostatic interactions. 
Plots of the degree of binding against the concentration of peptide at the membrane 
surface, cm, are given in Figure 7.10. Again, there were two obvious trends. Compounds 23 and 
61 both exhibited one line fitting the model from Equation 1.9. This suggests that these two 
peptides follow the expected mechanism involving the electrostatic interactions to the surface of 
the membrane and their binding constants, K, were determined. The other two compounds, 
however, did not appear to follow the typical interaction as their binding isotherms exhibited two 
distinct phases, one at a lower peptide concentration and one as the concentration increased. Both 
of the lines were for to the model described by Equation 1.9, allowing for the determination of 
two separate binding constants. Know the binding constants for the peptides allowed for the 
calculation of ∆G and ∆S using Equations 1.1 and 1.2. These values coupled with the 
experimentally measure ∆H gave a full set of thermodynamic data for the interaction of these 
peptides and POPC LUVs.  
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Figure 7.10: Plot for the degree of binding, Xb, as a function of the membrane surface 
concentration of peptide, cm. The binding isotherms were derived from the titration of 35 mM 
POPC LUVs into 23 (top left), 64 (top right), 39 (bottom left) and 61 (bottom right). Xb and cm 
were calculated as described in Chapter 1 of the text.  
 
 
 
 
 Compounds 23 and 61, with one set of data, exhibited the least favorable interaction with 
POPC LUVs, a therapeutically desirable characteristic. All of their thermodynamic data, ∆H0, K, 
∆G and ∆S, were the least favorable of the series, with the exception of the ∆H of compound 61. 
The other two compounds, 64 and 39, did exhibit increased affinity for zwitterionic LUVs, as 
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compared to compounds 23 and 61. However, there was not a large amount of interaction taking 
place. At low peptide concentrations, the thermodynamic data were minimal, but become more 
favorable as the peptide concentration increases. Even at their highest concentration, however, 
compounds 64 and 39 interact much less with POPC LUVs than magainin. The thermodynamic 
data is summarized in Table 7.4. 
 
Table 7.4: Thermodynamic data for a representative titration of 35mM POPC into the peptides 
at 25°C as derived from the equations discussed previously. 
Compound ∆H0,a  (kcal/mol) Kb  (M-1) ∆Gc  (kcal/mol) ∆Sd  (cal/mol·K)
23 na na na na
64 0.05 320.0 -3.41 11.62
39 0.06 327.8 -3.43 11.69
61 na na na na
23 0.67 211.0 -3.17 12.86
64 0.49 623.0 -3.81 14.43
39 0.49 627.2 -3.81 14.43
61 0.35 374.1 -3.51 12.95
M2a -15.90 2000.00 -7.00 -29.40
Lower Peptide Concentration
Higher Peptide Concentration
Magainin 2 amidee
 
a
∆H values are directly measured binding enthalpies and calculated using Equation 1.4. 
bBinding constants were generated from the lipid-into-peptide titrations using the model as 
described in the text. 
cFree energies were calculated using Equation 1.1.  
d
 Entropy was calculated using Equation 1.2.  
eThermodynamic parameters for Magainin analogue M2a as presented by Wieprecht and 
coworkers.23, 28 
 
 
 
Calcein Leakage Studies 
 
 As can be seen in Figure 7.11, with the exception of compound 61, the peptides induced 
calcein leakage of POPC LUVs did not appear to be concentration depending for any of the 
compounds in this series. Compounds 64 and 61 induced the most leakage with is consistent with 
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the thermodynamic data presented previously. The decrease in the electric charge in compound 
64 could allow for the peptide to maneuver around the positive charges of the head groups more 
easily, thus increasing the binding and causing leakage. The added flexibility of the lysine cluster 
in compound 61 due to the neighboring glycine, as suggested earlier in this chapter, could allow 
it to bind more easily to the surface of the membrane. With the N-terminus associated with the 
polar lipid head groups of the surface, the C-terminus with the larger Tic residue will insert into 
the bilayer. The larger residue could possibly form a larger pore, which consequently, would 
cause more leakage as observed in Figure 7.11. 
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Figure 7.11: The time dependent release of calcein from POPC LUVs induced by increasing 
concentrations of compounds 23 (top left), 64 (top right), 39 (bottom left), and 61 (bottom right) 
as measured by fluorescence.30-32  
 
 
 
 
 Peptide induced leakage of the 4:1 POPC/POPG LUVs was concentration dependent as 
can be seen in Figure 7.12 and further highlighted in Figure 7.13. Each compound, with the 
exception of compound 39, exhibited significant increase in the leakage as the peptide 
concentration increased. Compound 39, on the other hand, did not display an obvious 
dependence on the peptide concentration. One possible explanation is the increased charge 
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resulted in the repulsion of incoming peptides. As the charge decreased, the leakage increased. 
The increased leakage of compounds 64 and 61 is supported by the biological data as active 
compounds in the presence of anionic LUVs. 
 
 
 
Figure 7.12: The time dependent release of calcein from 4:1 POPC/POPG LUVs induced by 
increasing concentrations of compounds 23 (top left), 64 (top right), 39 (bottom left), and 61 
(bottom right) as measured by fluorescence.30-32  
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Figure 7.13: The total percent of calcein leakage from POPC (left) and 4:1 POPC/POPG LUVs 
(right) induced by increasing concentrations of compounds 23, 61, 39 and 61 as measured by 
fluorescence. 
 
 
 
 
Conclusions 
 
 The biological activity of these compounds is consistent with the observed  CD, ITC and 
fluorescence data. Compounds 64 and 61 exhibited increased interactions in the presence of 
anionic LUVs as compared to compound 23. The increased activity has been attributed to the 
decreased charge of compound 64 which reduces the repulsive electrostatic interactions between 
the peptide and membrane surface. It was concluded that the increased flexibility of the lysine 
cluster at the N-terminus due to the neighboring Gly as compared to the C-terminus with a Tic 
residue, resulted in the increased activity of compound 61. The increased charge of compound 39 
resulted in the repulsion of the peptide and therefore decreased its activity.  
 Compounds 64 and 61 exhibited different CD spectra, ITC thermograms and leakage 
assays from each other supporting the conclusion that they interact with anionic LUVs via 
different mechanisms. These different mechanisms could be attributed to the selectivity of these 
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peptides for bacteria strains with varying membrane compositions. Therefore, it is reasonable to 
believe that it is possible to design and build selectivity and potency into compounds in order to 
produce therapeutically useful agents. 
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CHAPTER EIGHT: INACTIVE COMPOUNDS AS NEGATIVE CONTROLS 
 
 
Introduction 
 
Several peptides were designed and synthesized that exhibited a broad range of activity 
against several strains of bacteria.1 Of these novel peptides, there were also peptides that did not 
show in-vitro activity against bacteria or mammalian cells. Compounds 14 and 34 are two of the 
inactive peptides and their sequences are given in Table 8.1.  In compound 34 the Tic residues 
have been replaced with Gly residues and therefore this analog doesn’t not contain the 
conformationally restrained Tic-Oic dipeptide unit required to impart local rigidity to the peptide 
backbone.  The lack of antimicrobial activity for compound 34 confirms that the Tic-Oic 
dipeptide units are critical for biological activity.  Compound 14 contains the Tic-Oic dipeptide 
unit, however the amino acid sequence between the Tic-Oic dipeptide units is different. Instead 
of the sequence Spacer #1-charge residue or Spacer #1-hydrophobic residue as followed in the 
active analogs, the intervening sequence for compound 14 is as follows: Spacer #1-hydrophobic 
residue-Spacer #1-charged residue.  Also the C-terminus of compound 14 consists of the C-
terminal residues found in magainin instead of a cluster of positively charged residues.  This 
analog is also inactive in antimicrobial assays confirming that the integrity of the sequence that 
has been designed for these AMPs is important for antimicrobial activity.   Although these two 
peptides did not exhibit biological activity they still provided critical comparative information.  
 
Table 8.1: Amino acid sequences of the peptides used as negative controls. 
Compound Amino Acid Sequence
23 Ac-GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK-CONH2
14 Ac-GK-Tic-Oic-GLGKE-Tic-Oic-GLGK-Tic-Oic-ELMGER-CONH2
34 Ac-GF-G-Oic-GK-G-Oic-GF-G-Oic-GK-G-KKKK-CONH2 
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Because compound 14 does not exhibit activity against bacteria (Table 8.2), clear 
differences in the data obtained from it and the data obtained from the active analogs would 
allow for the determination of the defining of parameters and behavior associated with biological 
activity.  
The other inactive peptide (Table 8.2), compound 34, is an analogue of compound 23 
with the Tic residues replaced with the more flexible and less hydrophobic Gly. Compound 34, 
therefore, served as a negative control as well as provided reinforcement that the Tic residue in 
the dipeptide turn unit is pertinent for biological activity. 
 
 
Table 8.2: Minimum inhibitory concentration (µM) of select bacteria strains and hemolytic 
activity.1 
Compound Salmonella Typhimurium
Staphylococcus Aureus 
ME/GM/TC resistant
Mycobacterium 
Ranae
Bacillus 
Subtillis
% hemolysis 
100/25 µM
23 10 µM 3 µM 10 µM 1 µM 14%
14 not active not active not tested not tested not tested
34 not active not active 100 µM 30 µM 3.30%/ 3.3%
 
 
Results and Discussion 
 
CD Studies 
 
CD spectra of compounds 14 and 34 in buffer and micelle environments. As emphasized 
in the previous chapters, the conformations adopted by the peptides in the presence of anionic 
and zwitterionic membrane models should be different than those observed in a buffer 
environment if the compound has the potential to selectively interact with bacteria verse 
mammalian cells. As can be seen in Figure 8.1, the spectra of compounds 14 and 34 in buffer 
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were not significantly different than those in their corresponding micelle environments. Both 
compounds 14 and 34 contained random coil components with a minimum at approximately 200 
nm and a maximum with almost positive intensity at what 220 nm.2-6 In the presence of SDS and 
DPC micelles, the CD spectra of compound 14 exhibited changes in the intensity at 
approximately 220 nm suggesting an increase in unordered structures.7, 8  The CD spectra in the 
presence of both DPC and SDS micelles were very similar to each other suggesting that there is 
no difference in the conformations adopted on binding to either micelle.  
The CD spectra of compound 34 exhibited fewer changes in the micelle environments 
than CD spectra of compound 14. There was a loss in the intensity in the presence of both DPC 
and SDS micelles when compared to the buffer spectra. Again, the DPC and SDS spectra were 
not only similar to the spectra of the peptide in buffer, but they were also similar to each other. 
 
   
 
Figure 8.1: Far-UV CD spectra of compound 14 (left) and compound 34 (right) in 40 mM 
phosphate buffer, pH = 6.8 (black), 80 mM DPC micelles in buffer (red) and 80 mM SDS in 
buffer (blue). 
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 “Pseudo” titration of LUVs into compounds 14 and 34. Zwitterionic and anionic LUVs 
were titrated into solutions of compounds 14 and 34 in an attempt to observe conformational 
changes with concentration dependencies. In the presence of POPC LUVs (Figure 8.2), CD 
spectra indicated that the conformations adopted by each compound were very similar to their 
corresponding spectra in buffer in regards to shape and intensity.  These similarities, even at high 
L/P ratios, support the conclusion that these peptides do not interact with the zwitterionic 
membrane models. 
 
 
Figure 8.2: Titration of 35 mM POPC LUVs into 100 µM compound 14 (left) and 200 µM 
compound 34 (right). 
 
 
 
 
Similar results were observed in the presence of the anionic membrane model 4:1 
POPC/POPG LUVs (Figure 8.3). With the active compounds, the spectra with increasing L/P 
ratios exhibited changes in their CD spectra with respect to the spectrum in buffer as well as to 
each other. Also, there was a transition from I-state to S-state observer and referred to as the 
“critical point.” Neither of these characteristics was observed with compounds 14 or 34. With the 
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exception of an emergence of a peak at approximately 195 nm for compound 14, neither peptide 
showed significant changes from their buffer spectrum. In fact, the spectra of compound 34 were 
essentially identical to the spectrum in buffer. Again, this data supports the conclusion that these 
peptides are inactive and serve as negative controls.  
 
 
 
Figure 8.3: Titration of 35 mM 4:1 POPC/POPG LUVs into 100 µM compound 14 (left) and 75 
µM compound 34 (right). 
 
 
 
 
ITC Studies 
 
The titration of 35 mM POPC LUVs into compounds 14 and 34 (Figure 8.4) supported 
the claim that these peptides do not interact with membrane models in a manner that would cause 
membrane disruption. Although the top panels of the thermograms appear to show some 
interaction, the integrated data in the bottom panel showed that the heat associated with each 
injection was minimal, less than 4.0 x 10-3 kcal/mol of injectant for compounds 14 and 34. Also, 
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the integrated heats were so small for the interaction that they were barely discernable from the 
background noise, supporting the conclusion that there is minimal binding to observe.  
 
 
Figure 8.4: ITC experiment of 35 mM POPC LUVs titrated into 100 µM compound 14 (left) and 
200 µM compound 34 (right). 
 
 
 
The interactions of these two peptides with anionic liposome models (Figure 8.5) 
displayed a slightly different result, but the same conclusion was reached. Compound 14 
exhibited a thermogram with less interference from the background noise than was observed 
with POPC LUVs;  however, the maximum amount of heat observed was approximately 4 
cal/mol of injectant. The thermogram for compound 34 portrayed a very similar interaction to 
other peptides in membrane environments with a distinct endothermic phase. The thermograms 
of the active compounds typically exhibited one of two characteristics, if not both. The 
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thermograms possessed an endothermic phase followed by an exothermic phase, as was the case 
of compound 23 (Figure 3.10). The second required characteristic was the absorption or release 
of a large amount of heat. Compound 34 did not possess an exothermic phase and the largest 
amount of heat absorbed was approximately 0.03 kcal/mol of injectant. Also, the interaction 
required a L/P molar ratio of approximately 150 before the peptide was completely bound, 
supporting the conclusion that there was a weak interaction taking place. 9, 10 
 
Figure 8.5: ITC experiment of 35 mM POPC LUVs titrated into 100 µM compound 14 (left) and 
50 µM compound 34 (right). 
 
 
 
Calcein Leakage Studies 
 
Peptide induced calcein leakage studies were used to determine if these peptides were 
membrane disruptors, and thus, biologically active. 11, 12 Studies were performed only at the 
maximum concentration of 20 µM (Figure 8.6). If these peptides were truly inactive, then they 
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would produce minimal leakage at the maximum concentration. Also, any peptide concentrations 
lower than 20 µM would induce less leakage. Interestingly enough, both compounds induced 
more leakage in the presence of POPC LUVs than 4:1 POPC/POPG LUVs. However, 50% 
leakage for compound 14 and approximately 30% for compound 34 in POPC was lower than 
most of the other compounds. An intriguing observation was that both compounds produced 10% 
or less leakage in the presence of the anionic membrane model. Again, these two compounds 
have proven to show little activity against membrane model systems, anionic or zwitterionic. 
 
 
 
Figure 8.6: The time dependence of the calcein leakage fluorescence of POPC (black) and 4:1 
POPC/POPG LUVs (red) induced by 20 µM compounds 14 (left) and 34 (right) as measured by 
fluorescence.4, 13, 14 
 
 
 
 
 
Conclusions 
 
Compounds 14 and 34 served as negative controls for our peptides. Neither compound 
exhibited in-vitro activity against different bacteria strains or mammalian red blood cells. Due to 
their inactive nature, different results should be, and were, observed in regards to CD, ITC and 
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fluorescence experiments when compared to active compounds. CD spectra of these compounds 
clearly indicated that they were not interacting with zwitterionic or anionic membrane model 
systems. The minimal heat and high L/P ratios required for completion of the reaction observed 
in the ITC thermograms supports the CD data. Also, the low percentage of calcein leakage from 
the liposomes suggests minimal interaction with the liposomes.  
The results for these inactive compounds were extremely different from all of the data 
presented thus far for the active compounds. CD, ITC and fluorescence experiments proved 
suitable and more than capable of detecting changes in the interactions between our peptides and 
membrane models due to small systematic modifications to the peptides.  In addition to proving 
the usefulness of these techniques and compounds 14 and 34 as negative controls, addition to the 
use of these compounds as negative controls, the loss of activity for Compound 34 due to the 
deletion of the Tic residue only strengthens the argument that the incorporation of Tic in the 
dipeptide unit is required for activity. 
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CHAPTER NINE: APPLICATION OF A RATIONAL DRUG DESIGN 
Introduction 
Most chemists and biologist are very familiar with the 20 naturally occurring RNA 
encoded amino acids, however the incorporation of unnatural amino acids into peptides and 
proteins is making a major impact on biochemical research and are becoming more common 
place.  Research involving the incorporation of unnatural amino acids has focused on a wide 
array of applications from drug discovery 1  to site(s) specific incorporation of unnatural amino 
into proteins.2-4  This protocol will focus on the rationale and logic used to incorporate unnatural 
amino acids into the design of novel antimicrobial peptides. 
The selectivity of AMPs for prokaryotic versus eukaryotic cells is believed to be derived 
from the differences in the chemical compositions of their respective membranes.5-8 Bacterial 
cells contain a high percentage of negatively charged phospholipids while mammalian cells 
contain a much higher concentration of zwitterionic phospholipids.9  Other differences include 
the incorporation of sterols, lipopolysaccharide, peptidoglycan etc into the membrane 
composition which induces changes in structure,8 transmembrane potential and polarizability.  
The membranes of different strains of bacteria also exhibit differing chemical compositions.5, 10, 
11
 The lipid bilayer of Gram positive bacteria is covered by a porous layer of peptidoglycan, 
while the structure of Gram negative bacteria is more complex with two lipid membranes 
containing lipopolysaccharides and porins.5, 10 The outer membrane of mycobacteria is the most 
complex consisting of a very thick mycolate-rich outer coat11  which is very difficult to 
penetrate.  There is an increasing amount of evidence in the literature supporting the concept that 
the selectivity and potency of a specific AMP is determined, in a large measure, by the chemical 
composition of the target membrane.8, 12 Thus it is reasonable to postulate that the membrane’s 
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physicochemical surface interactions with the physicochemical surface of the AMP defines 
organism selectivity.5, 10, 12-15 
Antimicrobial peptides have been extensively investigated as therapeutic agents to 
possibly replace current antibiotics because of their novel mechanism of killing bacteria.6, 16, 17  
An international health care crisis has arisen due to the dramatic and continued evolution of drug 
resistant strains of bacteria.18, 19 This ever evolving increase in resistance has been the driving 
force behind the intensive research effort to develop a new class of compounds that exhibit novel 
mechanisms of antibacterial activity.17, 18, 20, 21 Both natural and synthetic antimicrobial peptides 
exhibit a very high potential as new therapeutic agents because of their novel mechanisms of 
antibiotic activity coupled with the difficulty of bacteria to develop resistance to them.6, 17, 22, 23 
The most promising applications of AMPs thus far are focused on their clinical development as 
topical antibiotics.23  
Unnatural amino acids offer several major advantages over the 20 naturally ocurring 
amino acids including limited conformational flexibility,1, 24, 25, 25-28 improved enzymatic 
stability,29  pharmacodynamics,1 as well as control over charge distribution15, 30, 31 and electron 
density.3 Having such control over these amino acids will hopefully allow AMPs to be designed 
and built to perform in specific ways. In the case of our research, react with potency and 
selectivity. 
The Design Process 
 
Selection of Target or Model Natural Antimicrobial Peptide 
The first step in the de novo design of selective antimicrobial peptides involves selecting 
a naturally occurring antimicrobial peptide as a model.  In this approach the primary amino acid 
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sequence is not a major focus, but  knowledge of the secondary structure adopted by the peptide 
on interacting with a zwitterionic and an anionic micelle or a liposome and the resulting 
physiochemical surface properties is very critical. It is a very difficult process to sit down with a 
blank sheet of paper and design a series of potent selective antimicrobial peptides without some 
three-dimensional physicochemical model.  Thus the starting point for such a design process is 
either to determine using 2D-NMR and molecular modeling methods the SDS and DPC micelle 
bound conformations of an antimicrobial in your own laboratory 14 or use similar structural data 
reported in the literature.  From these structures the electrostatic surface potential maps may be 
developed. 
In order to obtain the desired potency and selectivity for prokaryotic and eukaryotic cells 
it is critical that the peptide interact with zwitterionic and anionic membrane models via different 
mechanisms, i.e. adopt different conformations on binding to zwitterionic and anionic membrane 
models.15, 16, 32, 33 The  physicochemical properties that lead to different mechanisms of binding 
are not clearly understood.33 However, factors such as hydrophobicity, structure, electronic 
charge, hydrophobic moment etc appear to play major roles in defining selectivity.10, 15, 33, 34 
Therefore in our design methodology it is more important to focus on the overall shape of the 
molecule and the spatial distribution of physicochemical properties, such as charge density and 
hydrophobicity, than the amino acid composition or sequence.14, 15 
In our laboratory we selected (Ala 8,13,18)magainin-2 amide, an analog of the magainin 
family of host defense peptides as our model because this peptide is active against Gram positive 
and negative bacteria, fungi and protozoa while exhibiting little mammalian cell toxicity.35  The 
magainin family has been extensively investigated and has been characterized as α-helical 
amphipathic cell-selective membrane-disruptors.36-38 The investigation of AMPs with model 
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membrane systems has provided a great deal of insight into the role played by physicochemical 
properties in the mechanisms of the anti-bacterial activity of these compounds.39  For our 
investigation of (Ala 8,13,18)magainin-2 amide, DPC micelles40  were selected as a simple model 
for zwitterionic lipids and SDS micelles41 were selected as a simple model for anionic lipids. 
Due to our previous experience in investigating peptide-micelle interactions,42-44, 44 we selected 
NMR as the method of choice for this study. Two-dimensional NMR and molecular modeling45 
investigations indicated that (Ala8,13,18)magainin-2 amide bound to DPC micelles adopts an α-
helical structure involving residues 2 to 16 with the four C-terminal residues converging to a 
loose β-turn like structure, while (Ala8,13,18)magainin-2 amide bound to SDS micelles adopts an 
α-helical structure involving residues 7 to 18 with the C- and N-terminal residues exhibiting a 
great deal of conformational flexibility.  The most plausible explanation for (Ala 8,13,18)magainin-
2 amide adopting different conformations on binding with SDS and DPC micelles is that 
different non-covalent (electrostatic and hydrophobic) interactions are occurring between the 
surface of the peptide and the two micelle surfaces.45 The observation of different binding 
conformations on interaction with anionic and zwitterionic micelles and or liposomes is critical 
for the development of cell-selective AMP.32, 45 The ultimate goal of the design process is to 
develop AMPs that will form membrane-disrupting pores in anionic liposomes while leaving 
zwitterionic liposomes intact.14  
Using the NMR determined SDS and DPC micelle bound conformations of (Ala 
8,13,18)magainin-2 amide, the electrostatic surface potential maps for these conformers were 
calculated indicating that the surface electron density of these peptides are very different and  
conformationally dependent. 
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In our laboratory we have focused on developing antimicrobial peptides that contain 
unnatural amino acids to control the conformation and physicochemical properties of the 
resulting peptide14 while also taking advantage of the inherent metabolic stability of unnatural 
amino acids.6  The guiding hypothesis for our work has evolved from the assertion that the 3D-
physicochemical surface properties of a cell’s membrane (bacterial or mammalian) interact with 
the 3D-physicochemical surface properties of the approaching AMP in a very specific way, thus 
defining the resulting organism selectivity and potency.   For the AMPs developed in our 
laboratory this hypothesis was supported by the development of 3D-QSAR which defines the 
physicochemical properties required for activity against Staphylococcus aureus (SA) and 
Mycobacterium ranae (MR) bacteria.  The AMPs developed in our laboratory exhibited different 
in vitro activity against SA and MR bacteria. The cell membranes of Staphylococcus aureus and 
Mycobacterium ranae are chemically different. Therefore, we hypothesized that the differences 
in the observed biological activity was a direct manifestation of the different physicochemical 
interactions that occur between the peptides and the cell membranes of the SA and MR 
bacteria.15  For this hypothesis to be correct different physicochemical descriptors must correlate 
with the anti-bacterial activity of these compounds against SA and MR bacteria.  There were five 
physicochemical descriptors specific to the SA QSAR.  These five physicochemical descriptors 
are: Jurs–Fractional-Positive-Surface-Area–3 (Jurs-FPSA-3), Jurs-Relative-Positive-Charge-
Surface-area (Jurs-RPCS), Jurs-Differential-Positively-charged-Surface-Area-3 (Jurs-DPSA-3), 
Jurs-total-Solvent-Accessible-Surface-Area (Jurs-SASA) and Jurs-TotAl-hydrophobic-Surface-
Area (Jurs-TASA). The five physicochemical descriptors specific to the MR QSAR model are: 
sum-of-all-atomic-polarizabilities (Apol), Conformer Energy, Jurs-Partial-Positively-charged-
Surface-Area-2 (Jurs-PPSA-2), Jurs-Relative-Negative-CharGe (Jurs-RNCG), and Jurs-Total-
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Polar-Surface-Area (Jurs-TPSA). This result supports the hypothesis that for any particular 
AMP, organism selectivity and potency are controlled by the chemical composition of the target 
cell membrane.15  Therefore, we believe that by varying the physicochemical and conformational 
properties of a peptide, it should be possible to design selectivity and potency for a particular 
membrane composition.  
 
Making a Cartoon Model 
The next step in the design process is to identify which of the following functionalities 
are critical for the desired biological potency and selectivity. 
1. Secondary Structure 
2. Molecular flexibility between  regions of limited conformational flexibility 
3. Molecular charge 
4. Charge density 
5. Flexibility between the regions of limited conformational flexibility and charge 
clusters. 
 
 In Figure 9.1 an example of this cartoon representation is given.  The cartoon starts at the 
far left with an N-capping residue.  This residue is normally a natural amino acid of neutral 
charge and may be a free amine or acetylated.  The second residue in the sequence is a natural 
amino acid that is either positively charged (Arg, Lys, His) or hydrophobic in nature (Phe, Trp, 
Tyr, Leu).  This particular residue defines the physicochemical character of the N-terminus.  The 
next two amino acids, residues 3 and 4, are unnatural amino acids that form a conformationally 
restrained dipeptide unit which is used to control local secondary structure and molecular 
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flexibility.  The use of conformationally restrained amino acids, such as Tic and Oic residues in 
our case, reduces the flexibility of the local peptide backbone and thus reduces the total 
conformational space that may be sampled by the peptide during lipid binding. The selection of 
the unnatural amino acids to be incorporated as the dipeptide will be discussed in a later section. 
If included, the fifth amino acid residue also referred to as a spacer, can be a Gly residue 
or an unnatural amino acid such as βAla, GABA or longer amino acid.  This spacer, if included 
in the sequence, provides molecular flexibility between the preceding conformationally 
restrained dipeptide and the following positively charged amino acid.  Increasing the number of  
-CH2- groups in the spacer, in our case by including unnatural amino acids such as β-Ala, Gaba 
or Ahx, the length of the peptide backbone increases, thus increasing the molecular flexibility of 
the local peptide chain.  This results in an increase in the total conformational space that may be 
sampled by the peptide during lipid binding. By combining regions containing conformationally 
restrained amino acids and regions of conformational flexibility into the peptide backbone 
regions of high and low molecular flexibility are created providing a fine tuning of the local 
verses total conformational space that may be sampled by the peptide during lipid binding. 
The next amino acid, residue 6, is a positively charged residue which maybe either a 
natural or unnatural amino acid.  By varying the number of -CH2- groups in the positively 
charged residue from 1 to 4 in the side chain of the basic residues (Lys, Orn, Dab, Dpr residues) 
the distance between the positive charge and the peptide backbone will decrease. This results in a 
less flexible side chain during binding, which is more important in the binding with zwitterionic 
lipids than with anionic lipids, and the positive charge density will reside closer to the peptide 
backbone.  The reason that side chain flexibility is more important in the binding of zwitterionic 
lipids than with anionic lipids is the following. Electrostatic interactions are responsible for 
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peptide-membrane binding while hydrophobic interactions are responsible for inducing a stable 
secondary structure onto the peptide.42, 46 The electrostatic interactions that occur between 
cationic peptides and zwitterionic lipids are more “complex” than those that occur with anionic 
lipids.46 The counter ions in solution are covalently bound to zwitterionic lipids, but are free 
flowing in an anionic lipid solution, thus their positive and negative charges have limited 
freedom of motion. As the positive charges of the incoming peptide approaches the surface of the 
zwitterionic lipid, the positive counter ions of the lipid can not be displaced from the surface and 
diffuse into solution away from the lipid, as is the case with the free flowing ions in anionic lipid 
solutions.  Therefore, both attractive electrostatic interactions between the positive charges of the 
peptide and the negative charges on the lipid, as well as the repulsive electrostatic interactions 
between the positive charges on the peptide and the positive charges of the lipid will be inversely 
synergistic in nature.46 Consequently, the binding process will require the conformation of the 
incoming peptide to adapt in response to these interactions so as to maximize the attractive 
interactions while concurrently minimizing these repulsive interactions. The selection of this 
residue is critically important and will be discussed in a later section. 
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Figure 9.1:    A cartoon representation of the important structural and physicochemical features 
to be incorporated into the new antimicrobial peptide is shown to aid in the design process. 
 
 
 
 
The seventh amino acid residue is another spacer and, if included, is the second spacer in 
the sequence. As with the previous spacer, it provides molecular flexibility between the 
preceding cationic residue and residues 8 and 9, the second conformationally restrained dipeptide 
unit.  The next amino acid residue, 10, is also an optional spacer that provides molecular 
flexibility between the preceding dipeptide and the following hydrophobic amino acid, residue 
11. The selection of the hydrophobic residue, which maybe natural or unnatural, is critical and 
size, aromatic character and electron density are factors that must be taken into consideration.  
The selection of the hydrophobic residue will be discussed later. 
The hydrophobic residue is followed by another spacer, which can be incorporated to 
provide molecular flexibility between the preceding hydrophobic residue and the following 
dipeptide unit, which is the third conformationally restrained unit of the sequence and 
incorporates residues 13 and 14. The amino acid sequence from the first dipeptide unit to the 
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third dipeptide unit is considered a repeat unit. This repeat unit may recur one to two more times 
and is followed by the fifth spacer, residue 15.  Residue 15 is the last spacer of the sequence and 
if included provides molecular flexibility between the last conformationally restrained dipeptide 
and a cluster of positively charged amino acids at the C-terminus.  The last three to six amino 
acids at the C-terminus make up the highly positively charged cluster at the C-terminus.  The 
position of the positively charged and hydrophobic residues may be switched depending on the 
charge and hydrophobic character of the physicochemical surface properties of the antimicrobial 
being modeled.   The net result of these modifications is to induce semi-rigid conformations onto 
the peptide backbone, as well as to induce specific regions of hydrophobicity and charge in 
hopes of dramatically changing the physicochemical surface properties presented to the lipid on 
binding. 
 
Converting the Cartoon Model into Amino Acid Sequence 
The conversion of a carton model of a potential peptide into an amino acid sequence 
consists of several steps. The first step is to select the conformationally restrained dipeptide 
building block. 
 
Selection of Conformationally Restrained Dipeptide Units 
Once a cartoon representation of the desired structure and physicochemical properties is 
created, it must be converted to an amino acid sequence. The first step in this process is to select 
the conformationally restrained dipeptide unit.  Our original skeletal design of an un-natural 
AMP incorporated placement of multiple L-Tic-L-Oic dipeptide units into the polypeptide 
backbone to induce an ordered structure onto the peptide.14 Kyle and co-workers reported, using 
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NMR and molecular modeling methods, that the dipeptide consisting of the un-natural amino 
acids (D)-Tetrahydroisoquinolinecarboxylic acid (Tic) and (L)-Octahydroindolecarboxylic acid 
(Oic) when placed in positions i+1 and i+2 of a four amino acid sequence induced a β-turn.27 
The AMPs developed in our laboratory have several Tic-Oic dipeptide units connected via one or 
two amino acid spacers with defined properties of charge and hydrophobicity. Knowing such 
properties about the amino acids allows for the design of peptides with well defined 
physiochemical properties that are able to maintain sufficient conformational flexibility, 
allowing the peptide to adopt different conformations when interacting with membranes of 
different chemical composition.14, 15, 31 
The structure of the Tic-Oic dipeptide conformationally restrained unit used in the AMPs 
designed in our laboratory is given in Figure 9.2.  The basic skeleton of he AMPs developed in 
our laboratory is given in Figure 1.3 from Chapter 1.  Spacer #1 defines the distance between 
successive Tic-Oic dipeptide units, and refers to amino acids 5 and 10 of the cartoon 
representation.  It is involved in defining the flexibility of any induced turn or helical structure.  
Spacer #2 defines the distance between the polypeptide backbone residues and the positively 
charged side chain amine.  It is involved in determining the overall surface charge density as 
well as the distance between the membrane surface and the polypeptide backbone and is residue 
6 in the cartoon. 
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Figure 9.2: The structure of the Tic-Oic dipeptide conformationally restrained unit used in the 
AMPs designed in our laboratory 
 
 
 
 
The cartoon representation discussed a repeating unit that started and stopped with the 
dipeptide unit. However, in the case of our peptides, the end of the last repeat unit only includes 
the first residue of the dipeptide unit, Tic. More specifically, our peptides contain one and a half 
repeat units, concluding with half of a dipeptide unit. Spacer #3 follows the last repeat unit and 
defines the distance between the last Tic residue and the C-terminal Lys residues, providing 
additional conformational flexibility on surface binding.14 
The purpose of a conformationally restrained dipeptide unit is to induce an ordered 
structure onto the peptide.  With this in mind, the first logical step in the selection of a 
conformationally restrained dipeptide unit would be constructing a simple tetra peptide to 
determine whether or not the dipeptide in fact provides the desired conformational rigidity.  The 
stereochemistry, using D or L isomers, as well as the placement of the amino acid residues in the 
sequence may be of great importance in determining the conformations of the dipeptide unit.  
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Five separate simple tetrapeptides, with the basic sequence Ala-Tic-Oic-Ala-NH2, were modeled 
using ChemDraw 3D. The tetrapeptides were designed by incorporating both the D and L 
stereoisomer as well as interchanging their order. A very simple approximation of the minimum 
energy conformations adopted by the five tetrapeptides Ala- L -Tic- L -Oic-Ala-NH2,  Ala- D -
Tic- L -Oic-Ala-NH2 , Ala-L-Tic- D -Oic-Ala-NH2 , Ala- L -Oic- L -Tic-Ala-NH2, and  Ala- L -Oic- 
D -Tic-Ala-NH2 were compared using ChemDraw 3D and can be seen in Figure 9.3.    
 
Figure 9.3: Stereoview of the ChemDraw 3D minimum energy structures for the tetrapeptide 
(hydrogen atoms not shown for clarity) Ala- L -Tic- L -Oic-Ala-NH2 (top left), 
Ala- D -Tic- L -Oic-Ala-NH2 (top right), Ala- L -Tic-D-Oic-Ala-NH2 (middle left),  
Ala- L -Oic- L -Tic-Ala-NH2 (middle right) and Ala-L-Oic- D -Tic-Ala-NH2 (bottom) 
 
 
 
256 
 
 
The CD spectra of three of these tetra peptides Ac-Ala-Tic-Oic-Ala-NH2, Ac-Ala- D -Tic-
Oic-Ala-NH2 and Ac-Ala-Oic- D -Tic-Ala-NH2 are shown in Figure 9.4.   These CD spectra 
clearly demonstrate that the stereochemistry of the alpha carbon can effect the solution 
conformation of the conformationally restrained dipeptide units. 
 
Figure 9.4:  The Far-UV Circular Dichroism spectra of the three tetrapeptides (1 mg/mL) 
dissolved in 40mM phosphate buffer (pH = 6.8). All CD spectra were obtained by acquiring 8 
scans on a Jasco J-815 CD Spectrometer using a 0.1mm cylindrical quartz cell (Starna Cells, 
Atascadero, CA) from 260 to 178nm at 20 nm/min, 1 nm bandwidth, data pitch 0.2nm, response 
time 0.25 sec and 5 mdeg sensitivity at room temperature (~25°C).  The CD spectrum (shown in 
BLACK) of the tetrapeptide Ac-Ala-Tic-Oic-Ala-NH2 exhibits an ordered turn containing 
secondary structure as indicated by the double minima in the CD spectrum at about 195 and 205 
nm, which is consistent with the presence of β-turn and helical conformers.47-49 The CD spectrum 
(shown in BLUE) of the tetrapeptide Ac-Ala-D-Tic-Oic-Ala-NH2 exhibits an ordered turn 
containing secondary structure as indicated by the double maximum in the CD spectrum at about 
195 and 205 nm, and a minimum at 185 nm, which is consistent with the presence of possible β-
turn conformers.47-49 The CD spectrum (shown in RED) of the tetrapeptide Ac-Ala-Oic-D-Tic-
Ala-NH2 exhibits an maximum in the CD spectrum at about 220 nm, and a minimum at about 
198 nm, which is consistent with a random coil conformers.47, 48  
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The Tic-Oic dipeptide is by no means the only choice for a conformationally restrained 
dipeptide unit. Of the Cα-tetrasubstituted α-amino acids available, α-aminoisobutyric acid (Aib) 
is the most commonly employed and studied residue and is limited to constrained right and left-
handed helical structures.50 However, additional Cα-tetrasubstituted α-amino acids are being 
developed and investigated.  Grauer and Konig26  have reported the syntheses of a series of novel 
Cα-tetrasubstituted α-amino acids to reduce the conformational flexibility of a peptide.  
Incorporation of Cα-tetrasubstituted α-amino acids derivatives into a peptide sequence can induce 
stable β-turns51 or 310 or α-helices.26, 52, 53 The novel Cα-tetrasubstituted α-amino acids developed 
by Grauer and Konig26 are given in Figure 9.5. 
 
 
Figure 9.5: Representative novel Cα-tetrasubstituted α-amino acids developed by Grauer and 
Konig26 
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There are several Cα-tetrasubstituted α-amino acids that are commercially available as 
either the Fmoc of tBoc protected analogs or the free amino acids and these are shown in Figure 
9.6. (R)-2-amino-1,2,3,4,-tetrahydronaphthalene-2-caroxylic acid and (S)-2-amino-1,2,3,4,-
tetrahydronaphthalene-2-caroxylic acid shown in Figure 9.6 are very interesting alicyclic α-
amino acids and have the potential to act as conformationally restrained dipeptide units. The 
advantage the 2-amino-1,2,3,4,-tetrahydronaphthalene-2-caroxylic acid  has over the Tic residue 
is that it contains an amide proton in the peptide which makes NMR studies much easier. 
 
 
 
Figure 9.6:  Six alicyclic α-amino acids commercially available as either the Fmoc of tBoc 
protected analogs or the free amino acids. 
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In Figure 9.7 stereoviews (using ChemDraw 3D version 10) of hexapeptides with the 
sequence of Ala-Ala-(2-amino-1,2,3,4,-tetrahydronaphthalene-2-caroxylic acid)-( 2-amino-
1,2,3,4,-tetrahydronaphthalene-2-caroxylic acid)-Ala-Ala are given. In the top panel of Figure 
9.7 the 2amino-1,2,3,4,-tetrahydronaphthalene-2-caroxylic acid stereochemistry has the RR 
stereochemistry , in the middle panel  the stereochemistry is SS and in the stereochemistry is SR 
in the bottom panel.  As can be seen in the Figures stereochemistry plays an important role in the 
resulting three dimensional structure and conformational flexibility of the peptide.  For an 
excellent review on the structure of extended and expanded amino acids including Cα-
tetrasubstituted α-amino acids see Vasudev et. al.50  
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Figure 9.7: Stereoviews of hexapeptides with the sequences of Ala-Ala-((R)-2-amino-1,2,3,4,-
tetrahydronaphthalene-2-caroxylic acid)-((R)-2-amino-1,2,3,4,-tetrahydronaphthalene-2-
caroxylic acid)-Ala-Ala (top), Ala-Ala-((S)-2-amino-1,2,3,4,-tetrahydronaphthalene-2-caroxylic 
acid)-((S)-2-amino-1,2,3,4,-tetrahydronaphthalene-2-caroxylic acid)-Ala-Ala (middle) and  
Ala-Ala-((R)-2-amino-1,2,3,4,-tetrahydronaphthalene-2-caroxylic acid)-((S)-2-amino-1,2,3,4,-
tetrahydronaphthalene-2-caroxylic acid)-Ala-Ala (bottom) 
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Selection of number, position and type of flexible spacers 
 
The amino acid sequences for the flexible spacers in our previous work were the natural 
amino acid glycine, which contains one carbon atom between the carbonyl carbon and the amide 
nitrogen, the β-peptide βAla with two carbons, the unnatural amino acids Gaba (gamma-
aminobutyric acid) and Ahx (6-aminohexanoic acid) with three and five carbons atoms, 
respectively. The average distance between the carbonyl carbon atom and the amid nitrogen 
atom is 2.46, 2.94, 4.68 and 6.91 Å for Gly, βAla, Gaba and Ahx, respectively.  Other longer 
alkyl spacers include the commercially available, 9-aminooctanoic acid (9-Aoa), 10-
aminodecanoic acid (10Ada), 12-aminododecanoic acid (12-Adda), and 16-aminopalmitic acid 
(16-Apa). The longer the amino acid backbone the more flexible the amino acid will be which 
allows it to occupy a larger amount of conformational space and participate in different intra-
molecular hydrogen bonding sequences.50 An excellent review of the structure of extended and 
expanded amino acids has been provided by Vasudev et. al.50 
A number of different α-amino acids have been used to control the conformation of 
antimicrobial peptides.33, 54, 55 In our approach we limit their use to the role of a flexible spacer.  
In addition to β-Ala, analogs of β-Leu andβ-Phe, shown in Figure 9.8, could also be considered 
as flexible spacers.  These analogs, which are commercially available, have the additional 
advantage of introducing hydrophobicity into the spacer, along with flexibility. 
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Figure 9.8:  Commercially available analogs of β-Leu and β-Phe 
 
The substituted analogs of β-Phe are particularly interesting. The availability of both 
electron withdrawing and donating groups on the phenyl ring allows for the control of the 
electron density of the aromatic ring, thus granting the β-Phe analogs the ability to play a dual 
role as both a flexible spacer and as a hydrophobic residue with varying electronic properties. 
These spacers can also be used to induce a rigid region onto the peptide backbone using 
derivatives of amino benzoic acid shown in Figure 9.9 (other possible derivatives may not 
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shown). These analogs provide both rigidity and aromatic character, or hydrophobicity, into the 
backbone. Incorporation of these residues as spacers, however, should be done with care. 
 
 
 
Figure 9.9:  A partial listing of the commercially available rigid spacers derived from benzoic 
acid 
 
 
 
 
Selection of number and position of hydrophobic properties 
The next step in the design process is the selection of hydrophobic residues to incorporate 
into the peptide.  There are two basic types of hydrophobic residues 1) aromatic and 2) non-
aromatic.  Hydrophobic residues are known to play a role in anchoring an antimicrobial peptide 
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to the membrane by inserting itself into the hydrophobic core of the membrane.30 Of all the 
naturally occurring amino acids, Wimley and White determined tryptophan to be the most 
hydrophobic.30, 30, 56, 57 It is believed to that the tryptophan residue remains located near the 
membrane interface and does not partition into deep into the hydrophobic core of the lipid.30 
Haug and co-workers developed a series of short lactoferricin based antimicrobial peptides 
incorporating different analogs of tryptophan.30 The net result of this investigation was the 
development of a novel class of shorter peptides with high antibacterial activity against several 
resistant strains of bacteria. Some of the hydrophobic and tryptophan analogs used by Haug and 
co-workers are given in Figure 9.10.30   Figure 9.10 gives a partial list of commercially 
available hydrophobic amino acids which may be used to modify the electronic character of the 
aromatic ring of Phe. 
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Figure 9.10: Some of the hydrophobic and tryptophan analogs used by Haug and co-workers30 
to developed a series of short lactoferricin based antimicrobial with high antibacterial activity 
against several resistant strains of bacteria. 
 
 
Non-aromatic residues include the natural amino acids Leu, and Ile.  Also derivatives of 
β-Leu shown in Figure 9.11 could be used as hydrophobic residues.  However it has been our 
experience that aromatic residues are preferable. 
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Figure 9.11: A partial list of commercially available hydrophobic amino acids which may be 
used to modify the electronic character of the aromatic ring of the amino acid residue Phe. 
 
 
 
 
Selection of number and position of electrostatic properties 
In our original work the positively charged amino acid residue was referred to as Spacer 
# 2 and is synomous with residue 6 of the cartoon representation. Spacer #2 consisted of amino 
acids Lys, Orn, Dpr or Dab, each decreasing the distance from the side chain nitrogen to the α-
carbon atom of the peptide backbone. Table 9.1 gives the average distances for each amino acid 
residues (Calculated using ChemDraw 3D, Cambridge Software) 
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Table 9.1: Distance from side chain nitrogen to α-carbon atom of the peptide backbone 
Peptide ID 23 43 53 45
Residue Lys Orn Dab Dpr
Average distance 4.76 Å 3.55 Å 2.99 Å 2.56 Å
# of carbons in 
side-chain 4 3 2 1
 
 
 
Oh and Lee reported29  the synthesis and biological evaluation of several antimicrobial 
peptides containing unnatural analogs of the amino acid Lys. These unnatural analogs of Lys are 
shown in Figure 9.12 and were designed to incorporate more positive charge (increased number 
of amino groups) and increase the side chain bulk.29 51  The increase in positive charge should 
result in an increase in the electrostatic attraction of the peptide to the surface of a bacterial 
membrane and thus greater antibiotic activity.58, 59  
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Figure 9.12:  Analogs of the amino acid Lys with increased positive charge and side chain bulk 
developed by Oh and Lee. 51 
 
 
 
 
One must remember, however, that not all cationic charges are created equal.  Arg 
residues contain a guanidinium group at the end of their side chain.  In this planar group the 
positive charge is delocalized over two different nitrogen atoms.  Therefore the positive charge is 
more dispersed as compared to the localized positive charge on the one nitrogen of the Lys side 
chain amino group.30, 60 Also, the work of Haug and co-workers has shown that incorporation of 
quarternary ammonium groups lead to analogs with similar or lower antimicrobial activity 
compared to analogs containing Lys residues.30 one possible explanation for this behaviour is 
269 
 
that by having both positive charge and hydrophobic character in close proximity to one another, 
an environment is created that interferes with the efficiency  of the electrostatic interaction 
between the peptide and lipid head groups.30  
 
Charge Density at the C-Terminus 
We have shown that by increasing the number of basic amino acid15  residues at the C-
terminus, the net positive charge density at the C-terminus also increases.  It has been previously 
observed that increased positive charge density, to a point, at the C-terminus can increase 
antibacterial activity while decreasing hemolytic activity. 14, 15 Organism selectivity has also been 
observed.14, 31  
 
Assemble the Amino Acids to obtain the desired structural and physicochemical properties 
In Figure 9.13 the amino acid sequence of a peptide, compound 46, (amino acid 
sequence; Ac-βAla-Fpa-Tic-Oic-βAla-Dpr-Tic-Oic-βAla-Fpa-Tic-Oic-βAla-Dpr-Tic-Dpr-Dpr-
Dpr-Dpr-CONH2) that was designed and synthesized in our lab, based on the design principals 
discussed here in.  Although this particular peptide is biologically active, (activity given in Table 
9.2) this protocol does not guarantee that all peptides designed in this manner will be biologically 
active and this peptide is used to illustrate the final step before peptide synthesis and purification.  
In the proceeding section, we will go through each residue from the cartoon representation and 
offer possible amino acids to incorporate. 
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Figure 9.13: Designed amino acid sequence incorporating the desired structural and 
physicochemical properties. 
 
 
Table 9.2: Minimum inhibitory concentration (µM) of select bacteria strains for compound 4614, 
31
  
Compound Salmonella 
typhimurium
Staphylococcus aureus 
ME/GM/TC resistant
Mycobacterium 
ranae
Bacillus 
subtillis
46 3 µM 30 µM 100 µM 0.3 µM
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Table 9.3: Minimum inhibitory concentration (µM) of specific Gram negative and other drug 
resistant bacteria strains for compound 46.14, 31 
Compound 46
Acinetobacter baumanii 
ATCC 19606 3.4
Acinetobacter baumanii 
WRAIR 3.4
Staphylococcus aureus 
ATCC 33591 109
Yersinia pestis CO92 219
Brucella melitensis 16M 219
Brucella abortus 2308 219
Brucella suis 23444 219
Bacillus anthracis AMES 6.8
Francisella tularensis 
SCHUS4 219
Burkholderia mallei 219
Burkholderia pseudomallei 219
 
 
 
The first residue, as previously mentioned, is normally a natural amino acid with neutral 
charge and it may be the free amine or acetylated.  In the case of our example, the N-capping 
residue, and residue 1, is βAla. The second residue defines the physicochemical character of the 
N-terminus and is a natural amino acid residue that is either positively charged (Arg, Lys, His, or 
an unnatural basic residue) or is hydrophobic in nature (Phe, Trp, Tyr, Leu).  Residue 2 (striped 
purple and gold) can also be a derivative of any of the above listed residues, such as Fpa, as in 
Compound 46. 
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Residues 3 and 4 are unnatural amino acids that form a conformationally restrained 
dipeptide unit. For compound 46 we selected two Cα-tetrasubstituted α-amino acids, Tic and Oic, 
as our dipeptide unit and together they control the local secondary structure and molecular 
flexibility of our peptide.  The use of conformationally restrained amino acids, such as Tic and 
Oic, reduces the flexibility of the peptide backbone, consequently decreasing the total 
conformational space that may be sampled by the peptide.  It should be noted that the two amino 
acids used as the conformationally restrained unit may be the same or different depending on the 
situation. 
The fifth residue is an optional spacer, as are all the spacers. In our series of peptides, the 
spacer immediately following the conformationally restrained dipeptide is referred to as Spacer 
#1 and can be a Gly residue or an unnatural amino acid such as β-Ala, GABA or longer amino 
acid, as previously mentioned. There are two Spacer #1 amino acids in the cartoon 
representation, residues 5 and 10, and when included in the sequence they provide molecular 
flexibility between the preceding conformationally restrained dipeptide and the following.  By 
increasing the number of -CH2- groups in the spacer, in our case by including unnatural amino 
acids such as, βAla, Gaba or Ahx, the length of the peptide backbone increases, thus increasing 
the molecular flexibility of the local peptide chain.  Other longer alkyl spacers that may also be 
employed include the commercially available, 9-aminooctanoic acid (9-Aoa), 10-aminodecanoic 
acid (10Ada), 12-aminododecanoic acid (12-Adda), or 16-aminopalmitic acid (16-Apa). The 
longer the amino acid backbone the more flexible the peptide will be, allowing it to occupy a 
larger conformational space and participate in different intramolecular hydrogen bonding 
sequences.50  For compound 46, the two Spacer #1 amino acids (residues 5 and 10, royal blue), 
are βAla which provides two -CH2- groups to the peptide backbone. 
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Residue 6 is either a positively charge natural or unnatural amino acid, and is also 
referred to as Spacer #2. By varying the number of –CH2- groups in the positively charged 
residue from 1 to 4 in the side chain of the basic residues (Lys, Orn, Dab, Dpr residues) the 
distance between the positive charge and the peptide backbone will decrease. Dpr has only one 
methylene group in its side for Compound 46, decreasing the flexibility greatly when compared 
to the naturally occurring Lysine. As the length of the side chain decreases the positive charge 
density will reside closer to the peptide backbone resulting in a less flexible side chain during 
membrane binding. As previously discussed, this flexibility is more important in the binding 
with zwitterionic lipids than with anionic lipids due to the covalently bound counter ions. 
Another optional spacer follows the positively charged residue. The seventh residue 
(teal), although excluded in Compound 46, would precede the dipeptide unit and provide 
molecular flexibility between the positively charged residue and the next dipeptide unit residues 
8 and 9. As before, the dipeptide is followed by a spacer. This spacer, residue 10, is the second 
Spacer #1 of the sequence and is also β-Ala. It provides molecular flexibility between the 
preceding dipeptide and the following hydrophobic amino acid, residue 11 (purple). When 
selecting a hydrophobic residue, which maybe natural or unnatural, factors including size, 
aromatic character and electron density must be considered. For our example peptide, compound 
46, Fpa was chosen and it must be noted, that Fpa was also the hydrophobic amino acid chosen 
for residue 2. 
The hydrophobic residue is followed by another spacer, residue 12, which can be incorporated to 
provide additional molecular flexibility between the hydrophobic residue and the third Tic-Oic 
dipeptide unit, residues 13 and 14. Residue 12, like residue 7, was excluded from Compound 46. 
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As mentioned previously, the section of the amino acid sequence from the first dipeptide unit to 
the third dipeptide unit is considered one repeat unit and a peptide can consist of up to three 
repeat units, although our peptides only incorporate 1.5. Following the last repeat unit is the final 
spacer, residue 15, and it is referred to as Spacer #3 in our series of peptides. Spacer #3 is not 
always included, as in compound 46, but when it is included it usually consists of the same 
amino acid residue that is used for Spacer #1. This particular spacer provides molecular 
flexibility between the last conformationally restrained dipeptide and the cluster of positively 
charged amino acids that can be found at the C-terminus.  The last three to six amino acids of the 
sequence make up a highly positively charged cluster.  These residues may be selected from the 
common basic residues (Lys, Orn, Dab, Dpr residues) or other unnatural basic amino acid 
residues and usually, but not always, the same as the amino acid used for Spacer #2, as is the 
case for compound 46. 
 
Preliminary Evaluation 
Once the peptide(s) have been synthesized and purified their potential as antimicrobial peptides 
must be evaluated.   In vitro screening against several strains of bacterial is critical in 
determining the activity of these compounds.  However, in most research laboratories these 
assays are not readily available.  Therefore samples must be submitted to commercial research 
organizations for testing.  This process can take 4-6 weeks to obtain results and depending on the 
number of peptides and assays to be screened, this can prove to be a relatively expensive 
operation.   We, there for, recommend the use of CD spectroscopy and calcein leakage studies as 
a first evaluation of these peptides.  If the CD spectra of the peptides do not exhibit different 
conformations in membrane model systems than they do in buffer, it is most likely that they are 
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not interacting with the membrane models, and therefore, it is unlikely they will interact with the 
membrane of a bacterial cell.32 The results from the calcein leakage assays are critical in 
determining if the peptide disrupts the membrane.31, 32, 61 Failure to induce calcein leakage, 
however, does not mean that the peptide will exhibit no antibiotic activity, but rather that any 
observed in vitro activity is derived interacting with an intracellular target. 
 
Preparation of POPC and POPC/POPG Liposomes 
Refer to chapter 2, Materials and Methods for procedures used.  
 
Dye release experiments 
Refer to chapter 2, Materials and Methods for procedures used.  
 
Circular Dichroism 
All CD spectra for preliminary evaluations were obtained using the parameters and 
procedures discussed in chapter 2.  
 
For an example of the observed differences in the CD spectra in these five different 
environments for compound 46 please see Figure 9.14. The shifts in wavelengths and changes in 
the intensity of the spectra in the anionic and zwitterionic micelle and bilayer membrane models 
as compared to the spectrum in buffer leads to the conclusion that this AMP does interact with 
membrane environments. Also, small changes in λmax and λmin were observed between the 
anionic and zwitterionic models suggesting that this compound may interact differently with the 
membrane system. If the biological activity of this particular compound were not already known, 
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this result would act as positive reinforcement that this peptide could possibly exhibit biological 
activity and selectivity. 
 
Figure 9.14: The Far-UV CDichroism spectra of compound 46  (1 mg/mL) dissolved in either 
40 mM phosphate buffer (pH = 6.8), 80 mM SDS or DPC micelles in buffer, or 10 mM POPC or 
POPC/POPG (4:1) LUVs in buffer.  
 
 
 
 
Calcein Leakage Assays 
Peptide induced calcein leakage was investigated using the praramters and procedures 
previously discussed in Chapter 2, materials and methods.  
The observed differences in calcein leakage from POPC and 4:1 POPC/POPG LUVs 
caused by compound 46 can be seen in Figure 9.15. The clear difference in the concentration 
dependency for the two types of membrane model systems suggests that there are two different 
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mechanisms of action occurring. This data supports the CD data in Figure 9.15 as positive 
enforcement for the possible use of this compound as a useful therapeutic agent. 
 
Figure 9.15:  The time dependent release of calcein from POPC (left) and 4:1 POPC/POPG 
LUVs induced by increasing concentrations of compound 46 as measured by fluorescence.62-64  
 
 
 
 
Conclusion for preliminary evaluation 
In this protocol the procedures and logic used in our laboratory to design antimicrobial 
peptides containing unnatural amino acids has been outlined.  This protocol does not guarantee 
to lead to potential selective antimicrobial agents on the first attempt.  However, careful selection 
and placement of amino acids with specific physicochemical properties in an iterative process of 
refinement based on information obtained from the CD and calcein leakage studies should 
ultimately lead to analogs exhibiting antimicrobial activity. Once compounds are designed that 
have shown possible bioactivity, in depth characterization investigations involving Circular 
Dichroism, Isothermal titration calorimetry and calcein spectroscopy should be performed as 
described in previous chapters. 
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CONCLUSIONS 
 Spectroscopic and thermodynamic studies have been conducted in order to gain a better 
understanding of the mechanisms for the lipid binding that occurs between an AMP and 
zwitterionic and/or anionic membrane models. The intent of these investigations was to 
determine which physicochemical characteristics of an AMP increased or decreased biological 
activity and then use that knowledge to design and synthesize novel AMPs with optimized 
parameters for increase organism selectivity and potency.  
 Each of the compounds investigated in this research exhibited different degrees of 
interactions with anionic and zwitterionic membrane models. The activity that the compounds 
exhibited against different bacteria strains also varied.  We concluded this to be due of the 
different physicochemical properties of the peptides resulting from the varying structural 
modifications made to the sequence of the reference peptide, compound 23. This peptide showed 
broad spectrum activity at low micromolar ranges while exhibiting minimal activity against 
mammalian red blood cells. Compound 23 appeared to interact predominately with the surface of 
zwitterionic POPC LUVs (S-state), while all of the evidence supports the formation of a toroidal 
pore into the bilayer of the anionic 4:1 POPC/POPG LUVs (I-state).   
 Lengthening the peptide backbone of compound 23 and incorporating unnatural amino 
acids as Spacer #1 does in fact play a role in the interactions with model membrane systems. CD 
spectra of compounds 23, 36, 29 and 37 clearly indicate that these peptides interact with 
zwitterionic and anionic micelles and liposomes differently and the different conformations 
adopted by the peptides are indicative of different mechanisms. The differences in the ITC data 
as compared to natural AMPs are due, in large part, to the fact that our peptides incorporate a 
high percentage of unnatural amino acids and were specifically designed to have regions of 
285 
 
limited conformational flexibility, as well as, region on increased conformational flexibility. The 
Spacer #1 peptides are believed to interact with POPC LUVs via a modified version of the 
“carpet” mechanism, as with compound 23, while forming pores in the presence of 4:1 
POPC/POPG LUVs. We have also presented evidence suggesting that the peptides with the 
shorter spacers, compounds 23 and 36, require a higher number of peptides to form a leakage 
inducing pore than compounds 29 and 37 with the longer backbones.   
 The length of Spacer #2 plays an important role in defining the mechanism of action 
between this series of peptides and zwitterionic and anionic membrane models. We hypothesized 
that because Spacer #2 defines the distance between the peptide backbone and the positively 
charged amine group, it determines the overall surface charge density of the peptide as well as 
the distance between the peptide backbone and membrane surfaces. The different spectra 
observed by CD coupled with the different thermodynamic mechanisms studied via ITC support 
this hypothesis. Also, there appears to be an optimal length for Spacer #2 which promotes 
antibacterial activity while maintaining minimal interaction with zwitterionic membranes. 
Compound 43, with the carbon spacer Orn, exhibited increased antibacterial activity in vitro as 
well as with the anionic membrane models when compared to compound 23, but also showed 
minimal interactions with the zwitterionic membranes. Compound 45, on the other hand, 
contained the shortest spacer and interacted the most with zwitterionic membranes, a 
therapeutically undesirable quality.  
Incorporating Spacer #3 into the peptide sequence of compound 23 did not have an 
increased effect on the interactions with anionic membrane models as concluded by CD, ITC and 
fluorescence leakage studies. There were similarities to each other and compound 23 in their 
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results to support the theory that the changes in the length of Spacer #3 played no role in the 
biological activity.  
Changing the number and location of the lysines in the positively charged cluster played 
an important role the in biological activity of compounds 64, 39 and 61. Compounds 64 and 61 
exhibited increased interactions via two different mechanisms in the presence of anionic LUVs 
as compared to compound 23. The increased activity has been attributed to the decreased charge 
of compound 64 which reduces the repulsive electrostatic interactions between the peptide and 
membrane surface. The increased flexibility of the lysine cluster at the N-terminus for compound 
61 was determined to attribute to its increased activity. The increased charge of compound 39 
resulted in the repulsion of the peptide and therefore decreased its activity.  
It was shown in Figure 3.2 that the percentage of anionic lipids present in the liposomes 
plays a critical role in the interactions with the peptides, supporting our hypothesis that the 
chemical composition, and thus the surface physicochemical properties, of the lipid membrane 
plays a very important role in determining the conformation adopted by these peptides upon 
binding to the surface.  The chemical composition of different strains of bacteria is very 
different, thus presenting different physicochemical properties to the approaching peptide.  By 
systematically modifying the structure of the peptide, we are able to create peptides with certain 
physicochemical properties that are compatible with the differing bacterial membrane surfaces. It 
is therefore reasonable to expect our peptides to be capable of interacting specifically with the 
membranes of various bacteria strains.  
 The rational drug design applied to building compound 46 is just one example of how the 
incorporation of unnatural amino acids into a peptide allows for the control of the 
physicochemical properties exhibited to bacteria cells. Other peptides that showed varying 
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selectivity included compounds 37, 64, and 61 against several Gram Negative and other drug 
resistant bacteria strains discussed. Therefore, this study shows that a rational approach may be 
utilized to design biologically active and selective AMPs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
